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Summary 
 
TNF family ligands and receptors fulfill a number of functions, mainly in the immune system. For 
example, the ligands BAFF and APRIL control growth and survival of mature B cells at various 
stages of differentiation. TNF family ligands usually form homotrimers, but heteromers have also 
been described for lymphotoxin α1β2 and for BAFF and APRIL. Interestingly, twenty BAFF 
homotrimers can assemble into virus-like particles coined BAFF 60-mer, which are superior to 
BAFF 3-mer regarding their ability to signal in primary B cells.  
A screen was performed in 293T cells, by co-transfecting differently tagged ligands, to identify six 
novel heteromers. The specificity of these novel heteromers, however, did not correspond to that of 
orphan receptors in the TNFR family.  
Little is known about heteromers of BAFF and APRIL, in particular their receptor-binding 
specificity and their ability to signal. A method to produce and purify heteromers of defined 
stoechiometry was developed, and the resulting reagents were used to demonstrate that 
BAFF2APRIL, like BAFF, binds to all BAFF receptors - namely BAFFR, TACI and BCMA -, 
while APRIL2BAFF and APRIL only binds to TACI and BCMA. Heteromers could signal via their 
cognate receptors, sometimes as potently and sometimes less potently than homomers, depending 
on the receptors. A promising system to measure the activity of single-chain homo- and heteromers 
in vivo was set up: it measures mature B cell rescue upon administration of single-chain ligands into 
BAFF-ko mice. 
To tackle the question of the physiological importance of BAFF 60-mer, a point mutation that 
prevents assembly of mouse BAFF into 60-mer while retaining its ability to form trimers was 
identified. This mutation (E247K) was introduced by homologous recombination into mouse 
embryonic stem cells that are now being used to generate knock-in mice.  
Results obtained in this work will help to better understand the role of various BAFF and APRIL 
forms that are elevated in a several autoimmune diseases. 
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Résumé 
 
Les ligands et récepteurs de la famille du TNF joue un rôle prédominant dans le système 
immunitaire. Par exemple, les ligands BAFF et APRIL contrôlent la croissance et la survie des 
cellules B matures à différents stades de différenciation. Ces ligands existent souvent sous forme 
d'homotrimères (3-mer), bien que des héteromères aient été décrits pour la lymphotoxine α1β2 et 
pour BAFF et APRIL. Dans le cas de BAFF, vingt trimères peuvent, telle une particule virale, 
s’assembler en 60-mer qui surpasse le 3-mer pour signaler dans des cellules B primaires. 
Un crible effectué dans des cellules 293T, par co-transfection de ligands différemment marqués, a 
permis d’identifier six nouveaux heteromères dont la spécificité n’a, hélas, pas correspondu à celle 
d’un récepteur orphelin de la famille du TNFR.  
Les connaissances sur la spécificité de liaison aux récepteurs et la capacité à signaler des 
heteromères de BAFF et d’APRIL sont fragmentaires. Une méthode pour produire et purifier des 
heteromères "simple chaîne" de stoechiométrie déterminée a été mise au point, et les réactifs ainsi 
obtenus utilisés pour démontrer que BAFF2APRIL, comme BAFF, lie tous les récepteurs de BAFF 
- c’est-à-dire BAFFR, TACI et BCMA -, alors qu’APRIL2BAFF et APRIL ne lient que TACI et 
BCMA. Les héteromères peuvent transmettre des signaux, parfois aussi bien et parfois plus 
faiblement que les homomères, selon les récepteurs. Un système prometteur pour mesurer l’activité 
des ligands simple chaîne in vivo a été mis au point. Il mesure la réapparition de cellules B matures 
dans des souris déficientes pour BAFF après administration des ligands.  
Pour s’attaquer à la question de l’importance physiologique du 60-mer de BAFF, une mutation 
empêchant l’assemblage en 60-mer sans affecter la capacité à former des trimères a été identifiée. 
Cette mutation (E247K) a été introduite par recombinaison homologue dans des cellules souches 
embryonnaires de souris qui sont utilisées pour obtenir des souris déficientes en BAFF 60-mer. 
Les résultats de ces travaux contribueront à mieux cerner le rôle des différentes formes de BAFF et 
d’APRIL produites en excès dans plusieurs maladies auto-immunes.  
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1. Introduction. 
1.1.1. Immune system and immunology. 
 
The immune system is a network of cells, tissues, and organs that work together to defend the body 
against attacks by “foreign” invaders. These are primarily microbes—tiny organisms such as 
bacteria, parasites and fungi, or viruses that can cause infections. The human body provides an ideal 
environment for many microbes. It is the task of the immune system to maintain the homeostasis of 
an uninfected body by preventing their entry or destroying them.  
 
Study of the immune system and its components is the subject of immunology. The concept of 
immunity and thereby immunology came from the observation that individuals who survived and 
recovered from certain infectious diseases were thereafter protected from the disease. Observations 
dating as far back as a plague in Athens, to attempts of inducing immunity by the Chinese and 
Turks in the 12th century and even later English physician Edward Jenner’s technique of inoculating 
fluid from cowpox pustule as a form of vaccination, have developed and increased the importance 
of studies in immunology [1]. 
 
The immune system has two broadly classified compartments – the innate immune system which is 
mostly referred to as non-specific immune responses and the adaptive or acquired immune system 
considered to form specific immune responses. 
 
1.1.2. Innate immunity. 
 
Innate immunity comprises of four main defensive barriers: anatomic, physiologic, endocytic and 
phagocytic, and inflammatory. Physiological barriers include temperature, pH, oxygen tension and 
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other soluble factors. For example, chickens display innate immunity to anthrax because of their 
high body temperature which inhibits its growth. The low pH in stomach does not allow survival of 
some organisms in the stomach.  A hydrolytic enzyme like lysozyme can cleave peptidoglycans in 
mucous secretions [1].  
Endocytic and phagocytic barriers function by engulfing macromolecules and internalizing them. 
Endocytosis can either be receptor-mediated or by pinocytosis carried out by non-specific 
membrane invagination. Specialized cells like blood monocytes, neutrophils and tissue 
macrophages participate in phagocytosis while endocytosis is carried out by virtually all cells.  
Inflammatory response are characterised by increased blood flow, capillary permeability and influx 
of phagocytic cells. It is a response involving several complex interactions leading to a cascade of 
events mediated by chemical mediators.  
The recognition of pathogens or danger signals are accomplished by cells of the innate immune 
system that express pattern recognition receptors (PRRs) These include the membrane bound Toll-
like receptors (TLRs), the retinoic acid-inducible gene I-like receptors (RLRs), the nucleotide 
oligomerization domain-like receptors (NLRs, also called NACHT, LRR and PYD domain 
proteins) and cytosolic DNA sensors [2]. Secreted PRRs include complement receptors, collectins, 
pentaxrin proteins. The PRR can sense two types of signals. One is Pathogen Associated Molecular 
Patterns (PAMPs). PAMPs include bacterial lipopolysaccharide "endotoxin" (LPS→TLR4), 
bacterial flagellin, lipoteichoic acid, lipoproteins and peptidoglycan (→TLR1,-2,-6), mannose 
residues, N-formylmethionine, fungal glucans, endogenous heat shock proteins, extracellular matrix 
molecules, and nucleic acid variants associated with viruses (vRNA→TLR3, unmethylated cytosin-
guanosin dinucleotide (CpG islands)→TLR9, dsRNA) and bacteria (bacterial DNA, unmethylated 
cytosin-guanosin dinucleotide (CpG)→TLR9). Effector cells of innate and adaptive immunity 
employ nonclassical pathways to secrete alarmins when they are activated by PAMPs or other 
alarmins. Endogenous alarmins and exogenous PAMPs therefore elicit similar responses, and can 
be considered subgroups of a larger set, the damage-associated molecular patterns (DAMPs)[3] . 
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1.1.3. Adaptive immunity. 
 
Acquired or adaptive immunity involves specifically recognizing and selectively eliminating 
foreign microorganisms and molecules. Unlike innate immunity, acquired immunity displays 
specificity, diversity, memory, self and non-self recognition.  But acquired immunity is not 
independent of innate immunity. Phagocytic cells are closely involved in activation of specific 
immune response. The cells of the adaptive immune system comprise of lymphocytes like B and T 
cells and antigen presenting cells like dendritic cells and also macrophages. Two broadly classified 
branches of acquired immune system involves humoral and cell mediated immunity.  Humoral 
immunity originated from the concept of conferring immunity to a non-immune individual and this 
involved interaction of B cells with antigens and their subsequent proliferation into antibody 
secreting plasma cells. The resulting complex of an antibody bound to an antigen can be eliminated 
by fusing to receptors on phagocytic cells or can activate the complement system leading to the 
lysis of foreign organism [1]. 
 
T cells that proliferate and differentiate into effector T cells in response to antigen are responsible 
for cell-mediated immunity, which can be carried out by immune T cells. T helper cells as well as 
Cytotoxic T Lymphocytes serve as effector cells in cell mediated immune reactions [1]. 
 
The most well-known receptors on B and T cells among many are the BCR and TCR respectively. 
These molecules are instrumental in antigen recognition mediating further signaling events. The B 
cell receptor consists of two heavy and two light chains composed of a variable region responsible 
for antigen recognition and diversity and a constant region responsible for the effector function.  
The diversity is created by gene re-arrangement in the form of somatic hypermutation: the variable 
region is encoded by V, D and J segments. Both light and heavy chain contribute to antigen-binding 
site generating a repertoire of as high as 1013 for the BCR. The constant region undergoes class 
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switching to generate antibodies of differing isotypes, which accomplish varying functions [1].  
 
1.1.4. Organs and Cells of the Immune System. 
 
On the basis of function immune organs can be categorized as primary (central) and secondary 
(peripheral) lymphoid organs. 
 Also known as bursa of Fabricus in birds the primary site of B cell maturation is bone marrow. 
Most of the cells of the immune system originate in the bone marrow (Fig 1), where many of them 
also mature. They then migrate to guard the peripheral tissues, circulating in the blood and in a 
specialized system of vessels called the lymphatic system. The other primary lymphoid organ is 
thymus, a flat, bilobed organ situated above the heart. Each of the lobules are organized into two 
compartments: cortex which is packed with thymocytes and the medulla sparsely populated with 
thymocytes. Immature lymphocytes (T cells) generated during hematopoiesis in the bone marrow 
mature and become committed to a particular antigenic specificity in the thymus [1, 4].  
The secondary lymphoid organs include lymph nodes and spleen. Lymph nodes are encapsulated 
bean shaped structures containing a reticular network packed with lymphocytes, macrophages and 
dendritic cells. They are found clustered at junctions of the lymphatics and serve as the first 
organized structure to encounter most antigens [4].  
Spleen is a large, ovoid secondary lymphoid organ situated high in the left abdominal cavity. 
Spleen primarily functions to filter blood and trapping blood borne antigens and thus responds to 
systemic infections. The spleen also consists of two compartments namely the red and the white 
pulp. The red pulp consists of a network of sinusoids occupied by macrophages and numerous 
erythrocytes and is the site of destruction and removal of old and defective red blood cells. The 
white pulp surrounds the arteries, forming a periarteriolar lymphoid sheath (PALS) populated 
mainly by T lymphocytes. Clusters of B-lymphocytes in the PALS form primary follicles 
occupying a more peripheral position.  Dendritic cells surrounding the B cells act as antigen 
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presenting cells to B cells upon antigenic challenge and the primary follicles thus develop features 
of secondary follicles like the germinal center [1, 4]. A summary of the major cells of the immune 
system has been described in Fig1. 
 
 
Fig 1. All the cellular elements of blood, including the lymphocytes of the adaptive immune system, arise from 
hematopoietic stem cells in the bone marrow. Taken from Charles Janeway (Immunobiology Immune system of Health 
and disease 2001)  
 
1.2.1. TNF family of ligands and receptors. 
 
A complex network of hormones, chemical mediators and cytokines maintains, regulates and 
connects a variety of cell types and enables a cross talk between various organs that form an 
organism. Cytokines are signaling molecules used extensively in intercellular communication. 
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Cytokines can be classified as proteins, peptides, or glycoproteins and include a large and diverse 
family of regulators produced throughout the body by cells of diverse embryological origin. 
Ligands and receptors of the tumour necrosis factor (TNF) superfamilies are examples of signal 
transducers with a role to play principally in the development, regulation and overall homeostasis 
of the immune system but also in other biological functions like inflammation, cell death or 
development of ectodermal appendages (Reviewed in [5-7]). TNF was first identified as a factor 
with antitumor activity [8] [9]. It was used in the treatment of soft tissue sarcomas and melanomas 
and was demonstrated to have potent antitumor activity with an acceptable safety profile [10-12]. 
The tumor necrosis factor (TNF) superfamily is composed of 19 ligands and 29 receptors.  
 
1.2.2. Structural features of TNF ligands and receptors. 
 
The ligands are Type II transmembrane proteins (i.e. intracellular N terminus and extracellular C 
terminus), with a conserved C-terminal domain termed the ‘TNF homology domain’ (THD). The 
THD is a 150 amino acid long sequence that assembles as trimers through a conserved network of 
aromatic and hydrophobic amino acid residues, has a sequence identity of ~20–30% between 
family members and is responsible for receptor binding. Atomic level structures are available 
among others for the THD of TNF [13],[14], LTα [15], CD40L [16] and TRAIL, RANKL [17], 
OX40L [18], EDA1, EDA2 [19-22]. The ligands are expressed as membrane-bound proteins, but 
soluble forms can be generated by proteolytic processing by various proteases. Metalloproteases of 
the ADAM (a disintegrin and metalloproteinase domain) family act on TNF and RANKL [23, 24], 
matrilysin acts on Fas ligand (FasL) [25], and members of the subtilisin-like furin family act on 
BAFF, EDA, TWEAK and APRIL-members of the TNF family [26, 27]. The event of processing is 
relevant for the physiological activity of some ligands like EDA [26, 28], whereas some ligands are 
functional only as membrane bound ligands like FasL cleavage [29]. For some ligands, like for 
TNF-related apoptosis-inducing ligand (TRAIL), the importance of processing remains unclear 
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[30]. The cleavage of BAFF seems to be important to generate soluble BAFF, which mainly is 
required for early development of mature naïve B cells by signaling via BAFFR [31]. THDs share a 
virtually identical tertiary fold and associate to form trimeric proteins. The THDs are β-sandwich 
structures containing two stacked β-pleated sheets, each formed by five anti-parallel β strands that 
adopt a classical ‘jelly-roll’ topology.  
Trimeric THDs are ~60 Å in height and resemble bell-shaped, truncated pyramids with variable 
loops protruding out of a compact core of conserved anti-parallel β strands [19, 21, 22]. The trimer 
is assembled such that one edge of each subunit (strands E and F) (illustration in Fig 2) is packed 
against the inner sheet of its neighbour, forming large and mostly hydrophobic interfaces, resulting 
in a very stable interaction [13, 21, 22]. CD40L contains a single disulfide bridge linking some of 
the loops (CD and EF loop) [13, 32]. Similar disulfide links are predicted to occur in FasL, LIGHT, 
TL1A, CD30L and CD27L, whereas TWEAK, EDA, APRIL and BAFF have a predicted disulfide 
bridge between β strands E and F. In TRAIL, a single cysteine residue (Cys230) in the EF loop is 
involved in the coordination of a Zn(II) ion, with each monomer contributing to one coordination 
position; the fourth coordination position is occupied by an internal solvent molecule or a chloride 
counter-ion [24–26]. This metal-binding site is unique so far in the TNF family, and affects the 
stability and bioactivity of TRAIL [26,28,29]. Incomplete Zn coordination, and formation of 
partially oxidized, disulfide-linked species of TRAIL, have been suggested to account for its 
hepatotoxicity [33]. 
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Fig 2. Structures of TNFSF ligands. Taken from Bodmer et al. (TIBS 2002). 
 
The TNF receptors are mostly Type I transmembrane proteins with an extracellular N terminus 
consisting of cysteine-rich domains (CRDs), which are pseudo-repeats typically containing six 
cysteine residues engaged in the formation of three disulfide bonds. The number of CRDs in a 
given receptor varies from one to four, except in the case of CD30 where the three CRDs have been 
partially duplicated in the human but not in the mouse sequence. Based on distinct structural 
modules that allows sequence comparison between TNF receptors, a classification has been 
introduced by Naismith and Sprang [34]. Each module type is designated by a letter (A, B, C and N 
for crystallized modules, and X for modules of unknown structure), and by a numeral indicating the 
number of disulfide bridges it contains. (Illustration in figure 2).  A typical CRD is usually 
composed of an A1–B2 or A2–B1 module or, less frequently by a different pair of modules. A1 
modules are 12–27 amino acids long, consist of three short β strands linked by turns, and contain a 
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single disulfide bridge connecting strands 1 and 3, yielding a characteristic C-shaped structure. A2 
modules contain a second disulfide bridge linking the second and third strands without affecting the 
overall structure. B modules are 21–24 amino acids long and comprise three anti-parallel strands 
adopting an S-shaped fold like a paper clip. In this case, the fold is constrained by two entangled 
disulfide bridges linking strands 1 and 3 in B2 modules. The first disulfide bridge is replaced by a 
hydrogen bond in B1 modules [35]. The structure of A and B modules is also reflected at the level 
of the primary sequence by the conservation of a few non-cysteine residues. Other modules are less 
frequent. So far, the N-terminal N1 modules have been found only in the TRAIL receptors, in 
which they precede the first A1–B2 CRD. Structurally, the N1 module resembles the second half of 
a B module [19, 20, 22]. The fourth CRD of TNF-R1 contains an A1–C2 module pair, in which the 
cysteine connectivity of C2 is different from that of a B2. 
 
      
   
 
 
 
 
 
 
 
 
Fig 3. The modules of TNFSF receptors. Taken from Bodmer et al. (TIBS, 2002). 
 
 TACI, BCMA and Fn14 also contain putative A1–C2 CRDs. Four unrelated modules of unknown 
structure that are found in DR3, GITR, BAFFR and viral CrmC have been collectively designated 
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as ‘module X’. The later described BAFF receptor (BAFFR) [36] contains a single X2 module 
whose sequence resembles an A module entangled with the beginning of a B module. TNF 
receptors are often viewed as monomers, principally because they appear in this form in crystal 
structures of ligand–receptor complexes. However, TNF-R1 has also been crystallized as both 
head-to-head and head-to-tail dimers [35], and there is genetic and experimental evidence that Fas, 
TNF-R1 and CD40 exist as preformed oligomers within the plasma membrane [37]. Self-
association of the receptors depends on an N-terminal pre-ligand association domain (PLAD) that 
includes the first CRD and that is not directly involved in ligand binding. 
 
1.2.3. Ligand Receptor Interaction. 
 
The first crystal structure of a TNF ligand (LTα) bound to its cognate receptor (TNF-R1) [15] 
followed by the structure of TRAIL bound to TRAILR2 [19, 20, 32] and then further ligand 
receptor complexes indicated that the basic signaling unit is a trimeric ligand bound to three 
monomeric receptors. The receptor ligand interactions could be of two major types: large elongated 
receptors contact ligands at the monomer-monomer interface, whereas small, compact receptors 
make most contacts with a single monomer of the trimeric ligand. There are promisquities in the 
ligand-receptor interactions, with some of the ligands and receptors having more than one binding 
partners (e.g. both TNF and LTα bind to TNFR1; BAFF binds to BCMA, TACI and BAFFR; 
APRIL share TACI and BCMA with BAFF) (Reviewed in [5],[6]). On the other hand, EDA1 and 
EDA2 that differ by only two amino acids bind respectively to EDAR and XEDAR with a strict 
specificity [38]. The receptor HVEM (Herpes Virus Entry mediator) interacts with LIGHT and 
LTα. As an illustration of the existence of non TNF ligands, the viral glycoprotein D hijacks 
HVEM to allow cellular entry of Herpes Simplex Virus [39]. Regarding signaling, receptors are 
perhaps pre-assembled at the cell surface in the absence of ligand. For Fas, this preferentially 
requires the PLAD (pre-ligand assembly) domain at the N-terminus of the receptor [37]. The PLAD 
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is believed to mediate self-association and to increase its responsiveness to ligand-mediated signals. 
Ligand receptor interactions seem to be conserved across species. Most of the human and mouse 
TNFSF ligands cross-react with the TNFSF receptors [40]. 
 
1.2.4. Signaling pathways and physiological importance of TNF proteins. 
 
Most TNF ligands can be expressed by cells of the immune system. Exceptions are TL1A, which is 
expressed by endothelial cells, and EDA1, which is expressed, in embryonic skin and in some 
ectodermal appendages. In contrast, TNF receptors are expressed by a wide variety of cells within 
and outside of the immune system (Reviewed in [6]). The type of signal transmitted by a ligand 
depends largely on the intracellular moieties of the TNF receptors and their ability to recruit various 
adapter and effector proteins. Some TNF family ligands can mediate cell death (FasL, TRAIL) by 
engaging caspase-activating receptors containing an intracellular death domain. Other ligands can 
lead to cell survival or differentiation (CD40L, BAFF, CD27L, 4-1BBL, OX40L, RANKL) or 
promote inflammatory reactions (TNF, RANKL) by activating signaling pathways such as those 
leading to activation of the transcription factor NF-κB or to the activation of mitogen-activated 
protein kinases (MAPKs) [6]. Of note, RANKL is essential for the formation of bone-resorbing 
osteoclasts [41] and EDA1 for the correct formation of ectodermal appendages such as hair, teeth 
and sweat glands [26, 28].  
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Fig 4. Diseases caused by TNF family members. Taken from review by Aggarwal et al. (Blood 2012) (*EDA-A1 is 
involved in X-linked hypohidroticectodermal dysplasia and not EDA-A2) 
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Fig 5. Table of TNFSF gene knockout phenotype of mice. Taken from Review by Aggarwal et al. (Blood 2012) 
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1.3.1. Structural forms of BAFF and APRIL, two homologs in the TNF 
superfamily. 
 
Most members of the BAFF family were discovered through genomic homology searches [27, 42, 
43]. Since some family members were discovered simultaneously by several laboratories, they 
possess multiple names (Reviewed in [44, 45]). The gene encoding BAFF is located on human 
chromosome 13q34 and mouse chromosome 8. BAFF is a Type II, 285 amino acid-long membrane-
bound protein, which can be released as a soluble trimeric ligand upon proteolytic processing at a 
furin consensus site. In humans, exon 1 of BAFF gene codes for the transmembrane domain and its 
flanking regions, exon 2 for the furin processing site, and exons 3–6 for the TNF homology domain 
(THD). The receptors bind to the THD. At neutral or basic pH, 20 trimers of soluble recombinant 
human BAFF associate into a 60-mer virus-like structure, which irreversibly dissociates into 
trimers at acidic pH, or when fused to N-terminal extensions such as a myc tag [46, 47]. An 
extended loop, known as the “Flap”, that is unique to BAFF in the TNF family is responsible for 
the association of the BAFF trimers [46]. BAFF 60-mer is a biologically active entity that can bind 
receptors and is moderately more active than trimers as found in in vitro assays [46, 48]. In recent 
past it was found that TACI among the BAFF and APRIL receptors gets solely activated by 
oligomerised BAFF/APRIL or recombinant 60-mer [49], however the physiological importance of 
this finding remains unknown. Endogenously produced BAFF 60-mer has been detected in 
supernatants of an histiocytic cell line [48] and in the sera of BAFF transgenic mice [49]. The gene 
for mouse BAFF contains an additional exon encoding a stretch of 30 amino acids located between 
the furin site and the THD. This extension may possibly interfere with 60-mer formation in the 
mouse, but may be not. A dominant negative form of BAFF (delta BAFF) has been described 
resulting from a splice variant in which exon 4 is skipped [50, 51]. This results in a molecule with a 
cryptic N-glycosylation site that arrests any trimer containing the mutant BAFF peptide (s) to be 
secreted [52]. Mice transgenic for delta BAFF exhibit reductions in peripheral B cell numbers and 
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impaired humoral responses [50] indicating towards a possible inhibitory role. BAFF is highly 
conserved across species. More than 75% homology is shared by chicken and duck than with 
murine and human BAFF [53-55]. The cross reactivity is also evident by the fact that recombinant 
human or murine BAFF are both effective on both chicken and mouse B cells [53-55]. BAFF 
polymorphisms have been found in mice but they do not show any phenotypic significance.  BAFF 
has several features unique to itself in the TNF superfamily (Reviewed in [44]). First, the axis 
involved with trimerization is shortened resulting in a somewhat flatter molecule than other TNF 
ligands. In addition, BAFF can interact with magnesium, and has an exceptionally deep and acidic 
cleft that in part explains its unique affinity for the comparatively basic BAFFR receptor, as well as 
its lower affinity for BCMA when compared to APRIL [56, 57].  
 
(Reviewed in [44, 45, 58]) The gene encoding APRIL is found on chromosome 17p13.3 in humans 
and chromosome 11 in the mouse [59]. The nomenclature of APRIL A Proliferation Inducing 
Ligand comes from its ability to induce proliferation in transfected fibroblasts. [60, 61]. The 250 
amino acid APRIL molecule shares only 20–30% homology with most other TNF family members; 
but displays nearly 50% homology with BAFF in the TNF-homology domain [49, 62, 63]. APRIL 
interacts with BCMA and TACI, but not with BAFFR. The structure of the APRIL gene is similar 
to that of BAFF though APRIL does not form 60-mers, but possesses residues close to the furin 
processing site in exon 3 that are crucial for binding to glycosaminoglycans. APRIL binds sulfated 
glycosaminoglycans at sites independent from those used to bind other receptors [64, 65]. Upon 
splicing between exon 1 and 3 a membrane bound uncleavable APRIL can be generated. The 
physiological significance of the binding to glycosaminoglycans is unclear but is believed to 
oligomerise APRIL in the extracellular matrix or at the surface of syndecan-positive cells and 
increases its accessibility to receptor TACI which also interacts with syndecans [66], or to 
intracellular BCMA [67] upon syndecan internalization. 
Another splice variant of APRIL lacking exon 3, known as APRIL β, is considered to be a 
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homologue of delta BAFF that also lacks the first sheet of the THD [59], and this may also regulate 
APRIL activity in a dominant-negative manner [50]. Another splicing event of intron in exon 6 
results in APRIL γ having a truncation of four amino acids at the C-terminal and is replaced by a 
single residue, but this isoform has not been further studied [59]. ESTs of murine APRIL have not 
shown similar sequences. Unlike human APRIL mouse APRIL exist as two variants differing by a 
single amino acid (Ala120) resulting from usage of two splice acceptor sites three nucleotide apart 
at the beginning of exon 4. Both isoforms can bind TACI and BCMA, but the shorter form in can 
also weakly interact with mouse BAFFR [40], but this may not be of physiological relevance.  
 
(Reviewed in [44, 45, 58]) APRIL gene has some interesting features. The TNF homology domain 
encoding region β sheets B to H is separated in two exons, whereas most TNF family members 
APRIL, BAFF, EDA and TWEAK use a single exon to encode this domain. Finally, the gene 
encoding APRIL lies 3’ of a TNF family member named TNF Weak Inducer of Apoptosis 
(TWEAK) [68, 69]. This particular organization of TWEAK and APRIL genes is conserved from 
mice to humans, indicating a possible functional relationship. Interestingly, messenger RNA for a 
fusion product of the TWEAK and APRIL genes resulting from the splicing between exon 6 of 
TWEAK and exon 2 of APRIL in humans and between exon 7 of TWEAK and exon 1 of APRIL in 
mice has been reported (termed TWE-PRIL) in T cells and various cell lines. The resulting 
TWEAK-APRIL fusion proteins in both species contain the complete THD of APRIL, indicating 
that TWE-PRIL could bind BCMA and TACI, but the processing event to yield an active soluble 
form would be similar to pathways characteristic of TWEAK [69]. Interestingly, the TWEAK 
receptor, Fn14, bears striking resemblance to BCMA both in terms of structure and TRAF binding 
capacity. 
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1.3.2. Cells and tissues expressing BAFF and APRIL. 
 
(Reviewed in [70-72]) Distinct cell lineages produce BAFF. It is constitutively produced by 
radiation resistant cells possibly stromal cells [73, 74] and also produced upon induction by cells of 
myeloid origin such as monocytes, macrophages, dendritic cells. Oher cell types like activated T 
cells, malignant B cells and CD34+ cells from cord blood [75-83], have shown BAFF expression.   
In patients with multiple myeloma bone marrow derived cells Bone marrow derived cells of patient 
with multiple myeloma show BAFF expression. Cytotrophoblast cells in the placenta [84] or even 
astrocytes also express BAFF [85]. To date, mechanisms regulating BAFF expression in these cells 
are not fully understood. Cytokines like IL10, IFN-γ increase BAFF expression in various cell types 
such as monocytes, macrophages and dendritic cells. Resting monocytes constitutively express a 
low level of membrane-bound BAFF but expression is up-regulated by IFN-γ and IL-10 [86]. IL-4 
also inhibits the up regulation of BAFF expression in monocytes stimulated with IL-10, but not 
with IFN-γ [87]. In myeloid cells, the binding of immune complexes increased BAFF processing in 
a manner that was dependent on the expression of high-affinity Fc receptor for IgG (FcγRI) [88]. 
BAFF expression can be induced by bacterial components like LPS and peptidoglycan that can also 
modulate BAFF secretion by macrophages, dendritic cells and, upon LPS stimulation only, 
monocytes [75, 86, 87]. Similar to BAFF, APRIL is expressed by monocytes, macrophages, 
dendritic cells , T cells, tumor infiltrating neutrophils [68, 75, 80, 83, 86]. APRIL is also produced 
by non-immune cells like epithelial cells and osteoclasts [60, 89]. APRIL expression in 
macrophages and dendritic cells is up-regulated by IFN-γ and IFN-γ treatment [75, 86]. LPS also 
induces APRIL expression in both macrophages and dendritic cells [75, 86]. In addition, APRIL 
expression is also induced upon CD40 ligation on dendritic cells. CD40 ligation also stimulates 
BAFF secretion from dendritic cells [86]. Similar to IL-4, activation with PMA/ionomycin is a 
negative regulator of BAFF expression [80]. In addition, acetylcholine receptor-pulsed DCs express 
reduced levels of BAFF [90]. Absence of suppressor of cytokine signaling-1 (SOCS-1) results in 
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the aberrant expression of BAFF in dendritic cells [91]. Neutrophils have been shown to synthesize 
and secrete the highest levels of BAFF, particularly following GCSF and IFN-stimulation [79]. 
However, BAFF is released from neutrophils after intracellular processing, rather than processing 
from the cell membrane like in  myeloid cells [79]. In addition another source of endogenous BAFF 
production could be neoplastic B cells for example in B cell chronic lymphocytic leukemia (B-
CLL) and multiple myeloma (MM) cells [76, 78, 84, 92, 93]. Epstein-Barr virus (EBV)-infected B 
cells have also been shown to express BAFF [94]. Whether normal B cells express BAFF is 
uncertain. Most reports agree that normal B cells do not express BAFF [84, 94], however, Kern et 
al. reported otherwise [92].  
 
1.3.3. BAFF, APRIL and the receptors in B cell survival. 
 
BAFF and APRIL play key roles in regulating the behavior of most mature B cell subsets. The 
signaling of BAFF and APRIL at different stages of B cell development is much dependent on the 
expression pattern of its receptors. BAFFR and then TACI are the first expressed among immature 
B cells in the bone marrow, followed by an increase in their expression through the transitional 
stages. In the pre-immune follicular and marginal zone pools, BAFFR and TACI reach relatively 
high and constant levels [95]. BAFF plays a major role in the differentiation of MZ B cells 
expressing uniformly high levels of BAFFR and TACI [96, 97]. Oligomeric BAFF is particularly 
effective at inducing marginal zone B cells and expression of CD23 surface markers [31].  
BAFFR provides the most crucial signal for the survival of all pre-immune B cell subsets from the 
transitional stage onwards as was observed by the profound B cell deficiency in the A/WySnJ 
mouse [58, 98-103], a characteristic that came across as a single autosomal trait arising from a 400 
bp insertion in the intracellular tail of BAFFR [96]. Ectopic BAFF expression or exogenous BAFF 
administration yields B cell hyperplasia and humoral autoimmune manifestations [42, 58, 104, 
105]. Both BAFF and BAFFR knockout mice display primary B cell deficiencies resembling the 
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pattern of the A/WySnJ [101, 106]. The transitional stage during B cell development determines the  
fate of a B cell, whether or not it will be selected positively or negatively. The availability of 
BAFF, along with the BCR signals within the competing cohort of emerging cells, decides the 
thresholds for negative and positive selection of cells. This is demonstrated in several studies using 
transgenic systems [74, 107, 108], showing that when BAFF is non-limiting, self-reactive 
clonotypes, instead of dying at the transitional stage, survive and mature. BAFF over expression 
does not rescue cells deleted at the immature stages, suggesting BCR signals, and not BAFFR, are 
indespensible at these stages. This may reflect the onset of BAFF receptor expression per se, but a 
more and more emerging studies indicate that differentiation-dependent changes in intra-cellular 
signaling systems that involve cross-talk between the BCR and BAFFR may have some effect 
[128–132]. 
(Reviewed in [58]) Antigen-experienced cells which are less well characterized than the pre 
immune B cells can also be influenced by BAFF during its development and subsequent 
maintenance. Competing naïve cells are more dependent on B cell survival factors which are 
limiting among them than antigen-experienced cells. The axis of BAFF-BAFFR mediated signaling 
plays a less critical role here. Instead the axis shifts towards APRIL-TACI or APRIL-BCMA, the 
later two receptors found on both memory and plasma cells, the cell types, especially memory cells 
must persist to confer protective immunity on a longer term. Hence different downstream signaling 
systems of TACI and BCMA dominate. B cell responses are generally categorized as either as T-
dependent (TD) or T independent (TI), depending on the presence or absence of cognate T cell help 
in initiating the response. T-independent antigens can be of two types. TACI has been shown to be 
upregulated dramatically on B cells following encounter with either TI-1 or TI-2 antigens [109] and 
this has been correlated with increase in number of antibody forming cells [110], but its precise 
significance is unclear. Some studies suggest that it could play a role in controlling cell cycle 
regulation [110]. A role of BAFF in regulation of cell cycle entry has been indicated, though the 
receptor mediating this effect was not mentioned [111].  
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(Reviewed in [58]) BAFF and APRIL can play a role in the establishment and evolution of 
germinal center reactions. The mechanism of action remain obscure. BAFFR up regulation could be 
by BCR engagement as well as concomitant CD40 ligation [112]. TD stimulation can result in 
TACI elevation as well, although but to a lesser extent than seen with TI antigens. The general view 
is that BAFFR is not required for the generation of GCs [113, 114]. Thus, even though not severe 
but, GCs generated in the absence of appropriate BAFF or BAFFR signaling are small, 
comparatively short-lived, and fewer in number. Follicular dendritic cells (FDC) networks do not 
mature in germinal center when BAFF and APRIL are blocked [115]. This may reflect a loss of 
FDC supporting signals secondary to the decreased number of B cells in the GC. High levels of 
TACI are found in rapidly proliferating short-lived plasma cells generated during either TI or TD 
responses, while BCMA is up regulated in long-lived plasma cells. Recent studies support a role for 
BCMA in maintaining long-lived plasma cell (LLPC) survival [116]. BCMA binds to both BAFF 
and APRIL, and is sensitive to the simultaneous absence of both the cytokines [117]. Osetoeclasts 
serves as a localized source of high levels of APRIL in bone marrow niches and is consumed by the 
long lived plasma cell for survival [118]. Resident bone marrow accessory cells express high 
amount of  proteoglycans [64], where long lived plasma cells co-exist indicating a network of 
APRIL, proteoglycans and BCMA expressing LLPC. The downstream effects of BCMA signaling 
in long-lived plasma cells are not yet extensively characterized, owing to the technical limitations 
of maintaining these rare populations of B cells in vitro. However, B cell and plasma cell lines 
reveal classical NF-κB activation, the upregulation of a number of proteins associated with antigen 
presentation and co-stimulation, and increased IL-2 production following BCMA ligation [119]. 
Memory B cells show an increased level of TACI, but inspite of this, memory cells seem to be 
independent for their needs of BAFF or APRIL [117]. 
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1.3.4. Signaling pathways downstream of BAFF, APRIL and their receptors. 
 
(Reviewed in [71],[72],[58]) BAFF receptor (BAFFR/BR3) is the first of the BAFF/APRIL 
receptors to be expressed on primary B cells. It engages various signaling cascades utilizing 
different downstream adapter molecules. The other important signal on B cells at this early cell 
stage comes from the BCR which employs mainly Src and tyrosine kinases activated upon receptor 
oligomerisation to initiate primary and secondary message systems. This involves the formation of 
a primary signaling complex leading to Ca2+ sensitive responses, recruitment of the MALT/Bcl-
10/CARMA complex, and classical NF-κ B activation [120]. In contrast, stimulation of BAFFR 
leads to the degradation of TRAF3 in a TRAF2-dependent manner. As TRAF3 is normally 
involved in the constitutive degradation of NF-κB inducing kinase (NIK), BAFFR-mediated 
TRAF3 elimination rescues NIK expression. NIK potently activates the alternative non-classical 
NF-κB2 pathway that degrades p100 into p52. This is of likely relevance in vivo as the B cell 
compartments of B cell-specific NIK-deficient (aly/aly), IKKα -null and NF-κB2 null mice are 
reduced, and as B splenocytes from these mice are unresponsive to BAFF and present impaired 
survival ex vivo [121-123]. Mice with basal IKKα activity but impaired responses to further 
activation of this kinase (IKKα-AA) display an intermediate phenotype, with B cells partially 
unresponsive to BAFF [105, 121, 124]. Conditional deletion of TRAF3 results in unrestricted p100 
processing and enhancement of BAFF mediated survival [125, 126]. Conversely, mice with 
constitutive expression of p52 have more B cells [127]. At the most fundamental level, it appears 
that each receptor exerts differential effects through the independent engagement of different NF-
κB systems. However, downstream integration seems to be a likely outcome given that p100, the 
major substrate for BAFFR signaling, is a target of the classical pathway [128].  
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Fig 6. Signaling downstream of BCR. Taken from review by Kurosaki et al. (Molecular Immunology 2011). 
 
 
 
Fig 7.  NF-κB signaling 
downstream of BAFFR. Taken 
from review by Mackay et al. 
(Nature reviews 2009) 
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Taken together, these data indicate that the non-canonical NF-κB pathway is a key downstream 
element of BAFF signals. However, the canonical NF-κB pathway can also mimic BAFF signaling, 
as inactivation of NEMO in B cells, and to a lesser extent NF-κB1, also leads to B cell deficiency, 
whereas expression of constitutively active IKKβ enlarges the peripheral B cell compartment and 
promotes survival of B cells ex vivo, which do not display further survival increase in response to 
BAFF. The sole presence of a functional BCR is not sufficient to allow mature B cells to survive, as 
observed in BAFFR-deficient B cells. Likewise, the expression of BAFFR alone does not allow for 
the survival of mature B cells in which the BCR has been conditionally deleted [129].  
 
There are signaling pathways other than NF κB downstream of BAFF. BAFF-mediated survival has 
been linked to upregulation of anti-apoptotic proteins like members of the Bcl-2 family, increased 
expression of anti-apoptotic proteins, to integrin-mediated localization of B cells in the marginal 
zone and to T cell-independent antibody class switching (Reviewed in [130]).  
 
Other than B cell survival, BAFF could play a role in glycolysis, protein synthesis and cell growth, 
in part through the activation of the protein kinase mammalian target of rapamycin (mToR; also 
known as FRAP1) in the context of mToR complex 1 as shown in Fig 8. The resulting cascade of 
signaling events lead to cell growth or cell survival (Reviewed in [130]). 
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Fig 8. Signaling pathways downstream of BAFF receptors; Taken from review by Mackay et al. (Nature Reviews 
2009) 
 
A trimeric BAFF or APRIL binds to three different receptors to generate a signal but for productive 
signaling a binding is not enough (Reviewed in [130]). For example, binding of APRIL to TACI is 
ineffective unless it is further multimerized, by binding to heparin sulfate proteoglycans (HSPG) 
[64, 131]. Only BAFF 60-mer but not trimers signal through TACI, but both forms of BAFF can 
initiate BAFFR-mediated effects [49]. Data obtained from in vitro studies show that TACI requires 
multimeric ligands like BAFF 60-mers, HSPG-bound APRIL or membrane-bound ligands, to signal 
but not soluble, trimeric ligands. 
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Trimeric intracellular adapter proteins TNF receptor-associated factors (TRAFs) bind  several 
receptors, including BCMA, TACI and BAFFR (Reviewed in [130]). The stability of interaction 
between these TRAF molecules and receptors are enhanced by avidity effects upon binding TRAF 
trimer binds to three receptors held in the correct geometry by the ligand [132] as affinity of TRAF 
to a monomeric receptor is low. Signaling via TACI to activate NF-κB transcription factor require 
TRAF2 and TRAF6 binding and these molecules held in close proximity[133] This possible state 
can be obtained when at least six receptors are recruited. Signaling via BAFFR involves the 
activation of the non-canonical NF-κB pathway, which selectively recruits TRAF3 for the purpose 
of degrading it, thereby minimizing the need for higher order receptor clustering to obtain an effect 
[125, 134, 135]. These facts for intracellular signaling perhaps serve the basis for the hypothesis 
that oligomeric ligands are necessary to induce signaling via TACI because of the downstream 
molecular requirements.  
 
TACI is a strong stimulator of the classical NF-κB1 pathway unlike BAFFR which is a strong 
activator of the alternative NF-κB2 pathway and weak activator of the classical NF-κB1 pathway in 
primary B cells, (Reviewed in [130]). TACI signaling is important for specific B cell types [110]. 
TACI has a dual role to play in the regulation of mouse B cell development. Excess number of B 
cells have been found in TACI- deficient mice indicating the negative effect of TACI on the size of 
the B cell compartment in vivo (Reviewed in [130]) whereas on the other hand, TACI is required 
for efficient T cell-independent type II humoral immune responses. The expression of TACI is on 
innate B cells (including marginal zone and B1 cells) that are involved in T cell-independent type II 
immune responses. This hints towards the possibility that TACI provides positive signals for the 
maturation or survival of plasmablasts derived from these cells [110]. There is evidence of a tight 
connection between TLR activation and TACI expression. Some studies have shown that following 
BCR ligation, BAFF and APRIL receptor expression levels change suggesting that overall BAFF 
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receptor profiles and thus ligand sensitivity can be altered by activation cues [109]. BAFF receptor 
expression can be altered by TLR stimuli, but unlike BCR ligation, TACI expression is 
preferentially increased by TLR9 and TLR4 signals. Although both of these TLRs act through 
MyD88-dependent mechanisms to increase TACI expression, their downstream mediators and their 
target B cell subsets are different. Interestingly, only TLR4 relies on c-Rel and p50 to increase 
TACI expression, whereas TLR9 does not. Furthermore, although all follicular and marginal zone 
B cells up-regulate TACI in response to TLR9 stimulation, only marginal zone B cells and a subset 
of follicular B cells respond to TLR4. This study shows that BAFF and APRIL enhance viability 
among quiescent and BCR-stimulated B cells. However, although viability among TLR stimulated 
B cells is enhanced by BAFF but not APRIL, suggests that TACI but not BAFFR may share 
survival promoting pathways with TLRs. A latest study show that TACI may participate in 
immunoglobulin class switching by activating B cells through adaptor Myd88 downstream of the 
TLR pathway [136].  
 
The phenotype of BCMA–/– mice is not so severe. They are generally healthy, but the survival of 
the long-lived bone marrow plasma cells is impaired in these mice [116]. BCMA can also promote 
the antigen-presenting function of B cells [119], although TACI and BAFFR  can also participate in 
BAFF mediated up-regulation of MHC class II expression [49]. BCMA also signals via the 
classical NF-κB pathway, a TRAF5-, TRAF6-, NIK-. and IKK-dependent pathway [137]. BCMA, 
though known to be a type III transmembrane protein, has been found in a human malignant 
myeloma cell line not on the cell surface, but in a perinuclear structure that partially overlaps the 
Golgi apparatus [138]. Upon transient or stable transfection, BCMA could be found located on the 
cell surface, as well as in a perinuclear Golgi-like structure. Apart from the NF-κB pathway, 
overexpression of BCMA activates Elk-1, the c-Jun N-terminal kinase, and the p38 mitogen-
activated protein kinase. Co-immuno-precipitation experiments performed in transfected cells 
showed that BCMA associates with TNFR-associated factor (TRAF) 1, TRAF2, and TRAF3. 
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Analysis of deletion mutants of the intra-cytoplasmic tail of BCMA showed that the 25-aa protein 
segment, from position 119 to 143, conserved between mouse and human BCMA, is essential for 
its association with the TRAFs and the activation of NF-kappa B, Elk-1, and c-Jun N-terminal 
kinase. BCMA belongs structurally to the TNFR family. Its unique TNFR motif corresponds to a 
variant motif present in the fourth repeat of the TNFRI molecule [138]. 
 
 
1.3.5. BAFF and APRIL in pathological conditions. 
 
The involvement of BAFF in the pathogenesis of autoimmune diseases is well studied by BAFF 
overexpression in mice models, which leads to autoimmune disease mimicking rheumatoid arthritis 
(RA), systemic lupus erythematosus (SLE) and primary Sjogren’s Syndrome (pSS) [42, 139, 140], 
as well as predisposition to B cell lymphoma increase in occurrence of B cell lymphoma [141]. In 
humans, an increased serum level of BAFF was reported in patients with RA and SLE [142], but 
the more consistent findings concerned pSS [42, 140, 143-145] with an increase in BAFF level 
reported in all reported findings  of patients with pSS [140, 146-148]. Studies have tried to establish 
the correlation between the serum level of BAFF and serum level of immunoglobulins and titers of 
autoantibodies and the major cell types influenced by BAFF involved in these pathologies [149, 
150]. 
It was mostly believed that BAFF is produced by cells of myeloid origin like monocytes, 
macrophages, dendritic cells, and neutrophils as well as unidentified non bone marrow–derived 
radiation-resistant cells, until some studies reported astrocytes as producers of BAFF and 
established a role of BAFF in B cell survival in multiple sclerosis and primary CNS lymphoma [85, 
151]. The same group also reported the presence of BAFF in Wegener’s granulomatosis. Other than 
BAFF, BAFF receptors have been also found up-regulated in multiple sclerosis. BAFF and APRIL 
being identified as major players in B lymphocyte survival led to the investigation of their role in 
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the pathogenesis of hematological B cell malignancies. It was found that they are produced by 
leukemic cells as well as the tumor microenvironment or both [152]. In addition to increased serum 
levels of BAFF and APRIL, the receptors of these ligands were also found up-regulated in various 
non Hodgkin’s lymphoma and multiple myelomas apart from being present in lymphoproliferative 
disorders [78, 84, 93, 153-155]. In a much aggressive form of B-CLL BAFF and APRIL can evade 
apoptosis in an autocrine manner [156].  Some studies also indicate that BAFF and APRIL can be 
produced by nurse-like cells, promoting lymphocytic leukemia in a paracrine manner [92]. APRIL 
is also implicated in multiple myeloma [157] and in promoting B1 cell related neoplasms [158]. 
 
1.4.1. First discovery of heteromers in the TNF family. 
 
TNF family ligands have been described to usually assemble as homotrimers. The first proof of 
existence of heteromeric complex formation among the TNF ligands came from the 
characterization of Lymphotoxin alpha-lymphotoxin beta complexes. Like many other TNF 
ligands, lymphotoxin alpha forms both soluble and surface-bound complexes in humans. LTα was 
originally believed to be functionally identical to TNF. Interestingly, biochemical characterization 
of a surface form of LT-a showed that it was a complex of two proteins [159, 160]. Surface LTα is 
does not retain the transmembrane region like TNF but is attached to the surface by forming a 
complex with surface LTβ [161, 162]. The predominant form of membrane bound LTα on human 
cells is believed to be most likely a trimer with an LTα1β2 stoichiometry, whereas the LTα2β1, form 
is a relatively minor component. LTβ-R a receptor for surface LTα has been identified and binds to 
LTα1β2 [163]. Trimeric LTα binds to TNFR1 and TNFR2 i.e. the 55–60- and 75–80-kDa forms of 
TNF receptors (referred to in the original paper as TNF-R55 and TNF-R75 [164]. The minor form 
of surface LT with LTα2β1 composition can bind to both TNFRs. The LTβR is structurally related 
to both TNFR1 and TNFR2, yet does not recognize either soluble LTα or TNF. The phenotypic 
differences between LTα- and LTβ-null mice led to the conclusion that the LT and TNF systems 
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are distinct. In general, the hLTα gene is expressed solely by lymphocytes and not by monocytes 
[165]. The expression of both LTα and LTβ in cell lines is dramatically induced following cell 
activation whereas LTβ gene transcription may be more constitutive, at least as revealed by analysis 
of primary murine splenocytes [166, 167]. LTα-deficient mice were found to lack lymph nodes 
[168], the spleen did not show the clear demarcation between T and B cell-rich regions, and 
germinal center formation was impaired [169, 170]. Furthermore, since the administration of 
soluble LTβR-Ig, but not TNF-R55-Ig treatment, during development could mimic much of the 
phenotype of the LTα- null mouse, it led to the conclusion that the surface LTαβ complex is 
involved in lymph node organogenesis and splenic organization [171]. Surface LTαβ plays a role in 
maintenance of splenic organization in the mature system as demonstrated by the use of the soluble 
LTβR to inhibit LTαβ function in normal adult mice [172]. Surface LTαβ complex possibly does 
not account for all the developmental functions of LTα, administration of LTβR-Ig, led to inhibition 
of LT function during development while it did not affect the development of mesenteric lymph 
nodes [171]. LTβ-deficient mice also possess mesenteric and cervical lymph nodes [173]. 
Expression of the LTα gene in transgenic mice under the control of the rat insulin promoter led to 
the formation of lymph nodes in unusual locations, indicating that LTα is involved in lymph node 
neo-organogenesis [174]. The fundamental signaling process follows the pattern of the TNF family 
where trivalent ligand engages together two or more receptors. The arrangement of the intracellular 
domains of the receptors are perhaps altered upon oligomerisation by the extracellular domains 
which is in turn translates into some further signal [175]. In the case of LTα1β2 on a cell surface, the 
three receptor binding clefts are not equivalent and therefore elucidating which receptors bind to 
which cleft serves as an important explanation of how signaling can occur. Efforts to produce 
recombinant soluble LT heteromeric complexes allowed the characterization of key aspects of this 
unique structure [176].  
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1.4.2. BAFF and APRIL heteromers. 
 
Elevated serum levels of BAFF have been associated with several pathologies, including 
autoimmune diseases. While dosing the amount of BAFF and APRIL in sera of patients with 
systemic immune-based rheumatic disease, researchers obtained different results depending on the 
anti-BAFF antibodies used in an ELISA assay [177]. They developed and characterized various 
monoclonal and polyclonal antibodies to measure elevated levels of the ligands BAFF, APRIL or 
BAFF-APRIL heteromers. These antibodies allowed the affinity purification of BAFF-APRIL 
heteromers produced from mammalian expression systems. The purified heteromers could then be 
tested for their biological activity by heteromer-induced proliferation on primary B cells. The 
activity could be inhibited by TACI-Ig but not BCMA-Ig or BAFFR-Ig. Based on this and other 
results confirming interaction based on co-expression in mammalian cell lines they concluded that 
BAFF-APRIL form heteromers and can be detected in serum and can be differentially recognized 
by adequate antibodies. However these studies could not highlight on the various stoichiometric 
forms of the heteromers and their receptor binding specificities.  
More recently, a study [178] described the generation of recombinant BAFF APRIL heteromers 
using a novel trimerization domain [179] [180]. After proteolytic processing, untagged BAFF 
APRIL heteromers was obtained for further biochemical characterization. Owing to the limitation 
of their method of production, the heterotrimers had a predominant stoichiometry of 2 APRIL to 1 
BAFF and a very small fraction of 1APRIL to 2 BAFF. The heterotrimers were less-potent inducers 
of B-cell proliferation than were BAFF or APRIL. They developed a bead based immunoassay and 
using the recombinant heterotrimers as a reference of quantification they measured endogenous 
heterotrimers in sera of patients with autoimmune diseases. Their studies indicate that serum levels 
of heterotrimers increased as disease state worsened as observed with respect to clinical parameters 
usually measured in SLE.  
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1.5. BAFF/APRIL inhibitors. 
 
(Reviewed in [181-184]) In certain autoimmune diseases blockade of BAFF leading to some 
improvement in disease prognosis has been achieved. Like in SLE, which is a systemic 
autoimmune disease in which the loss of tolerance to nucleic acids and their binding proteins, 
results in the generation of autoantibodies that initiate tissue-damaging inflammation. Current 
treatments for SLE are suboptimal with significant side effects. A human antibody targeting BAFF 
and overall B cell survival named Belimumab has been approved by the FDA and has been reported 
to have modest efficacy in phase II clinical trial. Mouse models of autoimmune diseases have 
shown the impact or BAFF/APRIL inhibition both at early and late stages of the disease [185, 186]. 
Using soluble receptors of BAFFR-Ig and TACI-Ig  (Atacicept) it was observed that the onset of 
the disease could be delayed effectively but reversal of established disease is more difficult to 
achieve and depends on the amount of concomitant systemic inflammation [187]. All therapeutic 
strategies however are inefficient to prevent both autoantibody formation as well as its deposition in 
kidneys, though they are effective in B cell depletion resulting in reduction of secondary lymphoid 
organ size and thereby reduction in total number of T and dendritic cells. In Lyn-deficient mouse 
[188], there is evidence that BAFF inhibition directly inhibits T cell activation, an effect that has 
not been observed in the other SLE strains. By contrast, in MRL/lpr mice, autoantibody producing 
plasma cells that are mostly generated in extra follicular foci are highly dependent on BAFF and 
APRIL and serum IgG autoantibody levels plummet within 1-2 weeks of receiving TACI-Ig; this is 
associated with a marked decrease in renal immune complex deposition and improved survival. T 
cell activation and interstitial nephritis are not affected by TACI-Ig in this strain [189]. These 
studies highlight the heterogeneity of responses to BAFF and BAFF/APRIL inhibition in multiple 
murine models of SLE and suggest that there may be subsets of humans that respond better to 
BAFF inhibition than others. Both Belimumab and Atacicept or TACI-Ig have been used for the 
treatment of rheumatoid arthritis [190, 191] (Reviewed in [181]). In Phase II studies Belimumab 
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had a modest effect on disease activity whereas no effect was observed in Phase II studies with 
TACI-Ig. In a phase II study, moderate, but not high or low doses of a different anti-BAFF antibody 
(LY2127399; Eli Lilly) that blocks both soluble and membrane BAFF, had beneficial effects in RA 
similar to that of TNF blockers (M Genovese, abstract 1923 presented at American College of 
Rheumatology Meeting, Philadelphia, 2009). A clinical trial of LY2127399 began in 2009 and is 
ongoing. The clinical efficacy of Belimumab, as evaluated by the SLE responder index, was 
demonstrated at week 52 in two large phase III clinical trials (BLISS-52 and BLISS-76), as well as 
by a decrease in severe flares and steroid-sparing effects [192]. Mechanistic studies in humans have 
shown that, as predicted by the mouse physiology, and based on its selective inhibition of BAFF, 
Belimumab depletes naive and transitional B cells within the first 6 months of treatment and 
depletes IgM+ memory B cells and IgM producing plasma cells with delayed kinetics but has no 
effect on class switched memory B cells even after 2 years of treatment [193],[194]. The effect of 
drug on T cell activation pathways and on monocytes remains to be determined. An important 
difference between the mouse and human/primate studies is that the kinetics of B cell depletion 
takes much longer in humans and is associated with delayed shrinkage of lymphoid organs [194]. 
This is consistent with the apparently delayed onset of action of Belimumab. 
BAFF overexpression has been detected in the brains of mice and patients with multiple sclerosis 
[195] and TACI-Ig had a beneficial effect in a mouse model of MS, though a phase II study of 
Atacicept for MS had to be terminated because of disease worsening (www.clinicaltrials.gov). It 
raises questions about the beneficial effects of B cell depletion in MS using anti-CD20 antibodies. 
Whether the negative effect of Atacicept was due to a decrease in Type I IFN (which is used for 
treatment in MS and increases serum BAFF levels) [151], or alterations in other cytokines such as 
IFN-γ or IL-10 remains unexplained. 
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2. Materials and methods 
Mice 
Mice were handled according to Swiss Federal Veterinary Office guidelines, under the 
authorization of the Office Vétérinaire Cantonal du canton de Vaud. 6-8 weeks-old C57Bl/6 mice 
were purchased from Harlan. TACI -/-, TACI -/- x BCMA -/- and BAFF -/- in the C57Bl/6 background 
(kindly provided by Martin Scott and Susan Kalled, BiogenIdec, Boston) were bred in the animal 
facility of the Department of Biochemistry of the University of Lausanne. 
 
Plasmids and plasmid construction. 
Plasmids used were form the collection of group Schneider and are identified by the prefix ps 
followed by a number. Some of these plasmids, especially mammalian expression vectors for Fc-
ligands, Flag-ligands, Receptor-Fc and receptor-GPI have been published [40], and details for 
others can be found in group Schneider’s plasmid register (available upon request). Plasmids 
produced in the frame of this work were constructed according to standard molecular biology 
techniques and are briefly described here. Plasmid maps are provided in Annex A. Plasmids for the 
expression of single chain TNF family members were constructed on a modular basis and comprise 
a) a N-terminal sequence that can be i) a signal peptide followed by a Flag tag, ii) a signal peptide 
followed by the Fc portion of human IgG1, excluding the stop codon or iii) the intracellular 
domain, transmembrane domain and part of the stalk of human BAFF, but excluding the TNF 
homology domain; b) the TNF homology domain of a TNF family ligand, excluding the Stop codon 
(Mono 1); c) a linker with sequence GGGGS; d) the TNF homology domain of a TNF family 
ligand, excluding the Stop codon (Mono 2); e) a linker with sequence GGGGS; f) the TNF 
homology domain of a TNF family ligand with its Stop codon (Mono 3); g) optionally, an IRES-
EGFP sequence. Typically, Mono 1 was first inserted in the vector of interest as a PstI/BamHI (or 
SalI/BamHI) fragment. Mono 2 was then inserted in the BamHI site 3’ of Mono 1 as a 
BglII/BamHI fragment. Its insertion in the correct orientation was checked by restriction. Note that 
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BglII and BamHI generate identical overhangs that can be ligated together without reconstituting 
either a BamHI or a BglII site. Mono 3 was then inserted after Mono 2 as a BamHI/EcoRI 
fragment, followed by an IRES-EGFP in an EcoRI/XbaI cassette. The following plasmids were 
generated: Fc-BAFF-BAFF-BAFF (ps2680), Fc-APRIL-BAFF-BAFF IRES-GFP (ps2883), Fc-
BAFF-APRIL-APRIL IRES-GFP (ps2877), Fc-APRIL-APRIL-APRIL IRES-GFP (ps2879), Flag-
BAFF-BAFF-BAFF IRES-GFP (ps2890), Flag-APRIL-BAFF-BAFF IRES-GFP (ps2886), Flag-
BAFF-APRIL-APRIL IRES-GFP (ps2889), Fc-APRIL-APRIL-APRIL IRES-GFP (ps2876). 
Representative plasmid maps are provided in annex A. 
Expression plasmids for full-length mBAFF with mutation E247K (ps2583) or E278K (ps2575) 
were prepared from a plasmid encoding full-length WT mBAFF (ps694). Plasmid maps are 
provided in annex A. 
 
Construction of a knock-in vector.  
A BAC clone containing the murine BAFF gene from the 129 mouse strain was purchased from 
Gene Service Cambridge (BAC BMQ-135D21) (ps2769). A 5663 bp SpeI fragment containing 
mBAFF exons 5 and 6 was excised from ps2769 and cloned in a modified pBluescript vector 
(ps2793) to yield plasmid ps2806. A PCR fragment containing the target mutation E247K was 
amplified by double PCR using ps2806 as template, cut with ApaI and cloned in a vector 
containing an ApaI cloning site to yield plasmid ps2839. A NeoR cassette flanked by LoxP 
recombination sites, kindly provided by Dr. Edith Hummler (Transgenic Animal Facility, 
University of Lausanne) (ps2787), was excised NotI/XbaI, blunted with Klenow enzyme, and 
cloned in the EcoRV site of ps2839 to yield plasmid ps2841. Finally, the ApaI fragment of ps2841 
was cloned in ps2806 to yield the targeting vector, ps2846, whose map is provided in annex A. 
mBAFF sequences located on the  5’- and 3’-edges of the targeting vector were amplified by PCR 
(using plasmids ps2806 and ps694 as templates, respectively) and cloned EcoRI/BamHI in 
pBluescript to yield ps2559 and ps2851. Maps are shown in Annex A. 
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Antibodies and recombinant proteins  
Unless specifically mentioned, recombinant proteins have been produced in house. The following 
proteins and antibodies have been used [applications are indicated in square brackets]: Flag-
mBAFF standard (Alexis APO-50N-040) [ELISA], anti-Flag M2 antibody (Sigma F3165) [WB], 
biotinylated anti-Flag M2 mouse IgG1 (Sigma F9291) [ELISA], mouse anti-human IgG Fc(gamma) 
fragment-specific (Jackson 209-005-139 or 209-005-098) [ELISA], horse radish peroxydase 
(HRP)-coupled streptavidin (Jackson 016-030-084 or eBioSciences) [ELISA],  HRP-coupled 
donkey anti-human Ig (H+L) (Jackson 709-036-149) [ELISA], HRP-coupled goat anti-human IgG 
(H+L) (Jackson 109-035-003) [WB], phycoerythrin (PE)-coupled goat anti-human IgG (SAB 
#2040-09) [FACS], PE-coupled goat anti-rat IgG (H+L) (SAB #3010-09) [FACS]. HRP-coupled 
anti-mouse [WB]. Rat IgG2a anti-TRAIL-R3 mAb572 [40] [FACS], rat IgM anti-human BAFF 
Buffy-2 [43] [WB] and mouse IgG1 anti-human APRIL Aprily 2 [64] [WB] were produced in 
house. Goat Fab’2 anti-mouse IgM µ chain (Jackson 115-006-020) [B cell stimulation]. Blocking 
rat IgG anti mBAFFR 9B9 was a kind gift from Antonius Rolink [196] [B cell stimulation]. Rat 
IgG1 anti mBAFF 5A8 (Alexis ALX-804-158) [ELISA] and biotinylated rat anti mBAFF IgG1 
1C9 (Alexis ALX-804-157B) [ELISA]. Polyclonal goat anti-mouse BAFF antibody (R&D 
AF2106) [WB]. 
 
Other reagents 
Reagents are listed with: Material; provider; catalogue number. [Methyl-3H]-thymidine (20 
Ci/mmol); PerkinElmer; NET027. [alpha-32P]-deoxycytidine 5’-triphosphate (dCTP, 3000 
Ci/mmol, 10 µCi/µl); Hartman; SCP-205. Phenazine methosulfate (PMS); Sigma; P9625. 3-[4,5-
dimethlythiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt 
(MTS); Promega; G1111. Lysozyme; Sigma Aldrich; L7651 G418 sulfate; Calbiochem; 345812. 
Pen/strep; Invitrogen; 15140-122. Polyfect; Qiagen; 301-105. SIGMAFAST OPD tablet set (o-
phenylenediamine dihydrochloride (OPD) and urea hydrogen peroxide tablets, Sigma, P9187). Pre-
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stained protein ladder for Western blot; NEB; P7703S, Peptide-N glycanase F (PNGaseF); 
(500’000 units/ml); NEB; P0704. Dual luciferase reporter assay system, Promega; E1910 
(containing 5 x concentrated passive lysis buffer, 50 x concentrated Stop and Glow solution to be 
reconstituted with Stop and Glow buffer just before use, and luciferase assay substrate to 
reconstitute, aliquot in 0.5 ml black tubes and store at -70°C). Liquemine (heparin solution, 5000 
IU/ml); Roche Pharma;B01AB01, TaKaRa LA polymerase (5U/ml); TaKaRa RR002. B cell 
isolation kit (negative selection); Miltenyi; 130-090-862.  
 
Cells and cell lines. 
Human embryonic kidney (HEK) 293T cells were grown in DMEM Glutamax supplemented with 
10% FCS. Chinese hamster ovary (CHO) cells and stable CHO transfectants were grown in 
DMEM-F12 (Gibco #31331) supplemented with 2% FCS and 0.2% NaHCO3. Jurkat or Fas-
deficient Jurkat (JOM2; a kind gift of Olivier Micheau, University of Dijon, France) cells lines 
expressing receptor:Fas fusion proteins (Jurkat-hBCMA:Fas-2309 cl13 [49], JOM2-hBAFFR:Fas-
2308 cl21, JOM2-hBAFFR:Fas-2308 cl11.1, JOM2-mBAFFR:Fas-2922 cl7, JOM2-hTACI:Fas-
2455 cl112) were cultured in RPMI supplemented with 10% FCS. Primary mouse B splenocytes 
were cultured in RPMI supplemented with 10% FCS and 0.5 mM β-mercaptoethanol. All media 
contained 5 µg/ml each of penicillin and streptomycin. 
 
Establishment and screening of stable CHO clones. 
Stably transfected CHO cells were generated as follow: 2 x 105 cells were seeded in a well of a 6-
well plate in 3 ml medium and left to attach overnight. The next day, medium was aspirated and 
replaced with 1.5 ml fresh medium. 1.5 µg of plasmid of interest was mixed with 100 µl medium 
(no FCS, no antibiotics) and 10 µl Polyfect for 5 min at room temperature (RT), after which time 
600 µl of complete medium was added and the mixture transferred to cells. 8 h later, supernatant 
was removed, cells were washed with PBS and 3 ml complete medium was added. 48h later, cells 
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were selected with medium containing 500 µg/ml of G418. After 2 passages in selection medium, 
resistant cells were cloned by inoculating 6 cm culture dishes with 4 ml of cells diluted 1/4000, 
1/800 and 1/300. When clones were clearly discernable and big enough, 12 of them (or sometimes 
more) were randomly selected, except in cases where plasmids contained an IRES-GFP, in which 
case green clones were identified by fluorescence microscopy. Clones were detached with a pipette 
mounted with a bend tip and transferred in wells of 96-well plates. Once clones became confluent, 
they were maintained for two additional weeks with bi-weekly passages. 20 µl of 2 weeks-old 
supernatants were analyzed for the presence of the protein of interest by western blot analysis with 
anti-Flag or anti-hFc. In some cases, proteins of interest were detected by ELISA. The best clones 
were amplified and frozen.   
 
Production of recombinant proteins 
Production by transient transfections: 
293 T cells were transfected with the calcium phosphate method. Briefly, confluent 293T cells were 
diluted 1/8 in 10 cm culture plates in 8 ml of DMEM 10% FCS and transfected 8 to 24 h later. For 
transfection, 7 µg of plasmid of interest and 1 µg of an EGFP expression plasmid (ps515) were 
mixed with 50 µl of 2.5 M CaCl2 and water was added to 500 µl. 500 µl of 2 x HeBS solution (50 
mM HEPES free acid, 280 mM NaCl, 1.5 mM NaHPO4, pH to 7.05) was added dropwise while 
vortexing and added within 1 min to 293T cells. Cells were washed 16 h later and cultured either in 
serum-free OptiMEM medium or in DMEM, 10% FCS. Supernatant were harvested after 7 days. 
When required, supernatants in OptiMEM were concentrated using centrifugal concentrators with 
cutoff at 30 or 10 kDa (Millipore, #UCF801024).    
Production from stably transfected CHO clones: 
Stable cell lines of interest were amplified and cultured according to the following scheme: 1 
confluent 10 cm plate in 8 ml medium was used to inoculate two 16 cm plates in 30 ml medium, 
which themselves were used, once confluent, to inoculate one 2 L roller bottle in 1 L medium. 
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Roller bottles were incubated for 14 days at 37°C under rotation at 3.5 rotations per minute, after 
which time cells were decanted, supernatant was centrifuged at 3000 rpm in 50 ml tubes, filtered at 
0.22 µm, supplemented with 0.05% NaN3 and kept at 4°C until purification. 
 
Affinity purification of Flag- and Fc-tagged proteins 
Fc-tagged proteins were purified from stable cell supernatants using 1 or 5 ml HiTrap Protein A-
Sepharose columns (GE Healthcare), and Flag-tagged proteins were purified on 1 ml anti-Flag M2-
Agarose columns (M2-Agarose gel was from Sigma, and HiTrap columns were prepared by GE 
Healthcare). Columns were equilibrated in 50 mM sodium-phosphate buffer pH 7.05 (buffer A), 
and supernatants loaded overnight with a peristaltic pump. Columns were washed with 5 volumes 
of buffer A and eluted with 50 mM Na-citrate pH 2.7 (buffer B). In some cases, for Fc-tagged 
proteins, elution was performed with a 30 to 70% gradient of buffer B over 10 column volumes, 
followed by a wash with buffer B using an AktaPrime liquid chromatography system (GE 
Healthcare). Eluted fractions of interest were neutralized with 1/10 volume of 1 M Tris-HCl pH 9, 
concentrated and their buffer exchanged for PBS. When required, the flow through was loaded 
again onto the column until depletion of the protein of interest. Eluted fractions of interest were 
pooled, proteins were concentrated and buffer exchanged to PBS with a centrifugal concentrator. 
The proteins were then sterilized by filtration at 0.22 µm on low protein binding filters (Millex-GV, 
SLGV013SL). Protein concentration was determined by A280 using extinction coefficient calculated 
for the mature protein sequence using the Protein Analysis Toolbox option of the MacVector 
progam, assuming that all Cys residues appear as half-cystines. All columns were stored in 20% 
EtOH, immersed in 20% EtOH.  In some cases, 0.5 M NaCl was added to both buffer A and B, 
without much incidence on the entire process.  
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Gel permeation chromatography. 
Purified proteins were concentrated to 200 to 300 µl, loaded onto a Superdex-200 gel permeation 
chromatography column (GE Healthcare) equilibrated in PBS and eluted at 0.5 ml/min in PBS with 
1 ml fraction collection and online UV monitoring at 280 nm. Fractions of interest were pooled, 
dosed and sterilized by filtration as required. A similar protocol was used for serum-free, 
concentrated cell supernatant in OptiMEM.  
 
Protein precipitation. 
500 µl of fractions eluted from the Superdex-200 column were supplemented with 20 µl of 1 mg/ml 
lysozyme and precipitated for 10 min on ice with 50 µl of 60% ice-cold trichloracetic acid (final 
conc ~5%). Samples were centrifuged at 13000 rpm for 5 min at 4°C in a tabletop centrifuge. 
Supernatant were discarded, tubes were briefly spun again and any supernatant remnants removed. 
Pellets were dissolved in reducing SDS-PAGE sample buffer for western blot analysis. When 
sample buffer turned yellow, an adequate volume of 1 M Tris-HCl pH9 was added to neutralize 
acid. 
 
ELISA 
A generic method is described first, followed by specific protocols. ELISA were performed in 96 
well Nunc maxisorp plates coated with proteins or antibodies in 100 µl of 50 mM NaHCO3 pH 9 
(carbonate buffer) or in PBS. Plates were saturated with 350 µl of 4% powdered skimmed milk in 
PBS, 0.5% Tween-20 (block buffer) for 1 h, unless mentioned otherwise. Plates were washed 4 
times with PBS, 0.05% Tween-20 (wash buffer). Ligands, purified or in cell supernatants, were 
adjusted to 100 µl with 0.4% milk in PBS 0.05% Tween-20 (incubation buffer) and incubated for 1 
h at 37°C unless stated otherwise. Plates were washed 4 times with wash buffer. Revealing reagents 
in 100 µl of incubation buffer were added as required for 1 h at 37°C, in two steps if required (e.g. 
biotinylated antibody followed by HRP-coupled streptavidin). Plates were washed 4 times with 
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wash buffer between each step and after the last incubation. Peroxydase activity was revealed with 
100 µl of OPD solution, and the reaction was stopped after colour development by the addition of 
50 µl of 2 N HCl. Absorbance was monitored at 490 nm with an ELISA reader. 
Detection of Flag-tagged ligands. 
Plates were coated with receptor-Fc fusion proteins at 1 µg/ml in carbonate buffer, followed by 
addition of Flag-tagged ligands in cell supernatant (usually 100 µl supernatant in DMEM-FCS or 
20 µl in OPTIMEM plus 80 µl incubation buffer) and revelation with biotinylated anti-Flag M2 
antibody at 0.5 µg/ml and HRP-conjugated streptavidin at 1/4000.  
Detection of Fc-tagged ligands. 
Plates were coated with mouse anti-human antibody at 5 µg/ml in carbonate buffer, followed by Fc-
tagged ligands in cell supernatants and revelation with HRP-coupled donkey anti-human antibody 
at 1/8000.  
Detection of heteromers. 
Plates were coated with mouse anti-human antibody at 5 µg/ml in carbonate buffer, followed by 
supernatants containing Flag-ligands and Fc-ligands and revelation with biotinylated anti-Flag M2 
antibody and HRP-conjugated streptavidin.  
Detection of mouse BAFF. 
Plates were coated overnight at RT with rat anti-mouse BAFF 5A8 at 3 µg/ml in PBS and blocked 
for 2 h. mBAFF-containing samples or purified Flag-mBAFF were then added for 3 h at RT. Bound 
mBAFF was detected with biotinylated rat anti-mouse BAFF 1C9 at 2 µg/ml in incubation buffer 
for 2 h at RT, followed by HRP-conjugated streptavidin.  	  
Immunoprecipitations 
0.5 to 1 ml of DMEM, 10% FCS supernatants of transfected 293T cells were mixed with 10 µl of a 
50% slurry of Protein A-Sepharose beads (GE Healthcare) or M2-Agarose beads (Sigma) and 
incubated for 1 h at 4°C on a rotating wheel. Samples were centrifuged for 1 min at 5000 rpm in a 
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tabletop centrifuge, beads were recovered with a wide-opening (cut) tip, loaded on micro-columns, 
washed with 4 x 200 µl of PBS and eluted with 15 µl of 50 mM Na-citrate pH 2.7. The eluate was 
neutralized and denatured with 5 µl of Tris 1M pH 9 and 10 µl of 3x concentrated reducing SDS-
PAGE sample buffer followed by heating for 3 min at 95°C.  
 
Enzymatic deglycosylation of proteins 
Immunoprecipitated, neutralized proteins were heated for 5 min at 95°C in PNGaseF denaturation 
buffer (1% of 2-mercaptoethanol and 0.5% of SDS). After cooling, samples were supplemented 
with 1% of NP40 and 50 mM of sodium phosphate pH 7.5 and digested overnight with or without 
500 Units of PNGaseF. Subsequently, SDS-PAGE sample buffer was added and proteins analyzed 
by western blotting. 
 
Western blotting. 
SDS-PAGE and Western blotting were performed according to standard procedures. Briefly, 
samples were resolved by electrophoresis at 200 Volts for 50-60 min on 12% or 15% 
polyacrylamide gels. A pre-stained protein ladder was used as molecular weight marker. Proteins 
were transferred by electrophoresis to nitrocellulose membranes for 1 h at 100 Volts. Membranes 
were stained briefly with Ponceau red, rinsed with deionized water, photocopied, saturated for 15 
min in block buffer (5% powdered skimmed milk in PBS, 0.5% Tween-20), probed with primary 
antibodies (Table 1) for 1 h at RT or overnight at 4°C in the presence of 0.05% azide, washed for 3 
x 15 min in PBS, 0.1% Tween-20, probed with secondary antibodies (Table 1) in milk for 1 h, 
washed and revealed with ECL reagent (GE Healthcare). In some instances, after revelation, blots 
were quenched by incubation overnight with sodium azide at 0.05% and H2O2 at 10%, rinsed with 
wash buffer and reprobed with adequate primary and secondary reagents. For detection, the co-
immunoprecipitated ligand was detected first, and the immunoprecipitated one second. 
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Table 1: Antibodies used for Western blot 
Antigen Primary antibody 
 (concentration or dilution) 
Secondary antibody 
 (dilution) 
Flag-tagged protein Anti-Flag M2 (1 µg/ml) HRP-anti-mouse (1/5000) 
Fc-tagged proteins HRP-anti-human (1/5000) --- 
hBAFF Buffy-2 (1 µg/ml) HRP-anti-rat H+L (1/5000) 
hAPRIL Aprily2 (1 µg/ml) HRP-anti-mouse (1/5000) 
mBAFF Goat polyclonal –R &D (0.5µg/ml)  HRP- anti-goat (1/5000) 
 
Cytotoxic assay. 
BAFF or APRIL preparations were titrated with 2-fold dilutions in 50 µl of RPMI, 10% FCS in 96-
wells cell culture plates. 50 µl of a confluent culture of receptor:Fas reporter cells (i.e. about 30’000 
to 50’000 cells per well) were added, and plates were incubated for 16 h at 37°C, 5% CO2. In some 
cases, anti-Flag M2 antibody was added at a final concentration of 1 µg/ml. After incubation, 20 µl 
of a 1:20 (v/v) mixture of PMS (0.9 g/ml in PBS) and MTS (2 mg/ml in PBS) was added to cells. 
After colour development (typically 2-5 h), A490 was monitored with an ELISA reader.  
 
NF-κB reporter assay. 
Confluent 293T cells were seeded in 96-wells culture plates at a 1/8 dilution in 100 µl of DMEM, 
10% FCS and left to adhere overnight. Medium was aspirated and replaced with 50 µl of fresh 
medium. Cells were transfected by adding 25 µl of a transfection mix, prepared as follows 
(quantities for 1 well): 0.65 µl of a plasmid mix containing a total of 70 ng plasmid (7.5 ng of NF-
κB luciferase reporter plasmid (ps1614), 7.5 ng of Renilla luciferase normalization plasmid 
(ps1615), 7.5 ng of an EGFP tracer plasmid (ps515), 25 ng of a full-length hBCMA expression 
plasmid (ps1303), the rest with empty PCR3 plasmid (ps015)), plus 3.25 µl DMEM without any 
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supplement, plus 0.35 µl of PolyFect. The mix was incubated for 5 min at RT before addition of 
20.7 µl of complete DMEM and addition to cells. 8 h later, medium was exchanged for fresh 
complete DMEM containing titrations of ligands of interest at the indicated concentrations. After 
24 h, cells were washed with 200 µl of PBS, lyzed in 50 µl of 1 x concentrated passive lysis buffer 
for 15 min on a shaking table. 25 µl of lysate was transferred to a black 96-well plate (PerkinElmer, 
6005270), 15 µl of firefly luciferase substrate was added and luminescence was monitored in a 
TopCount-NTX luminometer (Packard). 15 µl of Stop and Glow solution was then added and 
Renilla luciferase-generated luminescence was recorded again.  Ratio of firefly to Renilla luciferase 
activities were used to calculate the NF-κB fold-increase relative to unstimulated cells transfected 
with empty plasmid in place of BCMA. 
 
Flow cytometry. 
Receptor-ligand interaction assay. 
293T cell were co-transfected with the receptor-GPI of interest [hBAFFR (ps1589), hTACI 
(ps897), hBCMA (ps1467), hTNFR1 (ps1426), hEDAR (ps1431), hXEDAR (ps1432), hNGFR 
(ps1456), hKDR (ps1476), hDR6 (ps689), hTROY (ps1434), hRELT (ps1433), Mock (ps015)] and 
an EGFP tracer (ps515) [40]. Cells were detached by pipetting, transferred into round-bottomed 96-
well plates (about 350 µl/well corresponding to 2-3 x 105 cells) and centrifuged for 5 min at 1200 
rpm. Medium was aspirated, cells were resuspended in 50 µl of FACS buffer (PBS, 5% FCS) 
containing 0.1 µl of Liquemine and ligands of interest at the indicated concentrations, and 
incubated for 20 min on ice. 200 µl of FACS buffer was then added, cells were spun and 
resuspended in a) 50 µl of PE-coupled goat anti-human IgG at 1/500 in FACS buffer for 20 min on 
ice (for Fc-ligands) or b) 50 µl of M2-biotin at 1/500 in FACS buffer for 20 min on ice followed by 
a wash and staining with 50 µl of PE-coupled streptavidin at 1/500 in FACS buffer for 20 min on 
ice. After staining, cells were resuspended in 200 µl of FACS buffer and analyzed on a FACS scan 
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flow cytometer (BD Bioscience) using the Cell Quest program. Data was analyzed with the FlowJo 
application (Tree Star). 
Analysis of mature murine B cells. 
100,000 of total mouse splenocytes (prepared as described under “isolation of mouse B 
splenocytes”, but before MACS separation) were stained with anti-CD93-APC (AA4.1) at a 
concentration of 1/500 and anti-CD19 PECy5.5 (eBioscience 45-0193-80) at a concentration of 
1/500 in FACS buffer (PBS + 5% FBS). Cells were analyzed using the LSR II and SORP.  
 
Isolation of mouse B splenocytes. 
Spleens were homogenized in 8 ml of complete RPMI using a tight fitting Dounce homogenizer. 
Cells were transferred in a tube, and medium was added to 12 ml. Cells were centrifuged for 5 min 
at 1200 rpm (260 x g), resuspended in 3 ml of AKC buffer (150 mM NH4Cl, 1 mM KHCO3, 1 mM 
Na2-EDTA, pH 7.3) and incubated for 2 min on ice to lyse red blood cells. 6 ml of PBS, 2% FBS 
was added by spleen-equivalent. Cells were centrifuged, supernatant was discarded, the pellet was 
resuspended in 5 ml of PBS, 2% FCS, cells were filter cells through a 100 µm cell strainer and 
counted using a cell counter (Becton Dickinson). Cells were washed and resuspended at 108 
cells/ml in PBS, 2% FBS. A MACS B cell negative selection kit was used for isolation of B cells. 
Cells were added in 40 µl of MACS buffer/107 cells to which 10 µl of biotin beads/107 cells were 
added and incubated at 4 °C for 15 min. This was followed by addition of 30 µl of MACS 
buffer/107 cells to which 20 µl of anti-biotin beads/107 cells were added and incubated at 4°C for 
another 15 min. Cells were washed with 1-2 ml of MACS buffer/ 107 cells. In the meantime MACS 
LS column were equilibrated on a MACS magnet with 3 ml of MACS buffer. Cells were 
resuspended with MACS up to 500 µl for 108 cells and loaded onto the LS column. The column 
was washed with 3 ml of MACS buffer three times. Cells were spinned, counted and used for B cell 
proliferation assay. Generally B cell yield was 30-50% of the total splenocytes.  
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 [3H]-thymidine incorporation assay 
Ligands of interest were serially diluted in 200 µl of B splenocyte proliferation medium (RPMI 
10% FCS, 0.5 mM β-mercaptoethanol, antibiotics) supplemented with 2 µg/ml of anti-µ chain 
antibody. 100’000 splenic B cells purified by MACS with the B cell negative selection kit were 
added per well in 200 µl of medium. When required, anti-Flag M2 antibody or anti-BAFF-R 9B9 
antibody were added at a final concentration of 1 µg/ml and 0.25 µg/ml, respectively. Cells were 
grown for 48 h, after which time 1 µCi of tritiated thymidine was added per well and cells were 
cultured for an additional 18 h. Cells were harvested on white OptiPlate 1536 (Perkin Elmer 
6004290) with a 96-well plate harvester (Packard). Plates were dried before the addition of 50 µl of 
scintillator MicroScint TM 40  (Perkin Elmer 6013641). Radioactivity was counted with a Top 
Count-NTX liquid scintillation counter (Packard). 
 
ES cells screen by PCR 
Mrs. Anne-Marie Mérillat at the Transgenic Animal Facility of UNIL electroporated embryonic 
stem (ES) cells with the targeting construct, performed the selection, cloned cells and extracted 
genomic DNA from replicate cultures in six 96-well plates. 
Positive clones were screened by PCR using primers JT7164 (5’-CCTTCTATCGCCTTCTTGAC-
3’) and JT7165 (5’-GTGGAACAGATAAGGTGCCT-3’) under the following conditions: 
0.8 µl of ES cell gDNA diluted 1/15 in H2O 
1.8 µl of 10x TaKaRa PCR buffer   
2.88 µl of TaKaRa 2 mM each dNTP solution 
0.029 µl JT7164 at 100 µM 
0.029 µl JT7165 at 100 µM 
0.11 µl TaKaRa LA polymerase (5 U/ml) 
H2O to 18 µl 
In some cases, an additional primer (JT7162 3’-ACCCTGTTCCGATGTATTCA-5’) was added in 
the reaction (to amplify the WT allele). 
 
PCR amplification program: 
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1.- 3 min at 95°C 
2.- 30 sec at 95°C 
3.- 30 sec at 64°C (with 0.5°C decrease per cycle) 
4.- 2 min at 68°C (cycle 19 x to point 2.-) 
5.- 30 sec at 95°C 
6.- 30 sec at 54°C 
7.- 2 min at 68°C (cycle 29 x to point 5.-) 
8.- 7 min at 72°C 
9.- Store at 10°C 
 
Amplified DNA products were analyzed on agarose gels stained with ethidium bromide. 
 
Screen of ES cells by Southern blot 
30 µl of genomic DNA (from one well of a 96 well plate) was digested O/N with 40 U of HindIII 
restriction enzyme in a final volume of 40 µl in the presence of 1 mM spermidine. Samples were 
mixed with 8 µl of TAE loading buffer, loaded on a 1% TAE agarose gel and submitted to 
electrophoresis at 140 V for several hours in TAE buffer (40 mM Tris-Acetate at ~pH8.5, 1 mM 
EDTA). One lane with standards was cut and stained independently with GelRed (Biotium), while 
the remaining of the gel was treated under gentle agitation for 10 min in 0.25 N HCl, then 30 min in 
0.4 M NaOH, then 20 min in neutralizing buffer (500 mM Tris-HCl pH 7.2, 1.5 M NaCl, 1 mM 
EDTA). Hybond membranes were wet in water, then in 20 x SSC buffer (0.3 M Na3Citrate, 3 M 
NaCl). The gel was placed upside-down on a plexiglass plate covered with 2 layers of blotting 
paper dipping in 20 x SCC buffer. The paper and the side of the agarose gel were covered with a 
plastic film and the gel covered with the Hybond membrane, then 2 layers of wet blotting paper, 2 
layers of dry blotting paper, a bunch of absorbing paper, a plate and a weight. After blotting O/N, 
membranes were recovered and autocrosslinked with UV at 1200 J. Membranes were wet in 25 
mM sodium phosphate pH 7.2, 1 mM EDTA and added together with 15 ml of pre-hybridization 
solution (5.25 ml of 20% SDS, 7.5 ml of 1 M sodium phosphate pH 7.2, 150 µl 0.5 M EDTA, 750 
µl of  5% powdered skimmed milk, 1.35 ml H2O) in a hybridization tube and incubated for 30 min 
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or more at 65°C in a rotating oven. The radioactive probe was prepared as follows: 18 µl of a 
HindIII/BamHI fragment of ps2859 at 4.4 ng/µl was heated for 5 min at 95°C. After cooling, 3 µl 
of hexanucleotide mix (Roche, 11008404001), 3 µl of dNTP at 0.5 mM each (except dCTP), 5 µl of 
[32P]-dCTP at 10 µCi/µl and 1 µl of Kleenow (2U/µl) (Roche 11008404001) were added and the 
tube was incubated for 30 min at 37°C. A ProbeQuant G-50 column (GE Healthcare, 28917924) 
was dried by centrifugation (2 min, 3000 rpm in a tabletop centrifuge). The labelled probe was 
mixed with 20 µl of ProbeQuant buffer, loaded onto the column and centrifuged for 2 min at 3000 
rpm. The eluate, containing the labelled probe with about 2/3 incorporation, was denatured for 5 
min at 95°C, then added to the membrane in pre-hybridization buffer and incubated O/N at 65°C in 
the rotating oven. The membrane was then washed at RT with wash solution (40 mM sodium 
phosphate pH 7.2, 1% SDS, 5 mM EDTA pH 8), washed at 42°C for 20 min in 20 ml wash 
solution, and for 30 min at 50°C in 20 ml wash solution. The membrane was wrapped in Saran and 
exposed for 16 h to 7 days at -80°C between two amplifying screens.   The membrane was then 
stripped in 0.2 M NaOH for 15 min at RT under agitation, followed by 25 mM sodium phosphate 
pH 7.2, 1 mM EDTA for 15 min at RT. The membrane was re-hybridized with a NeoR-specific 
probe as described above for the 5’ BAFF probe, except that washing steps in wash solution were 
performed at 50 and 55°C. 
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3. Results 
 
3.1.  A screen for heteromers in the TNF family of ligands. 
 
3.1.1. Aims and objectives of research. 
 
TNF family ligands assemble as homotrimeric ligands, which is the basic unit for signal 
transduction through their cognate receptors. However there is also evidence of heteromer 
formation within TNF family ligands. The first heteromer was observed between LTα and LTβ and 
the predominant form of this heteromer with a LTα1β2 stoichiometry was found to specifically bind 
to LTβR and provide essential signals for lymph node formation (described in section 1.3.1). In 
addition, recent reports also suggested the formation of heteromers between BAFF and APRIL  
(described in section 1.3.2). These data raise the intriguing possibility that other heteromers may 
exist among TNF family ligands. The aim of the study was therefore to screen for novel interaction 
partners among TNF family ligands, with the potential of identifying novel receptor specificities. 
 
Some TNF family receptors are orphan, i.e. have no identified ligand. NGFR is a typical TNF 
receptor family member with no known TNF ligand. Instead, NGFR binds low affinity ligands of 
the neutrophin family (NGF, BDNF and neurotrophins), and shares these ligands with a family of 
high-affinity tyrosine receptor kinases (TrkA, B and C) [197] that are unrelated to TNF receptors. 
NGFR also associates with the membrane proteins Lingo and NogoR to regulate axonal growth and 
neuronal apoptosis [198]. The existence of a bona fide TNF ligand for NGFR cannot be excluded at 
the moment. The TNF family contains three additional orphan receptors, TROY, RELT and DR6. 
These receptors may function in a ligand-independent manner, or may interact with ligands or 
protein outside the TNF family. Thus, TROY appears to associate with Lingo to mediate signal 
transduction [199]. It is unlikely that the orphan receptors have a cognate TNF ligand that has not 
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yet been identified, but it is possible that these receptors may be specific for a heteromeric TNF 
ligand. The aim of the study was also to test if newly identified heteromers would specifically bind 
an orphan receptor. 
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3.1.2. Screen to identify heteromers in the TNF family. 
 
A screen was carried out to detect heteromers in the TNF family. For this purpose, Flag-tagged or 
Flag ACRP30 tagged [200] and Fc-tagged ligands were co-expressed in mammalian 293T cells, 
and culture supernatants were screened by ELISA or Western blotting for the presence of Flag-
ligands, Fc-ligands, and heteromers thereof  (Fig.10). This approach detected the interaction of 
most TNF ligands with themselves, and of LTα	   with LTβ. However, no interaction was seen 
between BAFF and APRIL, and some positive controls gave inconclusive or negative results (e.g. 
TRAIL or CD30L with themselves), suggesting that the screen was not fully reliable (Fig10). In 
addition, the number of false positives was relatively high, as judged by the number of heteromers 
that were detected in one direction only (Flag-ligand X with Fc-ligand Y, but not vice-versa). 
Despite these limitations, the following heteromers were detected: APRIL-EDA1, APRIL-EDA2, 
EDA1-EDA2, LIGHT-FasL, LIGHT-LTα	   and LIGHT-LTβ	   (Fig 11). Data of all ELISA or 
immunoprecipitation assays have been described in Fig. 10.1,2,3,4. 
Some of these interactions were additionally confirmed by co-immunoprecipitation (Fig 12). 
 
 
 
Fig 9. Recombinant TNF ligands  
Schematic representation of Flag tagged ligands, Flag ACRP tagged ligands and Fc tagged ligands produced in 
mammalian cells. The extracellular segment containing the TNF homology domain is fused either to the Flag sequence 
or the constant region of human IgG1(Fc portion). The ACRP sequence was used in some ligands. It allows for the 
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hexamerisation and detection by ELISA (using cognate receptors) by strengthening the binding avidity. 
 
 
Fig 10.1.  ELISA screen for the detection of heteromers in the TNF family. 
Cell culture supernatants of 293T cells co-transfected with either Flag-hAPRIL (plasmid number 429) or Flag-hCD30L 
(plasmid number 873) and 19 different Fc-ligands (the numbers indicating the plasmid numbers used in the lab) were 
analyzed by ELISA. A. Flag-hAPRIL was captured with hBCMA-Fc and revealed with biotinylated anti-Flag followed 
by HRP-coupled streptavidin. B. Fc-ligands were captured with anti-Fc, and revealed with a second, HRP-coupled 
anti-Fc. C. Fc-ligands were captured with anti-Fc, and Flag-tagged ligands in the heteromer, if present, were revealed 
with anti-Flag. D. Flag-hCD30L was immunoprecipitated with anti-Flag, and revealed by Western blotting with anti-
Flag. Panels E and F are like B and C. Positive controls are suitable Flag-ligand e.g. Flag-hBAFF in panel A, purified 
Fc-hFasL at 1 µg/ml in panels B and E or Flag-hLTα	   / Fc-hLTβ	   in panels C and F. A circled cross indicates that at 
least one ligand in the transfection was not expressed. 
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Fig 10.2.  Screen for the detection of heteromers in the TNF family. 
Cell culture supernatants of 293T cells co-transfected with respective Flag or Flag-ACRP tagged ligands (with 
indicated plasmid numbers) on top of the panel and 19 diferent Fc ligands (the plasmid numbers are as per designated 
in the lab) were analysed by ELISA to detect the expression of Flag and Fc ligands and to detect the heteromer 
formation as in Fig 10.1. Red line indicates limit of the negative control and red star indicates absence of ligands either 
not expressed or not done (ND).  
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Fig 10.2.  Screen for the detection of heteromers in the TNF family. 
Cell culture supernatants of 293T cells co-transfected with respective Flag or Flag-ACRP tagged ligands (with 
indicated plasmid numbers) on top of the panel and 19 diferent Fc ligands (the plasmid numbers are as per designated 
in the lab) were analysed by ELISA and coimmunoprecipitation to detect the expression of Flag and Fc ligands and to 
detect the heteromer formation as in Fig 10.1. Red line indicates limit of the negative control, green line indicates the 
limit of the signal obtained from the empty vector control (as in some cases negative control is higher or lower than the 
mock 015 value). The red star indicates absence of ligands that are  not expressed , Not done is indicated as ND and 
black star indicates possible minimal expression.  	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Fig 10.3.  Screen for the detection of heteromers in the TNF family. 
Cell culture supernatants of 293T cells co-transfected with respective Flag or Flag-ACRP tagged ligands (with 
indicated plasmid numbers) on top of the panel and 19 diferent Fc ligands (the plasmid numbers are as per designated 
in the lab) were analysed by ELISA and coimmunoprecipitation to detect the expression of Flag and Fc ligands and to 
detect the heteromer formation as in Fig 10.1. Red line indicates limit of the negative control, green line indicates the 
limit of the signal obtained from the empty vector control (as in some cases negative control is higher or lower than the 
mock 015 value). The red star indicates absence of ligands that are not expressed , Not done is indicated as ND and 
black star indicates possible minimal expression.  
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Fig 10.4.  Screen for the detection of heteromers in the TNF family. 
Cell culture supernatants of 293T cells co-transfected with respective Flag or Flag-ACRP tagged ligands (with 
indicated plasmid numbers) on top of the panel and 19 diferent Fc ligands (the plasmid numbers are as per designated 
in the lab) were analysed by ELISA and coimmunoprecipitation to detect the expression of Flag and Fc ligands and to 
detect the heteromer formation as in Fig 10.1. Red line indicates limit of the negative control, green line indicates the 
limit of the signal obtained from the empty vector control (as in some cases negative control is higher or lower than the 
mock 015 value). The red star indicates absence of ligands that are  not expressed , Not done is indicated as ND and 
black star indicates possible minimal expression.  
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       Fig 11. Summary of interactions detected in the ELISA-based screen for heteromers. 
 
 
 
Fig 12. Co-immunoprecipitation of Flag-ligands and Fc-ligands to confirm the heteromers.  
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The indicated Flag-tagged and Fc-tagged ligands were co-transfected in 293T cells. Cell supernatants were 
immunoprecipitated with anti-Flag or protein A (anti-Fc) beads and revealed by western blot with anti-Flag or anti-Fc 
antibodies, as indicated. The green traingles represent formation of the expected homomer (positive control). The blue 
traingles indicate formation of the heteromer.    The open triangles indicate no heteromer formation (negative control). 
The black star indicates that the immunoprecipiatation did not work while the blue star indicates the signal on the IP 
anti-Flag and WB anti-Fc may be non-specific and it needs to be repeated (with a pre-clearing step).  
 
Co-immunoprecipitations (Fig. 12) were done to confirm the strong interactions as marked in red in 
Fig. 11 (summary of the screen). The ligands, which showed the interactions by ELISA, were re-
expressed in 293 T cells and supernatants were immunoprecipitated for either Flag or Fc followed 
by immunoblotting. As seen on the blots, interactions between Flag-APRIL and Fc-EDA1 showed 
some discrepancies. Upon immunoprecipitation of Flag and anti Fc the respective ligands were 
shown to be present by the western blot anti-Flag or anti-Fc, but their putative interaction partner 
co-IP along with them were not revealed. It is possible that the level of Flag APRIL in this 
transfection was low enough to sufficiently co-IP EDA1 along with it and vice-versa. However, 
immunoprecitpations of Flag EDA1 with the Fc-ligands APRIL, EDA1, EDA2 and with the 
negative control of Fc-GITRL clearly indicate an interaction. Also, the interaction of EDA2 with all 
its above-mentioned partners worked in both the directions. For interaction of LIGHT with FasL, 
TL1A, LTα	   and LTβ,	   co-immunoprecipitation was performed in one direction only, but indeed 
revealed some association between these ligands. 
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3.1.3. Screen for novel receptor specificity. 
 
Newly identified heteromers were tested for their putative binding to orphan receptors (Fig 13). For 
this purpose, a FACS based assay was used as described [40]. This assay requires no ligand or 
receptor-specific antibodies and no protein purification. The extracellular domains of the receptors 
are fused to the C-terminal portion of TRAIL-R3, containing 5 repeats of a 15 amino acid sequence 
followed by a GPI anchor addition signal that targets the receptor to the membrane. This portion 
can be recognized by a monoclonal antibody (rat anti-hTRAIL-R3, LEIA), that allows monitoring 
of surface expression of the fusion receptors by FACS (Fig. 13B). Fusing receptors to a glycolipid 
anchor circumvents problems associated with use of full-length receptors like induction of cell 
death, intracellular retention or secretion in the case of OPG and DcR3. The receptor-expressing 
cells co-express EGFP, while non-transfected EGFP-negative cells serve as internal negative 
controls. 
Cell supernatants of the heteromeric combination of ligands containing Flag and Fc ligands were 
used to stain the receptors. The heteromers showed no binding to any of the orphan receptors (Fig. 
13A) although orphan receptors are expressed (Fig. 13B). The activity for some of the ligands were 
confirmed by staining on their cognate receptors (Fig. 14) while this was not confirmed for the rest 
of the series though it is unlikely that the ligands are not active. 
	   63	  
 
 
Fig 13. Interaction of heteromers with orphan receptors 
Human receptor-GPI’s are expressed in 293T cells A. Binding of homotrimers to orphan receptors. Binding of  ligands 
to receptors was revealed with anti-human (Fc) PE-antibody B. staining with anti-h TRAIL3 (rat) antibody indicating 
receptor expression  and GFP expression indicating transfection efficiency. * Problem in staining/detection. 
 
 
 
Fig 14. Interaction of heteromers with cognate receptors 
Human receptor GPI’s were expressed in 293T cells with GFP like in Fig 13 and stained with supernatants  of ligands 
as indicated. Binding was detected with biotinylated anti-Flag (M2) antibody followed by PE coupled Streptavidin or  
anti human Fc-PE. Receptor expression is shown by staining with anti-TRAILR3 antibody.  A. Staining of Flag APRIL-
Fc APRIL, Flag APRIL-Fc EDA1, Flag APRIL-Fc EDA2 on BCMA and empty vector control B. Staining of Flag 
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EDA1-Fc APRIL, Flag EDA1- Fc EDA1, Flag EDA1-Fc EDA2 on EDAR and empty vector. * Binding of Flag APRIL-
Fc EDA1 revealed by Fc staining on BCMA was unexpected. This staining was not repeated for confirmation. 
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 3.2. Characterisation of BAFF and APRIL heteromers. 
 
3.2.1. Aims and objectives of research. 
As described in section 1.3.2, a few studies reported heteromer formation between the closely 
related ligands BAFF and APRIL. BAFF and APRIL heteromers were found in sera of patients 
with autoimmune diseases. The aim of the present study is to further characterize these heterotypic 
interactions with respect to receptor binding and signaling ability. 
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3.2.2. Single chain recombinant heteromers. 
 
3.2.2.1. Validation of single chain method. 
 
Based on the results of the screen (section 3.1.2), it seemed to be difficult to study BAFF and 
APRIL interactions using tagged ligands. Based on the studies of Klaus Pfizenmaier [201] single 
chain trimers were designed (Fig. 15A). The goal was to produce defined heterotrimers that can be 
used to test their binding to desired receptors or their activity for functional assays. In a single chain 
trimer, short peptides link the N- and C-termini of adjacent monomers that are spatially close one to 
each other (Fig. 15B). A Flag tag was attached to the N-terminus in place of the trans-membrane 
segment of the natural protein.  
	  
 
 
 
 Fig 15. Single chain trimers  Cloning and structure. 
A. Molecular cloning strategy of single chain trimers. Flag-tagged vector with HA leader sequence was used as 
backbone. THD’s of TNF ligands were cloned using the indicated restriction enzymes in a cloning cassette with linkers 
connecting the monomers. B. Predicted structure of single chain homotrimers and heterotrimers of BAFF and APRIL 
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As the C-termini of ligands can play a structural role in the THD, addition of linkers can potentially 
interfere with ligand folding, expression, secretion and/or function. Therefore single chain LTαβ 
heteromers were designed as positive controls to validate this strategy. Flag-tagged single chain 
LT-[ααα], LT-[ααβ], LT-[ββα] and LT-[βββ] were all expressed and secreted (Fig. 16 C) as seen by 
immunoblotting of cell supernatants. Interestingly, single chain heteromers displayed the expected 
receptor binding specificities, with LT-[ααα] binding to TNFR1 but not LTβR, and LT-[ββα] 
binding to LTβR (Fig 16 E).  
 
 
 
Fig 16. Validation of the single-chain heteromer strategy with lymphotoxin α  and β .  
A. Cartoon showing conventional Flag-ligands (three individual Flag-tagged monomers associated via non-covalent 
interactions) and single-chain Flag-ligands (the C-terminus of monomer 1 is linked by a short peptide sequence to 
monomer 2, that itself is linked to monomer 3). It is noteworthy that the cartoon reflects the close proximity of the N- 
and C-termini of adjacent ligands. B. Receptor-binding specificity of hTNF, hLTα and of the hLTαβ heteromer. C. 
Supernatant of 293T cells transiently transfected with single chain lymphotoxin homotrimers (Flag-hLT- [ααα] and -
[βββ]) or heterotrimers (Flag-hLT- [ααβ] and -[ββα]), or with conventional Flag-hLTα ± Fc-hLTβ were analyzed by 
	   68	  
western blotting with anti-Flag and anti-Fc antibodies. D. Experimental strategy used in panel E to monitor receptor-
ligand interactions by ELISA to measure binding of the indicated ligands to hTNFR1-Fc (left) or hLTβR-Fc (right). 
Ligand binding was revealed with an anti-Flag antibody. 
 
3.2.2.2. Size characterization of single chain ligands  
 
Binding of an heteromer to a receptor could be explained in two ways: either a heterotrimeric 
ligand really forms and displays the observed receptor-binding specificities, or the proteins form 
larger structures containing both homotrimeric ligands each of which can bind to its cognate 
receptor(s). 
 
 
	  
 
Fig 17. Schematic representation of how single chain ligands may assemble.  A. Single chain heterotrimer. B. 
Putative larger oligomer containing two homotrimers of the first ligand and one homotrimer of the second ligand. 
 
In order to reduce false positives coming from homotrimeric ligands formed in larger aggregates, 
single chain heteromers were fractionated by size exclusion chromatography, and eluted fractions 
were tested for their content of Flag-tagged protein by immunobloting and for their receptor-
binding specificity by ELISA. An irrelevant heteromer of BAFF and TNF was used as control. For 
all ligands, a peak at around 40 kDa was identified, which most probably corresponds to 
homotrimers or heterotrimers. Most ligands, including conventional and single chain Flag-TNF, 
also displayed higher molecular weight material called. The trimeric fraction of TNF and of single 
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chain TNF bound its cognate receptor, as expected (Fig 18 A and B). Regarding the receptor-
binding activity of the negative control BAFF-BAFF-TNF, it was exclusively found in oligomers, 
suggesting that this heteromer is indeed inactive and that the receptor binding is due to homotrimers 
of TNF and BAFF present in the oligomers (Fig. 18 C). 
Single chain APRIL-APRIL-BAFF heterotrimer bound BCMA (Fig 18 D). The later result 
indicates that the preparation of APRIL-BAFF heteromers of defined stoichiometry should be 
possible.  
 	  
Fig 18. Gel permeation chromatography of conventional and single chain Flag-ligands reveals the presence of both 
homo and heterotrimers and of higher molecular weight oligomers. Concentrated serum-free supernatants of 
transfected 293T cells (TNF and BAFF-TNF) or purified BAFF-APRIL heteromers were loaded onto a Superdex-200 
gel filtration column and eluted with PBS. Fractions of 1 ml were collected, of which one half was precipitated with 5% 
ice-cold trichloroacetic acid and analyzed by immunoblot with anti-Flag. The other half of the fraction was used to 
monitor receptor-binding by ELISA. A. Conventional Flag-TNF. B. Single chain Flag-TNF. C. Single chain Flag-
BAFF-BAFF-TNF heteromer. D. Single chain APRIL-APRIL-BAFF heteromer. Sizes of SDS-PAGE molecular weight 
(in kDa) are indicated on the left, and those of size exclusion chromatography on the top of the figures. Open 
diamonds: binding of Flag-ligands to TNFR1-Fc by ELISA [OD490]. Open triangles: binding of Flag-ligands to 
BCMA-Fc.  
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3.2.2.3. Production of recombinant BAFF APRIL heteromers. 
 
Upon validation of the concept, the next step was to express single chain BAFF and APRIL in all 
stoechiometries. Single chain ligands were first cloned in a Flag vector and then subcloned into a 
Fc vector. The dimeric Fc tag should in theory incorporate two single chain ligands in the same 
molecule, which may be a signaling advantage for receptors known to respond to oligomerized 
ligand (see section 1.2.4). The ligands were thereafter expressed in mammalian cells and analysed 
by immunoblotting using anti-Flag, anti-Fc, anti-APRIL or anti-BAFF antibodies (Fig 19). 
It was not always easy to get equal protein expression levels in different transfections. To 
circumvent this problem and to improve expression efficiency, stable clones in CHO cells were 
established. In an attempt to increase production efficiency, recombinant ligands were expressed 
from plasmids containing an IRES-GFP to help for selection of the best producers based on the 
fluorescence of GFP (Fig. 20).  
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Fig 19. Single chain homotrimers and heteromers of BAFF	  and APRIL	  .	  
Cell supernatant of Flag and Fc-tagged single chain homo and heteromers of BAFF and APRIL expressed in 293T 
cells. Expression is analysed by western blot using A. anti-Flag (M2) or anti-human Fc, B. anti-APRIL (Aprily2) and C. 
anti-BAFF (Buffy2) antibodies. 
 
 
 
Fig 20. Stable CHO cells transfected with Fc-ABB in an IRES-GFP-containing vector. Untransfected CHO cells are 
shown as control. A GFP-positive clone producing Fc-ABB is shown on the right. A proportion of GFP-negative cells 
was often present, even after sub-cloning, and may represent dead cells having lost their GFP.   
 
 
3.2.2.4. Expression and purification of single-chain BAFF, APRIL and BAFF-
APRIL heteromers. 
 
Expression plasmids for Flag- and Fc-tagged BAFF, APRIL and BAFF-APRIL heteromers were 
constructed, usually with GFP co-expression thanks to an internal ribosomal entry site, and used for 
the generation of stable CHO cell lines. Clones were established either randomly, or by 2 or 3 
rounds of FACS sorting to select green cells. Proteins were affinity purified with anti-Flag or 
Protein A, followed by size fractionation on a Superdex-200 gel permeation chromatography 
column. All samples contained various ratios of high molecular weight aggregates and lower 
molecular weight species eluting in fraction 15 for single chain Flag-ligands and in fraction 12 for 
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single chain Fc-ligands (Fig. 21). Yield obtained in the “small” molecular weight fractions are 
summarized in Table 1. 
S200-purified single-chain ligands were analyzed by Western blot. As expected, single-chain 
heteromers reacted with both anti-BAFF and anti-APRIL antibodies, in addition to the anti-tag 
antibody (Fig. 22).  
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Fig 21. Gel filtration profiles of single-chain BAFF and APRIL heteromers. Elution profiles of affinity-purified Flag-
tagged (left) and Fc-tagged (right) single-chain ligands from a Superdex-200 column. Fractions collected for 
subsequent characterization of the proteins are indicated. For Flag-hBBB and Fc-hABB, the indicated fractions were 
re-analyzed. 
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Table 1. Purification yields after affinity purification and S200 size fractionation (for 1 L of cell 
supernatant). 
   Flag       Fc     
Single-chain ligand AAA ABB BAA BBB AAA ABB BAA BBB 
Yield in S200 fraction(s) of interest 40 µg 160 µg 400 µg 220 µg <10 µg 200 µg 600 µg 160 µg 
 
 
Fig 22. Western blot analysis of purified, size-fractionated Flag- and Fc-tagged single-chain ligands.  
A. 200 ng of single-chain, Flag-tagged hAPRIL (A) and hBAFF (B) homo- and heteromers eluting in Fr15 of the 
Superdex-200 column (see Fig. 20) were analyzed by western blotting with the indicated antibodies. 
B. 100 ng of single chain, Fc-tagged single-chain ligands eluting around fractions 12 (see Fig 20) were analyzed under 
reducing conditions as in A). The real amount of Fc-hAAA loaded was obviously less than 100 ng. 
Table 2. Molecular weight estimations for single-chain BAFF and APRIL heteromers 
    MW [kDa] Approximative Approximative  
  MW [kDa] N-link Theoric + MW [kDa] MW [kDa] WB/S200 
  Theoric Theor N-linked by WB DTT by S200 ratio 
ps2879 Flag-AAA 49.3 6 64.3 58 86 1.5 
ps2889 Flag-BAA   50 5 62.5 59.8 93 1.6 
ps2886 Flag-ABB 50.9 4 60.9 58.9 101 1.7 
ps2890 Flag-BBB   51.8 3 59.3 58 96 1.7 
        
ps2876 Fc-AAA 75.2 7 92.7 97.5 272 2.8 
ps2877 Fc-BAA 76 6 91 97.5 335 3.4 
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ps2883 Fc-ABB    76.9 5 89.4 92.4 509 5.5 
ps2680 Fc-BBB 78 4 88 100.3 509 5.1 
 
Single chain ligands migrated by SDS-PAGE with sizes of about 60 kDa and 100 kDa for Flag and 
Fc-tagged ligands, which are higher than the predicted molecular masses of about 50 and 75 kDa. 
For Flag-tagged ligands, the difference is most probably due to N-linked glycosylation. The 
difference of about 40 kDa between Flag-tagged and Fc-tagged ligands can however not be entirely 
explained by the presence of the 25 kDa Fc portion. We hypothesize that the rod-like structure 
(PQPQPKPQPKPEPEGS) that we have introduced between the Fc and the single-chain ligand 
could be responsible for this peculiar migration. Single-chain Flag-tagged ligands migrated on S200 
with a molecular weight 1.5 to 1.7 bigger than the expected one (Table 2). We find it unlikely that 
these molecules would assemble as dimers, and favour the hypothesis that the proteins have either 
an elongated shape and/or that the numerous and voluminous N-linked glycans account for this size 
difference. Regarding Fc-tagged AAA and BAA ligands, their apparent sizes correspond relatively 
well to the sum of the 50 kDa dimeric Fc plus 2 Flag-tagged single-chain ligands. Fc-tagged ABB 
and BBB are however bigger than expected and might represent dimers of the structure 
schematized above the S200 profiles in Fig. 21. 
 
3.2.3. Receptor binding specificity of BAFF-APRIL heteromers. 
 
Flag- and Fc-tagged single chain ligands post S200 were analysed for binding to the BAFF and 
APRIL receptors. The receptors used were either in the form of a receptor-Fc, where the binding for 
Flag ligands were detected by ELISA using a biotinylated anti-Flag (M2) antibody (Fig 23), or 
expressed as receptor-GPI in HEK 293T cells, where the binding of any ligand can be revealed with 
appropriate anti-tag secondary reagents. A heteromer consisting of two molecules of BAFF and one 
molecule of APRIL bound to all three receptors BAFFR, TACI and BCMA and hence retains the 
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properties of BAFF for binding to BAFFR, whereas a heteromer consisting of one molecule of 
BAFF and two molecules of APRIL had a binding pattern resembling that of APRIL, with binding 
to TACI and BCMA only, but not BAFFR. It therefore seems that at least two monomers of the 
same kind in an assembled trimer are required to bind a specific receptor.  
 
 
Fig 23. Binding specificity of Flag-tagged BAFF and APRIL single chain heteromers to plate-bound receptors. The 
binding of Flag-tagged single-chain hBAFF and hAPRIL heteromers to the indicated human receptors-Fc was 
monitored by ELISA, according to the principle shown in Fig16.  
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Fig 24. Binding specificity of Flag-tagged BAFF and APRIL single chain heteromers to receptors expressed at the 
cell surface.293T cells were co-transfected with an EGFP expression vector and the indicated receptor-GPI expression 
vectors. Cells were stained with single-chain hBAFF-APRIL heteromers and appropriate PE-coupled secondary 
reagents and analyzed by FACS. 
A. Scattergrams showing concentration-dependent ligand binding to various GPI-anchored receptors. EGFP 
expression approximately reflects receptor expression (x-axis; log scale from 100 to 104). Ligand binding is detected 
with PE (y-axis; log scale from 100 to 104).  B. Graphic representation of the data shown in A 
 
 
3.2.4.1. Signaling of BAFF APRIL heteromers on reporter cell lines.  
 
The recombinant ligands were shown to bind to their cognate receptors both expressed as a 
receptor-Fc or receptor-GPI. To gain insight into the signaling abilities of these ligands via these 
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receptors, they were tested on a surrogate cell death assay in which oligomerisation-dependent 
apoptotic Fas pathway can be initiated by BAFF and APRIL. For this purpose Jurkat (Fas-positive 
or Fas-deficient) cell lines expressing a fusion protein consisting of the extracellular domain of 
BCMA or TACI or BAFFR fused to the transmembrane and intracellular domain of Fas were used 
(as described in [49]). Some of the cell lines are responsive to only oligomerised ligands. A cell 
viability assay was performed using the Flag BAFF APRIL heteromers (in presence of anti-Flag 
used for cross-linking) in a dose-dependent manner on these cell lines.  
 
 
 
 
Fig 25. Activity of Flag-tagged BAFF and APRIL single-chain heteromers on receptor:Fas expressing reporter cell 
lines. Jurkat cells stably transduced with the indicated version of receptor:Fas fusion proteins were incubated with 
increasing concentrations of Flag-tagged single-chain ligands in the presence of a fixed (1 µg/ml) concentration of 
anti-Flag M2 antibody. Triggering of the fusion receptors induces the apoptotic Fas pathway that kills cells. Cell death 
was measured by the PMS/MTS assay. 
 
Due to limitation of gel filtration fractionated purified Fc ligands at the time of the assay, this assay 
was performed with non-fractionated Fc ligands, which showed similar results as Flag tagged 
fractionated ligands on reporter cell lines. 
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Fig 26. Activity of Fc-tagged BAFF and APRIL single-chain heteromers on receptor:Fas expressing reporter cell 
lines. Reporter cell lines as shown in Fig 25 were incubated with increasing concentrations of Fc-tagged single-chain 
ligands. Cell death was measured by the PMS/MTS assay. 
 
The results were consistent with the receptor binding data. APRIL-APRIL-APRIL and BAFF-
APRIL-APRIL signaled via BCMA and TACI while BAFF-BAFF-BAFF and APRIL-BAFF-BAFF 
signaled via all three receptor-Fas cell lines. An interesting observation was that APRIL-BAFF-
BAFF showed much less activity than BAFF-BAFF-BAFF on BAFFR-Fas cells. This could 
perhaps indicate that at least two molecules in an assembled trimer, though sufficient to bind to its 
cognate receptors, is not enough to generate an active signal. 
 
3.2.4.2. Signaling of BAFF APRIL heteromers on primary cell lines.  
 
Although the signaling abilities of the BAFF APRIL heteromers could be assessed on reporter cell 
lines, these remain an artificial set up not providing a clearer view of the signaling abilities of these 
heteromers on each of these receptors. To determine this, ligands were tested on primary B cells in 
a thymidine-incorporation assay, in which primary B splenocytes of WT or TACI-ko mice were 
stimulated with anti-B cell receptor antibodies and co-stimulated with single chain BAFF and/or 
APRIL proteins.  
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Fig 27. Activity of single chain BAFF and APRIL heteromers on primary murine B cells of WT and TACI-ko mice. 
A. Schematic representation of binding of single chain BAFF-APRIL homomers and heteromers on the respective 
receptors on murine B cells. B. Murine B cells from WT mice and TACI -/-mice were cultured under BCR-stimulating 
conditions with increasing concentrations of Flag and Fc ligands. For the Flag ligands a fixed (1 µg/ml) concentration 
of anti-Flag M2 antibody was used as a crosslinker. After 48 hours, cells were pulsed for 16 hours with thymidine, 
harvested, and counted. Proliferation of primary B cells was measured by thymidine incorporation. The black squared 
boxes on top of the graphs indicate the genotype of the mice and the red boxes indicate the receptors on splenocytes 
*Purified S200 fractionated Fc AAA was not available for this assay. 
 
MACS isolated WT splenocytes from adult C57Bl6 mice were stimulated with the various single 
chain ligands as indicated in Fig 27. As primary B cells do not express BCMA, WT B cells provide 
a picture of signaling via BAFFR and TACI. For all the Flag-tagged single-chain ligands, an anti-
Flag antibody was used as a cross-linker. To assess the signaling via BAFFR alone, proliferation 
assay was performed on TACI -/- B cells. As BAFFR -/- cells produce very little B cells, an anti-
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mouse BAFFR blocking antibody 9B9 (kindly provided by Antonius Rolink) was used to 
selectively block BAFFR, resulting in a TACI-only situation. 
 
 
 
Fig 28. Activity of single chain Flag-tagged BAFF and APRIL heteromers via TACI on primary murine B cells. 
Purified murine B cells from WT mice were cultured under BCR-stimulating conditions stimulated by Flag ligands in 
presence of anti-Flag antibody for a proliferation assay using thymidine as described in Fig 27. Cells were additionally  
incubated with 9B9 mBAFFR blocking antibody at 0.25 µg/ml. The black squared box on top of the graph indicates the 
genotype of the mice and the red box indicates the receptor on splenocytes. 
 
As seen in Fig 27, the Flag-tagged homomers of BAFF-BAFF-BAFF and APRIL-APRIL-APRIL 
signal better on WT and TACI -/-  cells as compared to the heteromers. Proliferation via BAFFR 
(TACI -/-  splenocytes) in the presence of Fc-tagged ligands, showed stronger signals than with Flag 
- ligands. The stronger signal could be due to the efficiency of Fc as a cross-linker than anti-Flag 
antibody. Both Flag and Fc BAFF-BAFF-BAFF showed strongest signaling as compared to the 
other ligands on TACI -/- splenocytes. 
 
3.2.4.3. BCMA-induced NF-κB luciferase reporter assay. 
 
Signaling via TACI and BAFFR could be measured on primary B cells obtained from mouse 
splenocytes. However signaling via BCMA was not possible by this method, as primary B 
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splenocytes express little or no BCMA. This receptor is indeed expressed later during B cells 
development and found on differentiated B cells like plasma cells and plasmablasts, which are 
difficult to work with. As a surrogate to measure signaling via BCMA, a NF-κB luciferase reporter 
assay was performed in HEK 293T cells expressing full-length BCMA.   
 
 
 
Fig 29. Signaling via BCMA in a NF-κB luciferase reporter assay 
293 T cells transiently co-transfected with full-length human BCMA and NF-κB reporter plasmids were stimulated with 
purified Flag-ligands at the indicated concentration in the presence or absence of anti-Flag antibody (M2). NF-κB 
activity is shown as fold induction compared to BCMA-transfected, but non-stimulated cells (concentration zero). 
 
 
All Flag-ligands were able to induce BCMA signaling as observed by the NF-κB activity on HEK 
293 T cells. All the homomers and heteromers showed similar EC50 of around 100 ng/ml, indicating 
that they have similar signaling capacities via BCMA.  
 
3.2.5. APRIL-BAFF-BAFF versus BAFF-BAFF-BAFF. 
 
APRIL-BAFF-BAFF showed weak signaling as compared to BAFF-BAFF-BAFF on reporter Fas 
cell line and also on primary splenocytes. This lead to the hypothesis that it may act as an inhibitor 
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of BAFF signaling via BAFFR. In order to demonstrate this, a competition assay was performed 
between Flag-BAFF-BAFF-BAFF and Flag-APRIL-BAFF-BAFF on BAFFR:Fas reporter cell lines 
by a PMS-MTS cell viability assay as well as a proliferation assay by thymidine incorporation on 
primary B cells isolated from TACI-BCMA double knock out mice. 
 
Fig 30. Competition of Flag-APRIL-BAFF-BAFF with Flag-BAFF-BAFF-BAFF trimeric fraction on BAFFR:Fas 
expressing reporter cell line (2308-21). Cells were incubated overnight with Flag BAFF-BAFF-BAFF at the indicated 
concentration with or without Flag APRIL-BAFF-BAFF added at a constant concentration of 2 µg/ml. Cell viability 
was measured the following day using PMS-MTS. 
 
 
 
Fig 31. Competition of Flag-APRIL-BAFF-BAFF with Flag-BAFF-BAFF-BAFF trimeric fraction on TACI -/-x 
BCMA -/-splenocytes expressing BAFFR only. MACS isolated murine B cells from spleen of a TACI-/-BCMA-/- mouse 
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were cultured under BCR stimulating conditions in the presence of Flag-BAFF-BAFF-BAFF or Flag-APRIL-BAFF-
BAFF at indicated concentrations in the presence of anti-Flag antibody (M2). Cells were also incubated with Flag- 
BAFF-BAFF-BAFF at increasing concentration with a constant concentration of Flag-APRIL-BAFF-BAFF of 2 µg/ml. 
Proliferation was measured by thymidine incorporation after 72 h. 
 
The assay on reporter cell lines as shown in Fig 30 shows the sensitivity of Flag-BAFF-BAFF-
BAFF on these BAFFR-Fas cells upto around 1ng/ml. The sensitivity of these cell lines to BAFF 
mediated killing was enhanced in presence of Flag APRIL-BAFF-BAFF at 2 µg/ml. This effect was 
perhaps mediated by the presence of Flag APRIL-BAFF-BAFF alone at 2 µg/ml independent of 
Flag BAFF-BAFF-BAFF. Including an additional control of killing in response to Flag APRIL-
BAFF-BAFF alone in a dose dependent manner and at a constant concentration of 2 µg/ml would 
confirm the fact if Flag APRIL-BAFF-BAFF can act via BAFFR better at a higher concentration. 
This would confirm that APRIL-BAFF-BAFF is a weak binder of BAFFR as compared to BAFF-
BAFF-BAFF  (as has already been shown in Fig 23 and 24) and it signals efficiently only at higher 
concentrations. The proliferation assay on B cells show Flag-BAFF-BAFF-BAFF signals via 
BAFFR both in presence and absence of the Flag-APRIL-BAFF-BAFF added in excess at a 
constant concentration. B cells also show some signal for proliferation with Flag APRIL-BAFF-
BAFF at the starting concentration of 1µg/ml. This is much in contrast with the earlier experiments 
(Fig 27) where no signal is seen on WT and TACI -/- cells. Based on results obtained in this 
particular experiment signaling via BAFFR in presence of APRIL-BAFF-BAFF at 2 µg/ml alone 
should be expected (black squares at 0.1 ng/ml of BAFF-BAFF-BAFF). It is possible that the signal 
obtained in presence of APRIL-BAFF-BAFF at 1µg/ml could be an aberrant signal. Hence the data 
obtained is not sufficient enough to draw conclusions.  It would be necessary to repeat this 
experiment (done once) to comment further on the putative inhibitory role of heteromer on 
homotrimer signaling. 
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3.2.6. In vivo effect of APRIL-BAFF-BAFF on B cell restoration. 
 
So far, the in vitro assays of binding on receptor-Fc and receptor-GPI and signaling measured on 
reporter Fas cells, and ex vivo on splenocytes from various receptor knockout mice indicated that 
APRIL-BAFF-BAFF binds and signals weakly as compared to BAFF-BAFF-BAFF. Our next 
attempt was to confirm these results in vivo.  The primary signals for the development of B cells are 
mediated by BAFFR. Our objective would be to dose BAFF -/- mice with Fc-BAFF-BAFF-BAFF 
and Fc-APRIL-BAFF-BAFF and look for B cell restoration.  
 
In order to do this assay, so far we have set up the conditions for B cell restoration in BAFF -/-  mice 
and optimized the necessary conditions for rescue of the phenotype. We injected a BAFF -/- mouse 
intraperitoneally with 100 µg of Fc-BAFF per injection three times at an interval of 7 days. The 
mouse was sacrificed on day 18. Spleen and lymph nodes were isolated and cell were stained with 
antibodies against mature and immature B cell surface markers (CD19, CD93) and analysed by 
flow-cytometry. WT and untreated BAFF -/- mice were used as controls (Fig 32). In addition total 
number of cells were also counted. This treatment successfully but partially restored mature B cells 
in a BAFF -/- mouse as compared to an untreated knock out mouse as has been shown in (Fig. 32). 
There was a clear increase in the percentage of CD19 B cells in the Fc-BAFF treated BAFF -/- 
mouse  both in the spleen and in lymph nodes. These conditions for the in vivo B cell restoration 
assay could be used to assess the in vivo activity of Fc-BAFF-BAFF-BAFF and Fc-APRIL-BAFF-
BAFF. 
	   86	  
 
 
Fig 32. Set up of the in vivo B cell rescue assay with administration of Fc-BAFF in BAFF -/- mice 
Adult C57Bl6 mice WT, untreated BAFF -/- and  BAFF -/- injected i.p with 100 µg of Fc hBAFF at Day 0,7,14, 
analysed on Day 18 . Spleen and set of six lymph nodes (inguinal, axillary, brachial) were isolated. Splenocytes (post 
RBC lysis) and lymphocytes were stained with anti-CD19 and anti-CD93 antibodies and analysed on LSRII. 
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3.3.  BAFF 60-mer deficient knock-in Mouse.   
 
3.3.1. Aim 
As described in section 1.3.4, some TNF family receptors respond better to oligomerised ligands. 
Both BAFF and APRIL present characteristic properties of oligomer formation, though their 
functional relevance and endogenous existence remain unclear. However receptors like TACI and 
perhaps BCMA too can be activated by oligomerised BAFF or APRIL [49] and also oligomerised 
BAFF may play a role in marginal zone B cell formation [31]. BAFF 60-mer has been shown to 
form upon over expression and has also been crystallized [46, 48]. Therefore, BAFF 60-mer could 
possibly be a biologically active form of soluble BAFF. 
 
The aim of this project was first to make a mutant murine BAFF that is unable to form a BAFF 60-
mer but that retains its ability to form a trimers and second to make a knock-in mouse with this 
mutant to assess the physiological role of BAFF 60-mer. 
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3.3.2. Identification of a Flap mutation in mouse BAFF. 
 
For the purpose of identifying the role of BAFF 60-mer in vivo, the aim was to create a knock-in 
mouse in which BAFF cannot associate as a 60-mer. The first step in this procedure was to identify 
a mouse BAFF mutant that trimerizes and retains normal binding to receptors, but that cannot 
associate as 60-mer. For human BAFF, it has been shown convincingly that an H218A mutation in 
the flap region fulfills all of these requirements [48]. However, results obtained previously in our 
laboratory suggested that mutation of the corresponding mouse residue (H242A) was insufficient to 
abolish 60-mer formation. The crystal structure of BAFF 60-mer suggests that several residues 
beside His218 might be important for ligand assembly through flap-flap interactions. In particular, 
Glu254 of one BAFF 3-mer contacts Lys252 of another 3-mer, and vice-versa (Glu278 and Arg276 in 
mouse BAFF). The same is true for the pair Glu223 and Lys216 (Glu247 and Lys240 in mouse BAFF). 
We reasoned that mutations E278K and E247K should generate electrostatic repulsion with Arg276 
and Lys240, respectively.  
 
Fig 33. Structural details of the Flap-Flap interaction region of the human BAFF 60-mer. (a) Electrostatic 
interactions between Glu254 and Lys252. (b) Electrostatic interactions between Glu223 and Lys216, which takes place 
underneath those of Glu254 and Lys252. Structural coordinates are from pdb accession number 1OTZ. 
 
Full length cDNAs of mouse BAFF WT, H242A, E247K and E278K (see plasmid maps in Annex 
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A), and of human BAFF WT and H218A as controls, were expressed in 293T cells (Fig. 34) using 
buffered medium, to avoid disruption of 60-mers because of medium acidification. Indeed, BAFF 
60-mer is stable at a neutral or alkaline pH but dissociates into trimer at acidic pH [48]. Processed 
BAFF was recovered in culture supernatants (Fig. 34). 	  
 
Mutant E278K was not well expressed for reasons that remain to be determined. WT mouse BAFF 
and mutants E247K and H242A were dosed by sandwich ELISA (capture with mAb 5A8, and 
detection with mAb 1C9) and by receptor binding ELISA (capture with BCMA-Fc, TACI-Fc or 
BAFFR-Fc, and detection with mAb 1C9). Results indicate that mAb 1C9 recognizes mouse BAFF 
also when it is bound to a receptor, but that it cannot recognize the H242A mutant, which 
presumably has a destroyed epitope (Fig. 34B). Recognition of mutant E247K by mAb 1C9 may 
also be partially affected, because amounts of E247K BAFF that gave a signal as intense as WT 
BAFF by immunoblot (revealed with a polyclonal anti-BAFF antibody) was recognized 4-fold less 
efficiently by 1C9 in the sandwich and receptor-binding ELISAs (Fig. 34 B,C,D). Taking this into 
account, it can be concluded that there is no obvious difference between WT and E247K mouse 
BAFF regarding their binding to receptors.   	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Fig 34. Mouse BAFF mutant E247K is expressed and binds BAFF receptors. 293T cells were transfected with 
various full-length BAFFs. Conditioned serum-free supernatants were analyzed for their BAFF content. A. Immunoblot 
of mouse BAFF revealed with polyclonal goat-anti-mouse antibody 852 (from R&D) and Immunoblot of human BAFF 
revealed with the rat mAb Buffy-2. 20 µl of supernatant were loaded on the gel. B. Mouse BAFFs were dosed by 
sandwich ELISA, using mAb 5A8 to capture and biotinylated mAb 1C9 to reveal. Purified recombinant Flag mouse 
BAFF was used as a concentration standard. C. Mouse BAFFs were dosed for their binding to hBCMA-Fc and  hTACI-
Fc. D. Same as C but binding to mBAFFR-Fc. In panels B, C and D 50 µl of supernatants were used (and 2-fold 
dilutions). 
  
3.3.3. E247K Flap mBAFF mutant is not functional as an oligomer. 
 
Upon identification of a suitable Flap mutant, the next step was to determine whether mouse 
BAFF E247K was impaired in its ability to form 60-mers. When analyzed by gel permeation 
chromatography, 60-mers were readily detected in the positive control (WT human BAFF) 
but not in its H218A mutant, as expected (Fig. 34A). WT mouse BAFF formed 
comparatively little high molecular weight oligomers, and these oligomers were still present 
in H242A BAFF and, to a lesser extent, in E247K BAFF, making it difficult to draw 
conclusions regarding BAFF 60-mer (Fig. 34B). Therefore a functional assay was used for 
the detection of BAFF 60-mer, based on a reporter cell line. To enhance the production of 
total mouse BAFF, WT and E247K mutant Flag-mBAFF were expressed in 293 T cells 
grown in complete rather than serum-free medium. The expression and concentration was 
determined by immunoblotting using Flag mBAFF purified protein as a standard (Fig. 36A). 
Both proteins were expressed almost equally. Crude supernatants were then concentrated, 
adjusted to similar concentrations and dosed on reporter BAFFR:Fas cell lines that were 
sensitive to oligomer alone and to both oligomers and trimers (Fig. 36B,C). Supernatants 
containing WT mouse BAFF displayed some toxicity towards the oligomer-sensitive reporter 
cells (presumably due to the presence of BAFF 60-mer), whereas those containing the E247K 
mutant did not. Both WT and E247K mutant mBAFF killed the oligomer- plus trimer-
sensitive cell lines indicating that the mutant cannot associate as an oligomer but can form 
trimers.	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Fig 35. Mouse BAFF forms high molecular weight oligomers less efficiently than human BAFF. BAFF-
containing supernatants of 293T cells transfected in serum-free medium were concentrated 20 x, and analyzed 
by size exclusion chromatography. Mouse BAFF was revealed by immunoblot with polyclonal anti-BAFF 
antibody 852, and human BAFF with mAb Buffy-2. A. WT human BAFF. B. Human BAFF H218A. C. WT mouse 
BAFF. D. Mouse BAFF E247K. E. Mouse BAFF H242A. The elution position of molecular weight standards (in 
kDa) are indicated at the top of the figure, and the migration position of molecular weight standards for SDS-
PAGE are shown on the left. 
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Fig 36. Mutant E247K mouse BAFF does not form active oligomers. 293T cells were transfected in complete 
medium with full length WT mBAFF and mBAFF E247K, and naturally processed BAFF was recovered in 
supernatants. A. Processed BAFF was quantified by immunoblot with a polyclonal goat anti-mouse BAFF 
antibody, using purified Flag-mouse BAFF as a standard. B. Oligomer-sensitive and C. Oligomer- plus 3-mer 
sensitive BAFFR:Fas reporter cell lines were dosed with WT and E247K mBAFF and tested for cell viability 
using the PMS/MTS assay. 
 
 
3.3.4.1. Generation of a Knock-In vector for E247K mutant mBAFF. 
 
To make the knock-in mouse deficient for BAFF-60mer, E247K mutant BAFF was selected 
as a target. A knock-in vector was constructed from a BAC clone containing the genomic 
BAFF sequence as a template. The principle of the knock-in method relies on the 
homologous recombination and thereby the exchange between a fragment of the genomic 
mouse BAFF region of interest with the fragment containing the mutation in the knock-in 
vector. The knock-in vector containing the fragment and mutation of interest for the mouse 
BAFF must meet some criteria, with at least 1 kb of unmodified sequence 3’ of the mutation 
and 3 kb 5’ of the mutation.  Briefly, a 5.6 kb SpeI fragment (Fig. 37) was chosen for the 
homologous recombination and was extracted from the BAC clone containing the genomic 
BAFF sequence. This 5.6 kb region contains exon 6, which is the target for introducing the 
mutation, flanked by a 4.5 kb region on its 5’ and a 1.1 kb region on its 3’. The SpeI fragment 
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was subcloned into a modified pBlueScript vector (without ApaI and BamHI sites). Using the 
BAC as a template, a E247K mutation with an additional silent mutation introducing a 
HindIII site was introduced by double PCR. This fragment of about 1500 bp was delimited 
by 2 ApaI sites. It was sublconed into a suitable intermediate vector, for the purpose of 
introducing the neomycin resistance cassette in the natural EcoRV present in the intro 3’ of 
exon 6. The ApaI fragment now containing the target mutation and NeoR cassette was cloned 
into the vector containing the SpeI genomic fragment and this served as the final knock-in 
vector. 
 
 
Fig 37.  Strategy for the construction of BAFF E247K knock-in. 
A. Hind III fragment of the WT mouse BAFF allele containing exons 5, 6 and 7. The HindIII fragment contains 
an SpeI fragment used for targeting. The SpeI fragment contains an ApaI fragment used to introduce the target 
mutation E247K in the targeting vector. The ApaI fragment contains an EcoRV site used to insert the floxed 
NeoR cassette. B. Predicted genomic sequence of a correctly recombined allele in ES cells. Mutation E247K 
creates a novel HindIII site, while the EcoRV site has been disrupted by insertion of the NeoR cassette. 
C. Predicted genomic sequence of a knock-in mouse after removal of the NeoR cassette (by crossing with a Cre-
expressing mouse). 
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3.3.4.2. Southern Blot probes for the detection of knock-in transgene. 
 
The knock-in vector, after electroporation into ES cells of 129 mice and successful 
recombination will yield the desired ES cells (containing a mutant allele and a WT allele) and 
confer cells with resistance to G418. After selection, clones need to be verified for the correct 
insertion of the mutant first by PCR and then by southern blot. Probes that would allow 
distinguishing recombined from WT alleles were therefore designed 5’ and 3’ of the targeted 
sequence. Genomic DNA isolated from embryonic stem cells (ES cells) of 129 mice were 
digested with a selection of restriction enzymes, then revealed by southern blot with the 5’ or 
3’ probe. Both probes gave clean signals while revealing the predicted fragment, as depicted 
in Fig. 38B. It should be noted that the molecular weight marker band at 1.6 kb contains 
some repetitive sequence giving background with any labelled probe.  
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Fig 38. Southern blot of wild type gDNA for the characterization of 3’ and 5’ probes.  
A. Schematic representation of the portion of interest of the mouse BAFF gene, with indication of the relevant 
restriction sites, location of the 5’- and 3’-probes, location of the SpeI fragment that will be used to construct 
the targeting vector, and predicted restriction fragments that could hybridize with one or both of the probes. 
B.   Southern blot of 3 different samples of WT genomic DNA digested with restriction enzymes BamHI, HindIII 
or XbaI, and revealed with 32P-labelled 5’ (left) or 3’ (right) probes. 
 
ES cells were electroporated with the SpeI fragment of the targeting vector. Genomic DNA 
extracted from G418-resistant clones were screened by PCR for the identification of correct 
recombination events. For this purpose, one of the primer was in the sequence of the NeoR 
and the second was 3’ of the targeting sequence. Therefore, an amplification product of the 
expected site can only be obtained in case of a correct recombination event, and not in case of 
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a random insertion (Fig. 39A). A fair number of positive clones were identified (Fig 39B). 
Genomic DNA of these clones were analyzed by Southern blot with the BAFF 5’ probe. 
Positive clones give the WT band at 10.4 kb plus a shorter, recombined band at 5.6 kb. This 
short band is also a signature for the presence of the K247E mutation that introduces a 
HindIII site (Fig 39C). Results were confirmed by hybridization with a probe specific for the 
NeoR cassette, to exclude an additional random insertion of the transgene. Several ES clones 
were found positive and further amplified. Amplified clones were confirmed by PCR (Fig. 
39D) and 4 of them were selected for injections (boxed in Fig. 39D). The process is now 
ongoing. 
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Fig 39. Screen for correct recombination events in ES cell clones. 
A. Scheme of the WT and recombined BAFF alleles in the region of interest. The targeting vector is a SpeI 
fragment of BAFF genomic DNA, where the K247E mutation was introduced in exon 6, generating a novel 
HindIII site, and a floxed NeoR cassette was introduced in intron 6-7. The position of the 1746 bp sequence 
amplified with oligos JT7164 (in the NeoR cassette) and JT7165 (in the BAFF gene, 3’ of the targeted sequence) 
and of the 5’ Southern blot probe (5’ of the targeted sequence) are shown. Relevant HindIII fragments 
generated by digestion of genomic DNA are also indicated (10.4 kb for WT, 5.6 kb and 6.7 kb for a recombined 
allele. 
B. Representative result of the primary PCR screen of ES cell clones (one quarter of plate N°3), showing 
positive amplification for 4 clones, 3 of which turned out to be true positives. 
C. Southern blot analysis of clones found positive in the primary screen, hybridized with the 5’ probe (top 
panels) followed by the NeoR probe (bottom panel). The 4 clones selected for generating knock-in animals are 
boxed. The ladder shown on the right was cut from the gel before transfer, and stained for DNA. 
D. 12 ES clones that were positive by Southern blot (plus 3 clones that gave no signal by Southern) were 
amplified and confirmed to be positive by PCR after amplification.  
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4. Discussion and future perspectives 
 
4.1.1. Novel interaction partners in the TNF family of ligands. 
 
TNF ligands form homotrimers owing to their structural properties. Homotrimer formation is 
a fundamental requirement for receptor binding and receptor oligomerisation for adequate 
signal transduction. Formation of a trimer thus decides the fate of the signaling event via the 
receptor.  LTα has been shown to form soluble homotrimers that bind to TNFR1. It forms a 
surface bound complex with LTβ that binds to LTβ-R. Formation of LTα-LTβ heterotrimers 
have been found to play a crucial role in lymph node formation. The discovery of six new 
interaction partners in the TNF family ligands in our study was therefore interesting. It is 
interesting to notice that the interacting partners are very closely related and can be classified 
as a sub-family on the basis of structural similarity. APRIL interacts with EDA1 and EDA2, 
EDA1 interacts with EDA2 and LIGHT interacts with FasL, TL1A, LTα, LTβ. APRIL and 
EDA1 are structurally similar as much as LIGHT is similar to FasL, TL1A, LTα, LTβ. 
The screening method undertaken to identify interaction partners had its own limitations. 
Some of the ligands in the combinations did not express themselves. Hence no conclusion 
could be reached about their heteromer forming abilities. Some interactions were not 
consistent and also showed very faint signal as compared to the negative controls. In some 
combination of Flag and Fc ligands signal was observed whereas the same ligand with the 
tags other way around yielded no signal. For example  Flag-APRIL and Fc-BAFF interacted 
but not Flag-BAFF and Fc-APRIL (Fig 11) making it unclear if a real heteromer forms or 
not. But in spite of these limitations seven  positive hits could be identified. These pair 
showed strong interaction signal (in red in Fig 11) and overcame all the limitations of the 
screening method. 
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It would be interesting to study if they arise in the same cell or tissue and whether the 
formation of these heteromers would be possible post translationally as well. The ratio 
between the homo versus heterotrimer formation would provide an indication of the 
predominant species providing some clues about its physiological relevance.  
However the study of heteromers in vivo remains technically challenging owing to their 
tendency to exchange among themselves [202]. Isolation of homogenous species of 
heteromers would be difficult. A recombinant form of heterotrimer may solve the purpose to 
an extent though the reliability of the study would depend on the yield of recombinant 
heteromers to be used for biochemical characterisation. To further validate these interactions, 
the need would be to use untagged forms of these ligands in co-transfection studies. This 
would also demand the characterisation of suitable antibodies meeting various criteria; 
capable of recognizing such an interaction pair and also be sensitive enough for heteromer 
detection. The physiological importance of these interactions remains unexplored in our 
studies. 
  
4.1.2. Novel receptor specificity of heteromers. 
 
Within the TNF family of receptors several receptors are still found to be orphan i.e. they do 
not have a binding partner within the TNF family of ligands. It was hypothesized that the 
novel interaction partners within the TNF ligands identified in this study may have some 
novel receptor-binding specificity with respect to these orphan receptors. Hence the various 
combinations containing the interaction partners were used in an assay to test their binding 
specificities. So far, none of the novel interaction partners exhibited binding to these orphan 
receptors, though further confirmatory tests proving the activity of the ligands (shown for 
some of the heteromers in annexure C for binding to cognate receptors) still needs to be 
carried out with adequate controls. Based on the current observation, if it holds true that the 
orphan receptors do not bind the heteromers, this could imply that there may be other 
candidates outside the TNF family receptors for the interacting ligands or they might bind to 
their cognate receptors and act as an activator or inhibitor or play redundant roles like the 
homotrimers. For e.g. LIGHT-FasL may bind to HVEM and Fas respectively. A species of 
LIGHT2FasL may bind to HVEM better than Fas while a species of FasL2LIGHT may bind 
to Fas better than HVEM and can generate or block the signaling via these receptors. 
 
The orphan receptors may actually have no binding partner within the TNF family ligands 
even if they have been classified as TNFSF receptors.  Nerve growth factor receptor  (NGFR) 
Nerve Growth Factor and other ligands outside the TNF family and plays a role not only in 
the nervous system [203, 204]but also in the immune system [205-210]. TROY is another 
orphan receptor, which has been shown to bind to ligand outside the TNF family [199, 211-
215]. It is possible that these receptors might induce signaling in a ligand-independent 
manner, though the deficiency of some of them in mice have not exhibited any prominent 
phenotype [216, 217]. 
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4.2.  BAFF APRIL heteromer characterization. 
 
4.2.1.1. Single chain ligands. 
 
Use of short peptide linkers (GGGGS) for the trimerisation of TNF homology domains have 
already been described before [201] as it prevents the dissociation of monomers and increases 
the activity of trimers linked in a single chain. However the method provides potential caveat. 
The linkers joining the C and N termini of the ligands could interfere with protein folding and 
its subsequent activity. Thus this method had potential limitation of interference with activity. 
Thus arose the need to validate this method and check if it would yield active forms of 
trimers. One way to validate this method was to check the expression and secretion of 
homotrimers and subsequently the binding to their cognate receptors. Another aspect to check 
was the ability of a single chain heteromer to mimic its naturally occurring form. Single chain 
LTα-LTβ homotrimers as well as heteromers were thus constructed. All the four single chain 
ligands expressed and could be efficiently secreted. They showed binding to their cognate 
receptors TNFR1 and LTβR respectively.  This was a validation of the proof of concept of 
the single chain method and it could be utilized further for BAFF-APRIL heteromer 
characterisation. The advantage of this method was that it could yield a homogenous species 
of heteromers.   
Although BAFF-APRIL heteromers could be produced, they had some limitations in their 
production method. As described before this method utilizes the linker, which is in close 
proximity to the C termini of the ligands. The combination of APRIL-BAFF-BAFF proved to 
be better in terms of expression and activity. It is possible that changing the order in which 
the linkers were inserted and the ligands were cloned had an impact on the overall folding 
and activity of the proteins. It is however difficult to comment that if the physiological 
activity of 2BAFF 1APRIL will be closer to the BAFF-BAFF-APRIL or APRIL-BAFF-
BAFF recombinant ligand.  
	   103	  
 
4.2.1.2. Production of BAFF-APRIL single chain heteromers. 
 
As the single chain method have been described previously [201] and also have been 
validated in our studies (LTα-LTβ heteromers), it was thus utilized to produce single chain 
BAFF-APRIL heteromers using Flag tag and Fc tag. Though this method met the desired 
objective, there were limitations of production of these heteromers in large amounts. It could 
be reasoned that although this method works for ligands like TNF and LTα very well, it has 
some limitations for BAFF-APRIL heteromer production. The yield of heteromers produced 
from established stable clones of CHO cells remained low. This could be due to the 
efficiency of the stable clone or because of the cloning method linking BAFF-APRIL in a 
particular sequence in a single chain, or both. To improve the efficiency of production and 
obtain a larger yield for further biochemical characterization, the order in which BAFF-
APRIL were linked was modified. A variant of BAFF-BAFF-APRIL and APRIL-APRIL-
BAFF was cloned by reversing the C terminal third ligand to the N-terminal position, 
resulting in APRIL-BAFF-BAFF and BAFF-APRIL-APRIL. To improve the efficiency of 
stable clones the IRES-GFP was inserted in the plasmid and it proved to be a useful way of 
selecting the best clones in terms of brightest GFP. However these efforts did not prove to 
drastically increase the yield of production of these heteromers and it was necessary to 
upscale the method for further production of heteromers. 
 
4.2.2. Size characterization of single chain heteromers. 
 
The rational behind adapting to the single chain method was to obtain a homogenous species 
of heteromers, which could be characterized exclusive of any homotrimeric ligands. However 
this method had the potential of generating higher order aggregates (as described in section 
3.2.2.2) consisting of a mixture of both and hence it was necessary to perform a size 
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exclusion chromatography using gel filtration to exclude this possibility. As described before 
(section 3.2.2.2 and 3.2.2.4) the Flag-tagged heteromers produced by transient transfection 
and fractionated from crude supernatant mostly folded and formed trimers and eluted at the 
fraction with the correct size, while there were more aggregation formed in purified ligands 
as seen by the presence of proteins in the higher molecular weight fractions. But these could 
be only aggregation caused due to the method of purification and not necessarily a mixture of 
homo and heteromers contributing to misleading results. 
 
4.2.3. Receptor binding specificity and signaling abilities of heteromers. 
 
The most sought after and obvious candidates to screen for the receptors of BAFF-APRIL 
heteromers were BAFFR, TACI, BCMA.  The latest group reporting the presence of BAFF- 
APRIL heteromers [178] studied the binding affinities of these heteromers and homomers 
using surface plasmon resonance experiments. They found that only BAFF bound to BAFFR 
while the heteromers bound to TACI and BCMA. They also measured the dissociation 
constant of the heteromers as compared to APRIL and BAFF with respect to TACI and 
BCMA and BAFFR. The biological activity of the recombinant heterotrimers were assessed 
in vitro doing a TACI-Jurkat NF-kB assay and looking at proliferation signals on primary B 
cells. The binding of 2 APRIL and 1 BAFF to TACI, BCMA but not BAFFR in our studies 
were consistent with previous studies on BAFF-APRIL heteromer. As expected the single 
chain BAFF-APRIL heteromers could bind to these receptors as shown in Fig. 23 by ELISA 
(receptor-Fc’s) or flow cytometric analysis in Fig. 24 (receptor-GPI’s). All the heteromers 
and homomers showed similar EC50 on TACI-Fc and BCMA-Fc while on TACI-GPI the 
EC50 was bit lesser than on BCMA-GPI  (as measured by the MFI) suggesting stronger 
binding to TACI. However the fact that receptor Fc’s are dimeric and receptor GPI’s may 
also oligomerise on the surface of cells contributing to a somewhat blurry picture about their 
precise binding affinities, must be taken into account. In both the previous studies describing 
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BAFF-APRIL heteromer formation, either the stoichiometry of these heteromers could not be 
determined [218] or only one of them APRIL2BAFF was defined owing to their limitations of 
recombinant protein production. BAFF2APRIL was thus not well characterized so far. In our 
studies we found that 2 BAFF and 1 APRIL can bind to all 3 BAFF-APRIL receptors namely 
BAFFR, TACI and BCMA. APRIL-BAFF-BAFF also shows binding to BCMA, TACI as 
good as BAFF-APRIL-APRIL, APRIL-APRIL-APRIL and also BAFF-BAFF-BAFF. 
However binding to BAFFR is many fold reduced for as compared to BAFF-BAFF-BAFF. 
This result could be explained by the fact that binding to BAFFR is facilitated primarily by 
BAFF and presence of one molecule of APRIL weakens the binding. 
Furthermore the signaling on BCMA:Fas Jurkat reporter cell lines and NF-κB reporter assay 
in 293 T cells show similar signaling capacities of all the four ligands. On TACI-Fas cells 
Flag BAFF-APRIL-APRIL shows much less signaling as compared to the other three ligands, 
which is in contrast with the binding data on TACI-Fc and TACI-GPI. The signaling ability 
of APRIL-BAFF-BAFF and BAFF-APRIL-APRIL on BAFFR-Fas cells seem to be 
consistent with the ELISA and FACS data. BAFF-APRIL-APRIL neither binds nor signals 
via BAFFR, whereas signaling via BAFFR is many fold reduced by APRIL-BAFF-BAFF as 
compared to BAFF-BAFF-BAFF. 
On primary splenocytes, results obtained for the signaling by the homo and heteromers  had 
some differences with the data obtained on receptor Fc’s or GPI and reporter Fas cells . On 
WT splenocytes all single chain Flag tagged homomers signaled better compared to 
heteromers while for the Fc heteromers the signal was stronger than Flag tagged ligands but 
still less than the Fc-homomers. Flag-BAFF-APRIL-APRIL signaled weaker as compared to 
Flag-APRIL-APRIL-APRIL on WT splenocytes (Fig. 27) which was in contrast to binding 
data on TACI-GPI, TACI-Fc and also signaling via TACI-Fas reporter cell lines, but on 
TACI only cells (+9B9 Fig. 28) both displayed similar signals. On BAFFR only cells (TACI 
ko splenocytes) the results obtained were consistent for all the ligands. On TACI only cells 
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(so far done with only fractionated trimeric Flag ligands) Flag BAFF-BAFF-BAFF showed 
strongest signals as compared to the rest. This raises the question whether heteromers play a 
role in signaling via BAFFR or TACI at all? 
 
4.2.4. Is APRIL-BAFF-BAFF is it an inhibitor or an activator of BAFFR 
mediated signals in B cells? 
 
This brings to the question concerning the physiological relevance of these heteromers and 
their possible role in autoimmune diseases. The first group reporting the formation of 
heteromers [218] had assessed the signaling capacity of BAFF-APRIL heteromers on a B cell 
proliferation assay. They found that the activity could be inhibited by TACI-Ig but not 
BCMA-Ig or BAFFR-Ig and they hypothesized that perhaps the predominant form of 
heteromers in sera would be of APRIL2BAFF stoichiometry. However the second group 
reporting the presence of BAFF-APRIL heteromers [178] could produce recombinant 
heteromers with a predominant stoichiometry of 2 APRIL to 1 BAFF and a very small 
fraction of 1APRIL to 2 BAFF as confirmed by Western blot and size exclusion 
chromatography. Signaling was similar to that of APRIL in the in vitro TACI-Jurkat assay. 
Atacicept and BCMA-Ig neutralized the activity of BAFF APRIL, and heterotrimers in the 
TACI-Jurkat assay. BAFFR-Ig only neutralized the activity of BAFF. The heterotrimers were 
less-potent inducers of B-cell proliferation than were BAFF or APRIL, as evidenced by the 
higher EC50 values for heterotrimers than those of BAFF or APRIL in the primary human B 
cell-proliferation assay. They developed a bead based immunoassay and using the 
recombinant heterotrimers as a reference of quantification they measured endogenous 
heterotrimers in sera of patients with autoimmune diseases. Their studies indicate an increase 
in serum levels of heterotrimers correlated with disease prognosis as indicated by clinical 
parameters used in SLE. These heteromers had very little activity on B cell proliferation on 
primary human B cells. 
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As per our studies, we found that APRIL-BAFF-BAFF signals weakly via BAFFR as 
compared to BAFF-BAFF-BAFF. This raises the question of whether they could they act as 
an inhibitor of homomeric BAFF with respect to BAFFR signaling.  
 
As described in section 3.2.5 we performed a competition assay on both reporter cell line as 
well as on primary B cells expressing BAFFR. As per our results in Fig. 30 and 31 a 
conclusive comment on the inhibitory role of APRIL-BAFF-BAFF on BAFF-BAFF-BAFF 
signaling via BAFFR cannot be drawn yet and needs to be repeated. But with the trends 
shown so far based on the binding data (ELISA and receptor GPI) APRIL-BAFF-BAFF may 
be a weak binder of BAFFR and activate signaling only at higher concetration. 
 
4.2.5. Potential effect of heteromer signaling via TACI or BCMA? 
 
As seen in Fig 26 and 27 on primary splenocytes the heteromers signal weaker than the 
homomers. But the results obtained on receptor GPI or receptor Fc  do not show weak 
binding. In addition to weak signaling via primary B cells also on TACI-Fas reporter cells 
Flag APRIL-BAFF-BAFF shows less potent effect than the rest of the ligands. TACI is a 
receptor that signal well via oligomerised ligands as described previously [49]. So it is 
possible that oligomerised heteromers if they exist will signal via TACI while trimeric 
heteromers may signal weakly or inhibit signaling of homomers. To understand if they would 
activate or inhibit signaling via TACI one could do the competition assay with APRIL-
APRIL-APRIL or BAFF-BAFF-BAFF on TACI only cells. A limitation of this step may be 
the usage of the blocking antibody 9B9, which provides a higher background and may make 
interpretation of results difficult.  
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Based on the current results with all the available reagents it seems all the homo and 
heteromers signal equally well via BCMA. Both in presence or absence of anti-Flag used as a 
cross linker the signal obtained was same. Therefore it is possible that the heteromers have a 
physiological importance with respect to BCMA signaling. Both trimeric as well as 
oligomerised forms of heteromers, if they exist, can signal via BCMA. During pathological 
conditions the heteromers are found in high levels in sera as reported previously [218] 
correlated with disease progression [178]. It is possible that most of the effects of the 
heteromers in these conditions are a result of BCMA-mediated signaling. 
 
4.2.6. BAFF-APRIL heteromer characterization in animal models: 
Requirement for powerful tools. 
 
Although we could purify and study recombinant BAFF-APRIL heteromers, the significance 
for their co-existence along with the commonly found BAFF and APRIL homomers in the 
autoimmune diseases remain to be further explored. Whether they aggravate the disease or 
their presence is beneficial remains unclear. In vivo, studies in mouse models of these 
autoimmune diseases could provide a better or clearer picture of what is possible in the 
human counterpart. But these endeavours are much dependent on novel and powerful tools to 
study these heteromers. We could produce human single chain heteromers. Our limitation for 
endogenous detection was lack of antibodies, which could detect these naturally occurring 
heteromers. Alternatively a BAFF-APRIL specific antibody could be produced which would 
serve as an important tool. For studies in mouse models, it would be necessary to construct 
single chain mouse BAFF-APRIL heteromers, characterise antibodies specific to them and 
thereby set up an ELISA and other detection methods. Measuring the levels of heteromers in 
animal models during disease progression would also serve as an important indication 
towards its possible biological role. 
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4.3.1 BAFF 60-mer deficient Knock-In mouse. 
 
TACI has been shown to be specifically activated by oligomerised BAFF or APRIL [49]. In 
addition, BAFF has been overexpressed and crystallised to form an oligomeric soluble BAFF 
consisting of twenty trimers (60mer) [46, 48] and its presence has been detected in BAFF-
transgenic mice [49]. These findings raise a possibility that BAFF-60mer may be a 
physiologically relevant species of BAFF having a role to play in TACI activation.  
Our studies aimed at identifying a mutant BAFF which retains its capacity to form trimers but 
does not form 60-mer. We targeted the extra loop in BAFF called the Flap region unique to 
the TNF family, required for association of BAFF trimers and holds the 60-mer together  and 
introduced mutations in full-length mouse BAFF. We identified some amino acid residues in 
the flap region which could possibly disrupt the 60-mer formation. Based on our hypothesis 
of disrupting salt bridge formation between oppositely charged amino acids like glutamate 
and lysine, we made few mutants and expressed them in 293T cells. We checked their 
expression and secretion. Based on their ability to bind to all BAFF receptors as seen by 
ELISA and their capacity to signal via reporter cell lines responsive specifically to only an 
oligomeric BAFF and oligomeric plus trimeric BAFF we selected a E247K mutant for further 
studies. 
Our aim was to introduce this mutation in a WT mouse. Thereby we adopted the strategy of a 
Knock-In mouse deficient for 60-mer but sufficient for trimer. Using molecular biology 
methods we constructed the Knock-In vector with a neomycin resistance gene and transfected 
ES cells for the production of the recombinant genome with the point mutation. Our probes 
designed for the detection of the transgene by Southern blot as well as the primers designed 
for the screening of the mutant BAFF proved to be efficient. The screening of the ES cells so 
far has also been successful. The rest of the process as mentioned before is currently ongoing. 
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4.3.2. Role of BAFF-60mer in vivo. 
 
To address the question about the possible role of BAFF-60mer in vivo the Knock-In mouse 
would be evaluated for a primarily TACI-deficient phenotype as the role of BAFF-60mer so 
far seems to be TACI mediated. TACI is a receptor of BAFF and APRIL, which seems to 
play a dual role in B cell survival. On one hand in in vitro assays TACI induces B cell 
proliferation on primary mouse B cells, while TACI-deficient mice have increased number of 
B cells indicating that it might act as a negative regulator of B cell survival. Some 
unpublished data indicate that signaling via TACI may up-regulate some death receptors like 
Fas, which lead to cell death. TACI has also been implicated in the T independent type II 
response and class switch recombination in a cross talk with TLR’s. TACI-deficiency leads 
to impaired TI II response marked by impaired class switching and an increase in unswitched 
Ig’s. In absence of BAFF-60mer, a potential activator of TACI in vivo, it is possible that 
these TACI-mediated responses would be impaired and would serve as a read out of the 
Knock-In mice. It is also possible that BAFF-60mer has a redundant role to play in activation 
of TACI and in its absence, oligomerised APRIL whose physiological presence is still in 
question may compensate for BAFF-60mer deficiency and activate TACI. Another 
possibility is that membrane-bound BAFF, whose functional relevance has been addressed in 
furin mutant BAFF-Tg mice but whose existence in WT conditions has not been identified 
yet, can also serve as a form of oligomerised surface-bound BAFF capable of activating 
TACI. 
One question that still remains to be addressed is the physiological existence of BAFF 60-
mer, as in a healthy condition it is impossible to detect its presence. It is only upon over-
expression in mammalian cells and in BAFF-Tg mice one could find a small fraction of total 
BAFF. Thus in BAFF 60-mer-deficient mice, the validation of its existence becomes 
challenging and one has to rely only on TACI-mediated effects as read-outs. To develop 
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methods that would allow for the detection of endogenous BAFF 60-mer would prove to be 
useful. As has been described before, there are some already available reporter cell lines 
(Jurkat BAFF receptor-Fas cell lines), which exclusively signals via oligomerised BAFF. 
Improvement of the sensitivity of these cell lines could improve the chances and possibilities 
of BAFF 60-mer detection.  
BAFF 60-mer in BAFF-Tg mice forms a very minor fraction of total BAFF. Also in healthy 
mice, although BAFF trimer can be detected, its level is obviously less than in BAFF-Tg 
mice. One could hypothesize that perhaps the major species of soluble BAFF detected in 
circulating sera is perhaps a trimer and BAFF 60-mer which may arise in a healthy condition 
exist in a very low level perhaps beyond the limit of detection. It is also possible that perhaps 
BAFF-60mer is a species which remains bound to surface receptors and thus is not found in 
circulation. In a BAFF 60-mer-deficient condition, it is possible that the majority of surface- 
bound BAFF will be absent. But to detect surface bound BAFF provides another challenge of 
characterizing tools like antibodies, which can recognize BAFF 60-mer bound to its surface 
receptors. 
If TACI activation were BAFF 60-mer-dependent, it would be interesting to see if levels of 
TACI expression (either the mRNA or the protein) are dependent upon BAFF-60mer ligation. 
This could be already tested on a WT mouse and if necessary can be used as a read out for 
the 60-mer Knock-In mice.  
As it is possible that BAFF 60-mer arises only in pathological conditions or in conditions 
with high levels of BAFF, as seen in BAFF-Tg mice, disease models of mice mainly with 
autoimmune diseases with an elevated level of BAFF could be used to assess the presence of 
60-mer and, if verified, the Knock-In mice could be induced to develop such disease 
conditions in order to detect the presence of BAFF 60-mer. Alternatively, a BAFF-Tg mouse 
which shows endogenous BAFF 60-mer can be developed having a E247K Flap mutant 
which would disrupt the 60-mer but not the trimer. In such a case, one limitation would be 
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that high BAFF levels might not provide a clear physiological status. It may also be possible 
that high levels of BAFF trimer compensate for the effect of a 60-mer. 
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-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC CTC GAC AAA ACT 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   L   D   K   T>
CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC 198
 H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I   S   R   T>
CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA 297
 P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H   N   A   K   T>
AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 396
 K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K   E   Y   K   C   K>
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG 495
 V   S   N   K   A   L   P   A   P   I   E   K   T   I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R>
GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG 594
 D   E   L   T   K   N   Q   V   S   L   T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E>
AAC AAC TAC AAG ACC ACG CCT CCC GTG TTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC 693
 N   N   Y   K   T   T   P   P   V   L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N>
GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA AGA TCT CCG CAG CCG CAG CCG 792
 V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   K   R   S   P   Q   P   Q   P>
                                                                                                                                
AAA CCG CAG CCG AAA CCG GAA CCG GAA GGA TCC CTG CAG GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA 891
 K   P   Q   P   K   P   E   P   E   G   S   L   Q   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q>
AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC 990
 K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y>
TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT 1089
 F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S>
CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA 1188
 L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E>
                                                                                                                               
CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCT GAA 1287
 L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   G   G   G   G   S   E>
ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA 1386
 T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q   K   G   S   Y   T   F   V   P   W   L   L   S   F   K>
AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC 1485
 R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y   F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y>
GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA 1584
 A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q   N   M   P   E   T>
CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG 1683
 L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E   L   Q   L   A   I   P   R   E   N   A   Q   I   S   L>
                                                                                                                               
GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCC GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA 1782
 D   G   D   V   T   F   F   G   A   L   K   L   L   G   G   G   G   S   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E>
ACA CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC 1881
 T   P   T   I   Q   K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V>
AAA GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT 1980
 K   E   T   G   Y   F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F> 
GGG GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG 2079
 G   D   E   L   S   L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L>
GAA GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG TGA 2178
 E   E   G   D   E   L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   *
CTA GTC CTG AAT TCC CCG GGT CTA GAG GGC CCT ATT CTA TAG TGT CAC CTA AAT
ps2680     Fc hBAFF mono1 hBAFF mono2 hBAFF mono3 in PCR3
hBAFF aa 140-285
Sp6
BamHI
PstI
BamHI/
BglII hBAFF aa 140-285linker
linker
XbaI
hBAFF aa 140-285
ApaI
BamHI
T7 HindIII HA signal hIgG1 aa 245-470
SalI
XhoI
-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC CTC GAC AAA ACT 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   L   D   K   T>
CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC 198
 H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I   S   R   T>
CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA 297
 P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H   N   A   K   T>
AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 396
 K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K   E   Y   K   C   K>
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG 495
 V   S   N   K   A   L   P   A   P   I   E   K   T   I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R>
GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG 594
 D   E   L   T   K   N   Q   V   S   L   T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E>
AAC AAC TAC AAG ACC ACG CCT CCC GTG TTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC 693
 N   N   Y   K   T   T   P   P   V   L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N>
GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA AGA TCT CCG CAG CCG CAG CCG 792
 V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   K   R   S   P   Q   P   Q   P>
                                                                                                                                
AAA CCG CAG CCG AAA CCG GAA CCG GAA GGA TCC CTG CAG AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC 891
 K   P   Q   P   K   P   E   P   E   G   S   L   Q   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S>
GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG 990
 D   V   T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L>
CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA 1089
 L   Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I>
AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC 1188
 R   S   M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P>
                                                                                                                               
CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG GGA GGA GGT GGA TCT AAG AAG CAG CAC TCT GTC CTG CAC 1287
 R   A   R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   G   G   G   G   S   K   K   Q   H   S   V   L   H>
CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA 1386
 L   V   P   I   N   A   T   S   K   D   D   S   D   V   T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G>
TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA 1485
 Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E>
GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT 1584
 G   Q   G   R   Q   E   T   L   F   R   C   I   R   S   M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H>
TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG GGA 1683
 L   H   Q   G   D   I   L   S   V   I   I   P   R   A   R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   G>
GGA GGT GGA TCC AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA GAG GTG ATG TGG CAA CCA 1782
 G   G   G   S   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D   V   T   E   V   M   W   Q   P>
GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC CAG GTC CTG TTT CAA GAC 1881
 A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S   Q   V   L   F   Q   D>
GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG CCC TCC CAC CCG GAC CGG 1980
 V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R   S   M   P   S   H   P   D   R> 
GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT 2079
 A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R   A   R   A   K   L   N   L   S>
CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG TGA TGA CCT GAA TTC CGC CCC TCT CCC TCC CCC CCC CCT AAC GTT ACT GGC CGA AGC CGC TTG GAA 2178
 P   H   G   T   F   L   G   F   V   K   L   *   
TAA GGC CGG TGT GCG TTT GTC TAT ATG TTA TTT TCC ACC ATA TTG CCG TCT TTT GGC AAT GTG AGG GCC CGG AAA CCT GGC CCT GTC TTC TTG ACG AGC 2277
ATT CCT AGG GGT CTT TCC CCT CTC GCC AAA GGA ATG CAA GGT CTG TTG AAT GTC GTG AAG GAA GCA GTT CCT CTG GAA GCT TCT TGA AGA CAA ACA ACG 2376
TCT GTA GCG ACC CTT TGC AGG CAG CGG AAC CCC CCA CCT GGC GAC AGG TGC CTC TGC GGC CAA AAG CCA CGT GTA TAA GAT ACA CCT GCA AAG GCG GCA 2475
CAA CCC CAG TGC CAC GTT GTG AGT TGG ATA GTT GTG GAA AGA GTC AAA TGG CTC TCC TCA AGC GTA TTC AAC AAG GGG CTG AAG GAT GCC CAG AAG GTA 2574
CCC CAT TGT ATG GGA TCT GAT CTG GGG CCT CGG TGC ACA TGC TTT ACA TGT GTT TAG TCG AGG TTA AAA AAC GTC TAG GCC CCC CGA ACC ACG GGG ACG 2673
TGG TTT TCC TTT GAA AAA CAC GAT GAT AAT ATG GCC ACA ACC ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC GAG CTG 2772
GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCT GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC 2871
AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC TTC 2970
AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC 3069
ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC 3168
TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GCG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG 3267
CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT 3366
CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA TGA ATT AAT TAA GAA TTA TCA AGC TTA TCG 3465
ATA CCG TCG AGT AGA TGA CTA GTC TAG AGG GCC CTA TTC TAT AGT GTC ACC TAA AT
ps2876     Fc hAPRIL mono1 hAPRIL mono2 hAPRIL mono3 IRES GFP in PCR3
hAPRIL aa 95-233
Sp6
BamHI
PstI
BamHI/
BglII hAPRIL aa 95-233linker
linker
EcoRI
XbaI ApaI
hAPRIL aa 95-233
IRES - GFP
T7 HindIII HA signal hIgG1 aa 245-470
SalI
XhoI
BamHI
-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC CTC GAC AAA ACT 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   L   D   K   T>
CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC 198
 H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I   S   R   T>
CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA 297
 P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H   N   A   K   T>
AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 396
 K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K   E   Y   K   C   K>
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG 495
 V   S   N   K   A   L   P   A   P   I   E   K   T   I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R>
GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG 594
 D   E   L   T   K   N   Q   V   S   L   T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E>
AAC AAC TAC AAG ACC ACG CCT CCC GTG TTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC 693
 N   N   Y   K   T   T   P   P   V   L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N>
GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA AGA TCT CCG CAG CCG CAG CCG 792
 V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   K   R   S   P   Q   P   Q   P>
AAA CCG CAG CCG AAA CCG GAA CCG GAA GGA TCC CTG CAG GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA 891
 K   P   Q   P   K   P   E   P   E   G   S   L   Q   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q>
AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC 990
 K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y>
TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT 1089
 F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S>
CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA 1188
 L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E>
CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCT AAG 1287
 L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   G   G   G   G   S   K>
AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG 1386
 K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D   V   T   E   V   M   W   Q   P   A   L   R   R   G>
AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG 1485
 R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S   Q   V   L   F   Q   D   V   T   F   T   M>
GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC 1584
 G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R   S   M   P   S   H   P   D   R   A   Y   N   S   C>
TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC 1683
 Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R   A   R   A   K   L   N   L   S   P   H   G   T   F>
                                                                                                                               
CTG GGG TTT GTG AAA CTG GGA GGA GGT GGA TCC AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG 1782
 L   G   F   V   K   L   G   G   G   G   S   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D   V>
ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT 1881
 T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y>
AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT 1980
 S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R   S> 
ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA 2079
 M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R   A>
                                                                                                                               
AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG TGA TGA CCT GAA TTC CGC CCC TCT CCC TCC CCC CCC CCT AAC GTT 2178
 R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   *   
ACT GGC CGA AGC CGC TTG GAA TAA GGC CGG TGT GCG TTT GTC TAT ATG TTA TTT TCC ACC ATA TTG CCG TCT TTT GGC AAT GTG AGG GCC CGG AAA CCT 2277
GGC CCT GTC TTC TTG ACG AGC ATT CCT AGG GGT CTT TCC CCT CTC GCC AAA GGA ATG CAA GGT CTG TTG AAT GTC GTG AAG GAA GCA GTT CCT CTG GAA 2376
GCT TCT TGA AGA CAA ACA ACG TCT GTA GCG ACC CTT TGC AGG CAG CGG AAC CCC CCA CCT GGC GAC AGG TGC CTC TGC GGC CAA AAG CCA CGT GTA TAA 2475
GAT ACA CCT GCA AAG GCG GCA CAA CCC CAG TGC CAC GTT GTG AGT TGG ATA GTT GTG GAA AGA GTC AAA TGG CTC TCC TCA AGC GTA TTC AAC AAG GGG 2574
CTG AAG GAT GCC CAG AAG GTA CCC CAT TGT ATG GGA TCT GAT CTG GGG CCT CGG TGC ACA TGC TTT ACA TGT GTT TAG TCG AGG TTA AAA AAC GTC TAG 2673
GCC CCC CGA ACC ACG GGG ACG TGG TTT TCC TTT GAA AAA CAC GAT GAT AAT ATG GCC ACA ACC ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG 2772
GTG CCC ATC CTG GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCT GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG 2871
AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC 2970
ATG AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC 3069
GAG GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC 3168
AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GCG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG 3267
CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA 3366
GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA TGA ATT AAT 3465
TAA GAA TTA TCA AGC TTA TCG ATA CCG TCG AGT AGA TGA CTA GTC TAG AGG GCC CTA TTC TAT AGT GTC ACC TAA AT
ps2877     Fc hBAFF mono1 hAPRIL mono2 hAPRIL mono3 IRES GFP in PCR3
hBAFF aa 140-285
Sp6
BamHI
PstI
BamHI/
BglII hAPRIL aa 95-233linker
linker
EcoRI
XbaI ApaI
hAPRIL aa 95-233
IRES - GFP
T7 HindIII HA signal hIgG1 aa 245-470
SalI
XhoI
BamHI
-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC GAT TAC AAA GAC 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   D   Y   K   D>
GAT GAC GAT AAA GGA CCC GGA CAG GTG CAG CTG CAG AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT 198
 D   D   D   K   G   P   G   Q   V   Q   L   Q   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D>
GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG 297
 V   T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L>
TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA 396
 Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R>
AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG 495
 S   M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R>
                                                                                                                                
GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG GGA GGA GGT GGA TCT AAG AAG CAG CAC TCT GTC CTG CAC CTG 594
 A   R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   G   G   G   G   S   K   K   Q   H   S   V   L   H   L>
GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT 693
 V   P   I   N   A   T   S   K   D   D   S   D   V   T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y>
GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC 792
 G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G>
CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA 891
 Q   G   R   Q   E   T   L   F   R   C   I   R   S   M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L>
CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG GGA GGA 990
 H   Q   G   D   I   L   S   V   I   I   P   R   A   R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   G   G>
GGT GGA TCC AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT 1089
 G   G   S   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D   V   T   E   V   M   W   Q   P   A>
CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG 1188
 L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S   Q   V   L   F   Q   D   V>
ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC 1287
 T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R   S   M   P   S   H   P   D   R   A>
TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA 1386
 Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R   A   R   A   K   L   N   L   S   P>
CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG TGA TGA CCT GAA TTC CGC CCC TCT CCC TCC CCC CCC CCT AAC GTT ACT GGC CGA AGC CGC TTG GAA TAA 1485
 H   G   T   F   L   G   F   V   K   L   *
GGC CGG TGT GCG TTT GTC TAT ATG TTA TTT TCC ACC ATA TTG CCG TCT TTT GGC AAT GTG AGG GCC CGG AAA CCT GGC CCT GTC TTC TTG ACG AGC ATT 1584
CCT AGG GGT CTT TCC CCT CTC GCC AAA GGA ATG CAA GGT CTG TTG AAT GTC GTG AAG GAA GCA GTT CCT CTG GAA GCT TCT TGA AGA CAA ACA ACG TCT 1683
GTA GCG ACC CTT TGC AGG CAG CGG AAC CCC CCA CCT GGC GAC AGG TGC CTC TGC GGC CAA AAG CCA CGT GTA TAA GAT ACA CCT GCA AAG GCG GCA CAA 1782
CCC CAG TGC CAC GTT GTG AGT TGG ATA GTT GTG GAA AGA GTC AAA TGG CTC TCC TCA AGC GTA TTC AAC AAG GGG CTG AAG GAT GCC CAG AAG GTA CCC 1881
CAT TGT ATG GGA TCT GAT CTG GGG CCT CGG TGC ACA TGC TTT ACA TGT GTT TAG TCG AGG TTA AAA AAC GTC TAG GCC CCC CGA ACC ACG GGG ACG TGG 1980
TTT TCC TTT GAA AAA CAC GAT GAT AAT ATG GCC ACA ACC ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC GAG CTG GAC 2079
GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCT GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG 2178
CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC TTC AAG 2277
TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC ACC 2376
CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC TAC AAC AGC CAC AAC GTC TAT 2475
ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GCG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC GAC CAC TAC CAG CAG 2574
AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC 2673
ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA TGA ATT AAT TAA GAA TTA TCA AGC TTA TCG ATA 2772
CCG TCG AGT AGA TGA CTA GTC TAG AGG GCC CTA TTC TAT AGT GTC ACC TAA AT
T7 HindIII
ps2879     Flag hAPRIL mono1 hAPRIL mono2 hAPRIL mono3 IRES GFP in PCR3
hAPRIL aa 95-233
Sp6
BamHI
PstI
BamHI/
BglII hAPRIL aa 95-233linker
EcoRI
XbaI ApaI
hAPRIL aa 95-233
IRES - GFP
linker
-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC CTC GAC AAA ACT 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   L   D   K   T>
CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC 198
 H   T   C   P   P   C   P   A   P   E   L   L   G   G   P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I   S   R   T>
CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA 297
 P   E   V   T   C   V   V   V   D   V   S   H   E   D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H   N   A   K   T>
AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 396
 K   P   R   E   E   Q   Y   N   S   T   Y   R   V   V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K   E   Y   K   C   K>
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG 495
 V   S   N   K   A   L   P   A   P   I   E   K   T   I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R>
GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG 594
 D   E   L   T   K   N   Q   V   S   L   T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E>
AAC AAC TAC AAG ACC ACG CCT CCC GTG TTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC 693
 N   N   Y   K   T   T   P   P   V   L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N>
GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA AGA TCT CCG CAG CCG CAG CCG 792
 V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P   G   K   R   S   P   Q   P   Q   P>
                                                                                                                                
AAA CCG CAG CCG AAA CCG GAA CCG GAA GGA TCC CTG CAG AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC 891
 K   P   Q   P   K   P   E   P   E   G   S   L   Q   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S>
GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG 990
 D   V   T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L>
CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA 1089
 L   Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I>
AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC 1188
 R   S   M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P>
                                                                                                                               
CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG GGA GGA GGT GGA TCT GAA ACA GTC ACT CAA GAC TGC TTG 1287
 R   A   R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   G   G   G   G   S   E   T   V   T   Q   D   C   L>
CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA 1386
 Q   L   I   A   D   S   E   T   P   T   I   Q   K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E>
AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG 1485
 K   E   N   K   I   L   V   K   E   T   G   Y   F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q>
AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT 1584
 R   K   K   V   H   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y>
TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT 1683
 S   A   G   I   A   K   L   E   E   G   D   E   L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F>
                                                                                                                               
GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCC GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA GGA 1782
 G   A   L   K   L   L   G   G   G   G   S   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q   K   G>
TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT TTT 1881
 S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y   F   F>
ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG 1980
 I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S   L   V> 
ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA 2079
 T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E   L   Q>
CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG TGA CTA GTC CTG AAT TCC GCC CCT 2178
 L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   * 
CTC CCT CCC CCC CCC CTA ACG TTA CTG GCC GAA GCC GCT TGG AAT AAG GCC GGT GTG CGT TTG TCT ATA TGT TAT TTT CCA CCA TAT TGC CGT CTT TTG 2277
GCA ATG TGA GGG CCC GGA AAC CTG GCC CTG TCT TCT TGA CGA GCA TTC CTA GGG GTC TTT CCC CTC TCG CCA AAG GAA TGC AAG GTC TGT TGA ATG TCG 2376
TGA AGG AAG CAG TTC CTC TGG AAG CTT CTT GAA GAC AAA CAA CGT CTG TAG CGA CCC TTT GCA GGC AGC GGA ACC CCC CAC CTG GCG ACA GGT GCC TCT 2475
GCG GCC AAA AGC CAC GTG TAT AAG ATA CAC CTG CAA AGG CGG CAC AAC CCC AGT GCC ACG TTG TGA GTT GGA TAG TTG TGG AAA GAG TCA AAT GGC TCT 2574
CCT CAA GCG TAT TCA ACA AGG GGC TGA AGG ATG CCC AGA AGG TAC CCC ATT GTA TGG GAT CTG ATC TGG GGC CTC GGT GCA CAT GCT TTA CAT GTG TTT 2673
AGT CGA GGT TAA AAA ACG TCT AGG CCC CCC GAA CCA CGG GGA CGT GGT TTT CCT TTG AAA AAC ACG ATG ATA ATA TGG CCA CAA CCA TGG TGA GCA AGG 2772
GCG AGG AGC TGT TCA CCG GGG TGG TGC CCA TCC TGG TCG AGC TGG ACG GCG ACG TAA ACG GCC ACA AGT TCA GCG TGT CTG GCG AGG GCG AGG GCG ATG 2871
CCA CCT ACG GCA AGC TGA CCC TGA AGT TCA TCT GCA CCA CCG GCA AGC TGC CCG TGC CCT GGC CCA CCC TCG TGA CCA CCC TGA CCT ACG GCG TGC AGT 2970
GCT TCA GCC GCT ACC CCG ACC ACA TGA AGC AGC ACG ACT TCT TCA AGT CCG CCA TGC CCG AAG GCT ACG TCC AGG AGC GCA CCA TCT TCT TCA AGG ACG 3069
ACG GCA ACT ACA AGA CCC GCG CCG AGG TGA AGT TCG AGG GCG ACA CCC TGG TGA ACC GCA TCG AGC TGA AGG GCA TCG ACT TCA AGG AGG ACG GCA ACA 3168
TCC TGG GGC ACA AGC TGG AGT ACA ACT ACA ACA GCC ACA ACG TCT ATA TCA TGG CCG ACA AGC AGA AGA ACG GCA TCA AGG CGA ACT TCA AGA TCC GCC 3267
ACA ACA TCG AGG ACG GCA GCG TGC AGC TCG CCG ACC ACT ACC AGC AGA ACA CCC CCA TCG GCG ACG GCC CCG TGC TGC TGC CCG ACA ACC ACT ACC TGA 3366
GCA CCC AGT CCG CCC TGA GCA AAG ACC CCA ACG AGA AGC GCG ATC ACA TGG TCC TGC TGG AGT TCG TGA CCG CCG CCG GGA TCA CTC TCG GCA TGG ACG 3465
AGC TGT ACA AGT AAT GAA TTA ATT AAG AAT TAT CAA GCT TAT CGA TAC CGT CGA GTA GAT GAC TAG TCT AGA GGG CCC TAT TCT ATA GTG TCA CCT AAA 3564
T
T7 HindIII
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-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC GAT TAC AAA GAC 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   D   Y   K   D>
GAT GAC GAT AAA GGA CCC GGA CAG GTG CAG CTG CAG AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT 198
 D   D   D   K   G   P   G   Q   V   Q   L   Q   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D>
GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG 297
 V   T   E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L>
TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA 396
 Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R>
AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG 495
 S   M   P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R>
                                                                                                                                594
GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG GGA GGA GGT GGA TCT GAA ACA GTC ACT CAA GAC TGC TTG CAA 594
 A   R   A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   G   G   G   G   S   E   T   V   T   Q   D   C   L   Q>
CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA 693
 L   I   A   D   S   E   T   P   T   I   Q   K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K>
GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG 792
 E   N   K   I   L   V   K   E   T   G   Y   F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R>
AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA 891
 K   K   V   H   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S>
GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT 990
 A   G   I   A   K   L   E   E   G   D   E   L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G>
                                                                                                                               
GCA TTG AAA CTG CTG GGA GGA GGA GGA TCC GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA GGA TCT 1089
 A   L   K   L   L   G   G   G   G   S   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q   K   G   S>
TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT TTT ATA 1188
 Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y   F   F   I>
TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG ACT 1287
 Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S   L   V   T>
TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA CTT 1386
 L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E   L   Q   L>
GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG TGA CTA GTC CTG AAT TCG CCC CTC TCC 1485
 A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   * 
CTC CCC CCC CCC TAA CGT TAC TGG CCG AAG CCG CTT GGA ATA AGG CCG GTG TGC GTT TGT CTA TAT GTT ATT TTC CAC CAT ATT GCC GTC TTT TGG CAA 1584
TGT GAG GGC CCG GAA ACC TGG CCC TGT CTT CTT GAC GAG CAT TCC TAG GGG TCT TTC CCC TCT CGC CAA AGG AAT GCA AGG TCT GTT GAA TGT CGT GAA 1683
GGA AGC AGT TCC TCT GGA AGC TTC TTG AAG ACA AAC AAC GTC TGT AGC GAC CCT TTG CAG GCA GCG GAA CCC CCC ACC TGG CGA CAG GTG CCT CTG CGG 1782
CCA AAA GCC ACG TGT ATA AGA TAC ACC TGC AAA GGC GGC ACA ACC CCA GTG CCA CGT TGT GAG TTG GAT AGT TGT GGA AAG AGT CAA ATG GCT CTC CTC 1881
AAG CGT ATT CAA CAA GGG GCT GAA GGA TGC CCA GAA GGT ACC CCA TTG TAT GGG ATC TGA TCT GGG GCC TCG GTG CAC ATG CTT TAC ATG TGT TTA GTC 1980
GAG GTT AAA AAA CGT CTA GGC CCC CCG AAC CAC GGG GAC GTG GTT TTC CTT TGA AAA ACA CGA TGA TAA TAT GGC CAC AAC CAT GGT GAG CAA GGG CGA 2079
GGA GCT GTT CAC CGG GGT GGT GCC CAT CCT GGT CGA GCT GGA CGG CGA CGT AAA CGG CCA CAA GTT CAG CGT GTC TGG CGA GGG CGA GGG CGA TGC CAC 2178
CTA CGG CAA GCT GAC CCT GAA GTT CAT CTG CAC CAC CGG CAA GCT GCC CGT GCC CTG GCC CAC CCT CGT GAC CAC CCT GAC CTA CGG CGT GCA GTG CTT 2277
CAG CCG CTA CCC CGA CCA CAT GAA GCA GCA CGA CTT CTT CAA GTC CGC CAT GCC CGA AGG CTA CGT CCA GGA GCG CAC CAT CTT CTT CAA GGA CGA CGG 2376
CAA CTA CAA GAC CCG CGC CGA GGT GAA GTT CGA GGG CGA CAC CCT GGT GAA CCG CAT CGA GCT GAA GGG CAT CGA CTT CAA GGA GGA CGG CAA CAT CCT 2475
GGG GCA CAA GCT GGA GTA CAA CTA CAA CAG CCA CAA CGT CTA TAT CAT GGC CGA CAA GCA GAA GAA CGG CAT CAA GGC GAA CTT CAA GAT CCG CCA CAA 2574
CAT CGA GGA CGG CAG CGT GCA GCT CGC CGA CCA CTA CCA GCA GAA CAC CCC CAT CGG CGA CGG CCC CGT GCT GCT GCC CGA CAA CCA CTA CCT GAG CAC 2673
CCA GTC CGC CCT GAG CAA AGA CCC CAA CGA GAA GCG CGA TCA CAT GGT CCT GCT GGA GTT CGT GAC CGC CGC CGG GAT CAC TCT CGG CAT GGA CGA GCT 2772
GTA CAA GTA ATG AAT TAA TTA AGA ATT ATC AAG CTT ATC GAT ACC GTC GAG TAG ATG ACT AGT CTA GAG GGC CCT ATT CTA TAG TGT CAC CTA AAT
T7 HindIII
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-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC GAT TAC AAA GAC 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   D   Y   K   D>
GAT GAC GAT AAA GGA CCC GGA CAG GTG CAG CTG CAG GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA 198
 D   D   D   K   G   P   G   Q   V   Q   L   Q   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q   K>
GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT 297
 G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y   F>
TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG 396
 F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S   L>
GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC 495
 V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E   L>
                                                                                                                                
CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCT AAG AAG 594
 Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   G   G   G   G   S   K   K>
CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA 693
 Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D   V   T   E   V   M   W   Q   P   A   L   R   R   G   R>
GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT 792
 G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S   Q   V   L   F   Q   D   V   T   F   T   M   G>
CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT 891
 Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R   S   M   P   S   H   P   D   R   A   Y   N   S   C   Y>
AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG 990
 S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R   A   R   A   K   L   N   L   S   P   H   G   T   F   L>
                                                                                                                               
GGG TTT GTG AAA CTG GGA GGA GGT GGA TCC AAG AAG CAG CAC TCT GTC CTG CAC CTG GTT CCC ATT AAC GCC ACC TCC AAG GAT GAC TCC GAT GTG ACA 1089
 G   F   V   K   L   G   G   G   G   S   K   K   Q   H   S   V   L   H   L   V   P   I   N   A   T   S   K   D   D   S   D   V   T>
GAG GTG ATG TGG CAA CCA GCT CTT AGG CGT GGG AGA GGC CTA CAG GCC CAA GGA TAT GGT GTC CGA ATC CAG GAT GCT GGA GTT TAT CTG CTG TAT AGC 1188
 E   V   M   W   Q   P   A   L   R   R   G   R   G   L   Q   A   Q   G   Y   G   V   R   I   Q   D   A   G   V   Y   L   L   Y   S>
CAG GTC CTG TTT CAA GAC GTG ACT TTC ACC ATG GGT CAG GTG GTG TCT CGA GAA GGC CAA GGA AGG CAG GAG ACT CTA TTC CGA TGT ATA AGA AGT ATG 1287
 Q   V   L   F   Q   D   V   T   F   T   M   G   Q   V   V   S   R   E   G   Q   G   R   Q   E   T   L   F   R   C   I   R   S   M>
CCC TCC CAC CCG GAC CGG GCC TAC AAC AGC TGC TAT AGC GCA GGT GTC TTC CAT TTA CAC CAA GGG GAT ATT CTG AGT GTC ATA ATT CCC CGG GCA AGG 1386
 P   S   H   P   D   R   A   Y   N   S   C   Y   S   A   G   V   F   H   L   H   Q   G   D   I   L   S   V   I   I   P   R   A   R>
                                                                                                                               
GCG AAA CTT AAC CTC TCT CCA CAT GGA ACC TTC CTG GGG TTT GTG AAA CTG TGA TGA CCT GAA TTC CGC CCC TCT CCC TCC CCC CCC CCT AAC GTT ACT 1485
 A   K   L   N   L   S   P   H   G   T   F   L   G   F   V   K   L   *
GGC CGA AGC CGC TTG GAA TAA GGC CGG TGT GCG TTT GTC TAT ATG TTA TTT TCC ACC ATA TTG CCG TCT TTT GGC AAT GTG AGG GCC CGG AAA CCT GGC 1584
CCT GTC TTC TTG ACG AGC ATT CCT AGG GGT CTT TCC CCT CTC GCC AAA GGA ATG CAA GGT CTG TTG AAT GTC GTG AAG GAA GCA GTT CCT CTG GAA GCT 1683
TCT TGA AGA CAA ACA ACG TCT GTA GCG ACC CTT TGC AGG CAG CGG AAC CCC CCA CCT GGC GAC AGG TGC CTC TGC GGC CAA AAG CCA CGT GTA TAA GAT 1782
ACA CCT GCA AAG GCG GCA CAA CCC CAG TGC CAC GTT GTG AGT TGG ATA GTT GTG GAA AGA GTC AAA TGG CTC TCC TCA AGC GTA TTC AAC AAG GGG CTG 1881
AAG GAT GCC CAG AAG GTA CCC CAT TGT ATG GGA TCT GAT CTG GGG CCT CGG TGC ACA TGC TTT ACA TGT GTT TAG TCG AGG TTA AAA AAC GTC TAG GCC 1980
CCC CGA ACC ACG GGG ACG TGG TTT TCC TTT GAA AAA CAC GAT GAT AAT ATG GCC ACA ACC ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG 2079
CCC ATC CTG GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCT GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG 2178
TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG 2277
AAG CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG 2376
GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC AAC 2475
TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC GGC ATC AAG GCG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG CAG 2574
CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC 2673
CCC AAC GAG AAG CGC GAT CAC ATG GTC CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA TGA ATT AAT TAA 2772
GAA TTA TCA AGC TTA TCG ATA CCG TCG AGT AGA TGA CTA GTC TAG AGG GCC CTA TTC TAT AGT GTC ACC TAA AT
T7 HindIII
ps2889     Flag hBAFF mono1 hAPRIL mono2 hAPRIL mono3 IRES GFP in PCR3
hBAFF aa 140-285
Sp6
BamHI
PstI
BamHI/
BglII hAPRIL aa 95-233linker
linker
EcoRI
XbaI ApaI
hAPRIL aa 95-233
IRES - GFP
-TA ATA CGA CTC ACT ATA GGG AGA CCC AAG CTT AAT CAA AAC ATG GCT ATC ATC TAC CTC ATC CTC CTG TTC ACC GCT GTG CGG GGC GAT TAC AAA GAC 99
                                                         M   A   I   I   Y   L   I   L   L   F   T   A   V   R   G   D   Y   K   D>
                                                                                              
GAT GAC GAT AAA GGA CCC GGA CAG GTG CAG CTG CAG GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA 198
 D   D   D   K   G   P   G   Q   V   Q   L   Q   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q   K>
GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT 297
 G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y   F>
TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG 396
 F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S   L>
GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC 495
 V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E   L>
                                                                                                                                
CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCT GAA ACA 594
 Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   G   G   G   G   S   E   T>
GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG 693
 V   T   Q   D   C   L   Q   L   I   A   D   S   E   T   P   T   I   Q   K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R>
GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC 792
 G   S   A   L   E   E   K   E   N   K   I   L   V   K   E   T   G   Y   F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A>
ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA 891
 M   G   H   L   I   Q   R   K   K   V   H   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L>
CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT 990
 P   N   N   S   C   Y   S   A   G   I   A   K   L   E   E   G   D   E   L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D>
                                                                                                                               
GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG GGA GGA GGA GGA TCC GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT GAA ACA 1089
 G   D   V   T   F   F   G   A   L   K   L   L   G   G   G   G   S   E   T   V   T   Q   D   C   L   Q   L   I   A   D   S   E   T>
CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA TTG GTC AAA 1188
 P   T   I   Q   K   G   S   Y   T   F   V   P   W   L   L   S   F   K   R   G   S   A   L   E   E   K   E   N   K   I   L   V   K>
GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC CAT GTC TTT GGG 1287
 E   T   G   Y   F   F   I   Y   G   Q   V   L   Y   T   D   K   T   Y   A   M   G   H   L   I   Q   R   K   K   V   H   V   F   G>
GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC ATT GCA AAA CTG GAA 1386
 D   E   L   S   L   V   T   L   F   R   C   I   Q   N   M   P   E   T   L   P   N   N   S   C   Y   S   A   G   I   A   K   L   E>
GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA TTG AAA CTG CTG TGA CTA 1485
 E   G   D   E   L   Q   L   A   I   P   R   E   N   A   Q   I   S   L   D   G   D   V   T   F   F   G   A   L   K   L   L   *   
                                                                                                                               
GTC CTG AAT TCC GCC CCT CTC CCT CCC CCC CCC CTA ACG TTA CTG GCC GAA GCC GCT TGG AAT AAG GCC GGT GTG CGT TTG TCT ATA TGT TAT TTT CCA 1584
CCA TAT TGC CGT CTT TTG GCA ATG TGA GGG CCC GGA AAC CTG GCC CTG TCT TCT TGA CGA GCA TTC CTA GGG GTC TTT CCC CTC TCG CCA AAG GAA TGC 1683
AAG GTC TGT TGA ATG TCG TGA AGG AAG CAG TTC CTC TGG AAG CTT CTT GAA GAC AAA CAA CGT CTG TAG CGA CCC TTT GCA GGC AGC GGA ACC CCC CAC 1782
CTG GCG ACA GGT GCC TCT GCG GCC AAA AGC CAC GTG TAT AAG ATA CAC CTG CAA AGG CGG CAC AAC CCC AGT GCC ACG TTG TGA GTT GGA TAG TTG TGG 1881
AAA GAG TCA AAT GGC TCT CCT CAA GCG TAT TCA ACA AGG GGC TGA AGG ATG CCC AGA AGG TAC CCC ATT GTA TGG GAT CTG ATC TGG GGC CTC GGT GCA 1980
CAT GCT TTA CAT GTG TTT AGT CGA GGT TAA AAA ACG TCT AGG CCC CCC GAA CCA CGG GGA CGT GGT TTT CCT TTG AAA AAC ACG ATG ATA ATA TGG CCA 2079
CAA CCA TGG TGA GCA AGG GCG AGG AGC TGT TCA CCG GGG TGG TGC CCA TCC TGG TCG AGC TGG ACG GCG ACG TAA ACG GCC ACA AGT TCA GCG TGT CTG 2178
GCG AGG GCG AGG GCG ATG CCA CCT ACG GCA AGC TGA CCC TGA AGT TCA TCT GCA CCA CCG GCA AGC TGC CCG TGC CCT GGC CCA CCC TCG TGA CCA CCC 2277
TGA CCT ACG GCG TGC AGT GCT TCA GCC GCT ACC CCG ACC ACA TGA AGC AGC ACG ACT TCT TCA AGT CCG CCA TGC CCG AAG GCT ACG TCC AGG AGC GCA 2376
CCA TCT TCT TCA AGG ACG ACG GCA ACT ACA AGA CCC GCG CCG AGG TGA AGT TCG AGG GCG ACA CCC TGG TGA ACC GCA TCG AGC TGA AGG GCA TCG ACT 2475
TCA AGG AGG ACG GCA ACA TCC TGG GGC ACA AGC TGG AGT ACA ACT ACA ACA GCC ACA ACG TCT ATA TCA TGG CCG ACA AGC AGA AGA ACG GCA TCA AGG 2574
CGA ACT TCA AGA TCC GCC ACA ACA TCG AGG ACG GCA GCG TGC AGC TCG CCG ACC ACT ACC AGC AGA ACA CCC CCA TCG GCG ACG GCC CCG TGC TGC TGC 2673
CCG ACA ACC ACT ACC TGA GCA CCC AGT CCG CCC TGA GCA AAG ACC CCA ACG AGA AGC GCG ATC ACA TGG TCC TGC TGG AGT TCG TGA CCG CCG CCG GGA 2772
TCA CTC TCG GCA TGG ACG AGC TGT ACA AGT AAT GAA TTA ATT AAG AAT TAT CAA GCT TAT CGA TAC CGT CGA GTA GAT GAC TAG TCT AGA GGG CCC TAT 2871
TCT ATA GTG TCA CCT AAA T
T7 HindIII
ps2890     Flag hBAFF mono1 mono2 mono3 IRES GFP in PCR3
hBAFF aa 140-285
Sp6
Enzyme cutters
BamHI
PstI
BamHI/
BglII hBAFF aa 140-285linker
linker
EcoRI
XbaI
hBAFF aa 140-285
ApaI
IRES - GFP
 TAA TAC GAC TCA CTA TAG GGA GAC CCA AGC TTG GTA CCG AGC TCG GAT CCA 51
 CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC AGG AAA GCC ACC ATG GAT GAG 102
                                                          M   D   E>
 TCT GCA AAG ACC CTG CCA CCA CCG TGC CTC TGT TTT TGC TCC GAG AAA GGA 153
  S   A   K   T   L   P   P   P   C   L   C   F   C   S   E   K   G>
 GAA GAT ATG AAA GTG GGA TAT GAT CCC ATC ACT CCG CAG AAG GAG GAG GGT 204
  E   D   M   K   V   G   Y   D   P   I   T   P   Q   K   E   E   G>
 GCC TGG TTT GGG ATC TGC AGG GAT GGA AGG CTG CTG GCT GCT ACC CTC CTG 255
  A   W   F   G   I   C   R   D   G   R   L   L   A   A   T   L   L>
 CTG GCC CTG TTG TCC AGC AGT TTC ACA GCG ATG TCC TTG TAC CAG TTG GCT 306
  L   A   L   L   S   S   S   F   T   A   M   S   L   Y   Q   L   A>
 GCC TTG CAA GCA GAC CTG ATG AAC CTG CGC ATG GAG CTG CAG AGC TAC CGA 357
  A   L   Q   A   D   L   M   N   L   R   M   E   L   Q   S   Y   R>
 GGT TCA GCA ACA CCA GCC GCC GCG GGT GCT CCA GAG TTG ACC GCT GGA GTC 408
  G   S   A   T   P   A   A   A   G   A   P   E   L   T   A   G   V>
 AAA CTC CTG ACA CCG GCA GCT CCT CGA CCC CAC AAC TCC AGC CGC GGC CAC 459
  K   L   L   T   P   A   A   P   R   P   H   N   S   S   R   G   H>
 AGG AAC AGA CGC GCT TTC CAG GGA CCA GAG GAA ACA GAA CAA GAT GTA GAC 510
  R   N   R   R   A   F   Q   G   P   E   E   T   E   Q   D   V   D>
 CTC TCA GCT CCT CCT GCA CCA TGC CTG CCT GGA TGC CGC CAT TCT CAA CAT 561
  L   S   A   P   P   A   P   C   L   P   G   C   R   H   S   Q   H>
 GAT GAT AAT GGA ATG AAC CTC AGA AAC ATC ATT CAA GAC TGT CTG CAG CTG 612
  D   D   N   G   M   N   L   R   N   I   I   Q   D   C   L   Q   L>
 ATT GCA GAC AGC GAC ACG CCG ACT ATA CGA AAA GGA ACT TAC ACA TTT GTT 663
  I   A   D   S   D   T   P   T   I   R   K   G   T   Y   T   F   V>
 CCA TGG CTT CTC AGC TTT AAA AGA GGA AAT GCC TTG GAG GAG AAA GAG AAC 714
  P   W   L   L   S   F   K   R   G   N   A   L   E   E   K   E   N>
 AAA ATA GTG GTG AGG CAA ACA GGC TAT TTC TTC ATC TAC AGC CAG GTT CTA 765
  K   I   V   V   R   Q   T   G   Y   F   F   I   Y   S   Q   V   L>
 TAC ACG GAC CCC ATC TTT GCT ATG GGT CAT GTC ATC CAG AGG AAG AAA GTA 816
  Y   T   D   P   I   F   A   M   G   H   V   I   Q   R   K   K   V>
 CAC GTC TTT GGG GAC GAG CTG AGC CTG GTG ACC CTG TTC CGA TGT ATT CAG 867
  H   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q>
 AAT ATG CCC AAA ACA CTG CCC AAC AAT TCC TGC TAC TCG GCT GGC ATC GCG 918
  N   M   P   K   T   L   P   N   N   S   C   Y   S   A   G   I   A>
 AGG CTG GAA GAA GGA GAT GAG ATT CAG CTT GCA ATT CCT CGG GAG AAT GCA 969
  R   L   E   E   G   D   E   I   Q   L   A   I   P   R   E   N   A>
 CAG ATT TCA CGC AAC GGA GAC GAC ACC TTC TTT GGT GCC CTA AAA CTG CTG 1020
  Q   I   S   R   N   G   D   D   T   F   F   G   A   L   K   L   L>
 TAA ACT AGT CCT GAA TTC TGC AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG 1071
  * 
 CAT GCA TCT AGA GGG CCC TAT TCT ATA GTG TCA CCT AAA T
T7 HindIII
ps694      m BAFF full in PCR3
mBAFF 1-309
NotI XhoI
XbaI ApaI Sp6
EcoRI PstI
BamHI
EcoRI
 TAA TAC GAC TCA CTA TAG GGA GAC CCA AGC TTG GTA CCG AGC TCG GAT CCA 51
 CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC AGG AAA GCC ACC ATG GAT GAG 102
                                                          M   D   E>
 TCT GCA AAG ACC CTG CCA CCA CCG TGC CTC TGT TTT TGC TCC GAG AAA GGA 153
  S   A   K   T   L   P   P   P   C   L   C   F   C   S   E   K   G>
 GAA GAT ATG AAA GTG GGA TAT GAT CCC ATC ACT CCG CAG AAG GAG GAG GGT 204
  E   D   M   K   V   G   Y   D   P   I   T   P   Q   K   E   E   G>
 GCC TGG TTT GGG ATC TGC AGG GAT GGA AGG CTG CTG GCT GCT ACC CTC CTG 255
  A   W   F   G   I   C   R   D   G   R   L   L   A   A   T   L   L>
 CTG GCC CTG TTG TCC AGC AGT TTC ACA GCG ATG TCC TTG TAC CAG TTG GCT 306
  L   A   L   L   S   S   S   F   T   A   M   S   L   Y   Q   L   A>
 GCC TTG CAA GCA GAC CTG ATG AAC CTG CGC ATG GAG CTG CAG AGC TAC CGA 357
  A   L   Q   A   D   L   M   N   L   R   M   E   L   Q   S   Y   R>
 GGT TCA GCA ACA CCA GCC GCC GCG GGT GCT CCA GAG TTG ACC GCT GGA GTC 408
  G   S   A   T   P   A   A   A   G   A   P   E   L   T   A   G   V>
 AAA CTC CTG ACA CCG GCA GCT CCT CGA CCC CAC AAC TCC AGC CGC GGC CAC 459
  K   L   L   T   P   A   A   P   R   P   H   N   S   S   R   G   H>
 AGG AAC AGA CGC GCT TTC CAG GGA CCA GAG GAA ACA GAA CAA GAT GTA GAC 510
  R   N   R   R   A   F   Q   G   P   E   E   T   E   Q   D   V   D>
 CTC TCA GCT CCT CCT GCA CCA TGC CTG CCT GGA TGC CGC CAT TCT CAA CAT 561
  L   S   A   P   P   A   P   C   L   P   G   C   R   H   S   Q   H>
 GAT GAT AAT GGA ATG AAC CTC AGA AAC ATC ATT CAA GAC TGT CTG CAG CTG 612
  D   D   N   G   M   N   L   R   N   I   I   Q   D   C   L   Q   L>
 ATT GCA GAC AGC GAC ACG CCG ACT ATA CGA AAA GGA ACT TAC ACA TTT GTT 663
  I   A   D   S   D   T   P   T   I   R   K   G   T   Y   T   F   V>
 CCA TGG CTT CTC AGC TTT AAA AGA GGA AAT GCC TTG GAG GAG AAA GAG AAC 714
  P   W   L   L   S   F   K   R   G   N   A   L   E   E   K   E   N>
 AAA ATA GTG GTG AGG CAA ACA GGC TAT TTC TTC ATC TAC AGC CAG GTT CTA 765
  K   I   V   V   R   Q   T   G   Y   F   F   I   Y   S   Q   V   L>
 TAC ACG GAC CCC ATC TTT GCT ATG GGT CAT GTC ATC CAG AGG AAG AAA GTA 816
  Y   T   D   P   I   F   A   M   G   H   V   I   Q   R   K   K   V>
 GCC GTC TTT GGG GAC GAG CTG AGC CTG GTG ACC CTG TTC CGA TGT ATT CAG 867
  A   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q>
 AAT ATG CCC AAA ACA CTG CCC AAC AAT TCC TGC TAC TCG GCT GGC ATC GCG 918
  N   M   P   K   T   L   P   N   N   S   C   Y   S   A   G   I   A>
 AGG CTG GAA GAA GGA GAT GAG ATT CAG CTT GCA ATT CCT CGG GAG AAT GCA 969
  R   L   E   E   G   D   E   I   Q   L   A   I   P   R   E   N   A>
 CAG ATT TCA CGC AAC GGA GAC GAC ACC TTC TTT GGT GCC CTA AAA CTG CTG 1020
  Q   I   S   R   N   G   D   D   T   F   F   G   A   L   K   L   L>
 TAA ACT AGT CCT GAA TTC TGC AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG 1071
  * 
 CAT GCA TCT AGA GGG CCC TAT TCT ATA GTG TCA CCT AAA T
T7 HindIII
ps2355      m BAFF H242A full in PCR3
mBAFF 1-309
NotI XhoI
XbaI ApaI Sp6
EcoRI PstI
BamHI
EcoRI
H242A
 TAA TAC GAC TCA CTA TAG GGA GAC CCA AGC TTG GTA CCG AGC TCG GAT CCA 51
 CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC AGG AAA GCC ACC ATG GAT GAG 102
                                                          M   D   E>
 TCT GCA AAG ACC CTG CCA CCA CCG TGC CTC TGT TTT TGC TCC GAG AAA GGA 153
  S   A   K   T   L   P   P   P   C   L   C   F   C   S   E   K   G>
 GAA GAT ATG AAA GTG GGA TAT GAT CCC ATC ACT CCG CAG AAG GAG GAG GGT 204
  E   D   M   K   V   G   Y   D   P   I   T   P   Q   K   E   E   G>
 GCC TGG TTT GGG ATC TGC AGG GAT GGA AGG CTG CTG GCT GCT ACC CTC CTG 255
  A   W   F   G   I   C   R   D   G   R   L   L   A   A   T   L   L>
 CTG GCC CTG TTG TCC AGC AGT TTC ACA GCG ATG TCC TTG TAC CAG TTG GCT 306
  L   A   L   L   S   S   S   F   T   A   M   S   L   Y   Q   L   A>
 GCC TTG CAA GCA GAC CTG ATG AAC CTG CGC ATG GAG CTG CAG AGC TAC CGA 357
  A   L   Q   A   D   L   M   N   L   R   M   E   L   Q   S   Y   R>
 GGT TCA GCA ACA CCA GCC GCC GCG GGT GCT CCA GAG TTG ACC GCT GGA GTC 408
  G   S   A   T   P   A   A   A   G   A   P   E   L   T   A   G   V>
 AAA CTC CTG ACA CCG GCA GCT CCT CGA CCC CAC AAC TCC AGC CGC GGC CAC 459
  K   L   L   T   P   A   A   P   R   P   H   N   S   S   R   G   H>
 AGG AAC AGA CGC GCT TTC CAG GGA CCA GAG GAA ACA GAA CAA GAT GTA GAC 510
  R   N   R   R   A   F   Q   G   P   E   E   T   E   Q   D   V   D>
 CTC TCA GCT CCT CCT GCA CCA TGC CTG CCT GGA TGC CGC CAT TCT CAA CAT 561
  L   S   A   P   P   A   P   C   L   P   G   C   R   H   S   Q   H>
 GAT GAT AAT GGA ATG AAC CTC AGA AAC ATC ATT CAA GAC TGT CTG CAG CTG 612
  D   D   N   G   M   N   L   R   N   I   I   Q   D   C   L   Q   L>
 ATT GCA GAC AGC GAC ACG CCG ACT ATA CGA AAA GGA ACT TAC ACA TTT GTT 663
  I   A   D   S   D   T   P   T   I   R   K   G   T   Y   T   F   V>
 CCA TGG CTT CTC AGC TTT AAA AGA GGA AAT GCC TTG GAG GAG AAA GAG AAC 714
  P   W   L   L   S   F   K   R   G   N   A   L   E   E   K   E   N>
 AAA ATA GTG GTG AGG CAA ACA GGC TAT TTC TTC ATC TAC AGC CAG GTT CTA 765
  K   I   V   V   R   Q   T   G   Y   F   F   I   Y   S   Q   V   L>
 TAC ACG GAC CCC ATC TTT GCT ATG GGT CAT GTC ATC CAG AGG AAG AAA GTA 816
  Y   T   D   P   I   F   A   M   G   H   V   I   Q   R   K   K   V>
 CAC GTC TTT GGG GAC GAG CTG AGC CTG GTG ACC CTG TTC CGA TGT ATT CAG 867
  H   V   F   G   D   E   L   S   L   V   T   L   F   R   C   I   Q>
 AAT ATG CCC AAA ACA CTG CCC AAC AAT TCC TGC TAC TCG GCT GGC ATC GCG 918
  N   M   P   K   T   L   P   N   N   S   C   Y   S   A   G   I   A>
 AGG CTG AAA GAA GGA GAT GAG ATT CAG CTT GCA ATT CCT CGG GAG AAT GCA 969
  R   L   K   E   G   D   E   I   Q   L   A   I   P   R   E   N   A>
 CAG ATT TCA CGC AAC GGA GAC GAC ACC TTC TTT GGT GCC CTA AAA CTG CTG 1020
  Q   I   S   R   N   G   D   D   T   F   F   G   A   L   K   L   L>
 TAA ACT AGT CCT GAA TTC TGC AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG 1071
  * 
 CAT GCA TCT AGA GGG CCC TAT TCT ATA GTG TCA CCT AAA T
T7 HindIII
ps2575      m BAFF E278K full in PCR3
mBAFF 1-309
NotI XhoI
XbaI ApaI Sp6
EcoRI PstI
BamHI
EcoRI
E247K
 TAA TAC GAC TCA CTA TAG GGA GAC CCA AGC TTG GTA CCG AGC TCG GAT CCA 51
 CTA GTA ACG GCC GCC AGT GTG CTG GAA TTC AGG AAA GCC ACC ATG GAT GAG 102
                                                          M   D   E>
 TCT GCA AAG ACC CTG CCA CCA CCG TGC CTC TGT TTT TGC TCC GAG AAA GGA 153
  S   A   K   T   L   P   P   P   C   L   C   F   C   S   E   K   G>
 GAA GAT ATG AAA GTG GGA TAT GAT CCC ATC ACT CCG CAG AAG GAG GAG GGT 204
  E   D   M   K   V   G   Y   D   P   I   T   P   Q   K   E   E   G>
 GCC TGG TTT GGG ATC TGC AGG GAT GGA AGG CTG CTG GCT GCT ACC CTC CTG 255
  A   W   F   G   I   C   R   D   G   R   L   L   A   A   T   L   L>
 CTG GCC CTG TTG TCC AGC AGT TTC ACA GCG ATG TCC TTG TAC CAG TTG GCT 306
  L   A   L   L   S   S   S   F   T   A   M   S   L   Y   Q   L   A>
 GCC TTG CAA GCA GAC CTG ATG AAC CTG CGC ATG GAG CTG CAG AGC TAC CGA 357
  A   L   Q   A   D   L   M   N   L   R   M   E   L   Q   S   Y   R>
 GGT TCA GCA ACA CCA GCC GCC GCG GGT GCT CCA GAG TTG ACC GCT GGA GTC 408
  G   S   A   T   P   A   A   A   G   A   P   E   L   T   A   G   V>
 AAA CTC CTG ACA CCG GCA GCT CCT CGA CCC CAC AAC TCC AGC CGC GGC CAC 459
  K   L   L   T   P   A   A   P   R   P   H   N   S   S   R   G   H>
 AGG AAC AGA CGC GCT TTC CAG GGA CCA GAG GAA ACA GAA CAA GAT GTA GAC 510
  R   N   R   R   A   F   Q   G   P   E   E   T   E   Q   D   V   D>
 CTC TCA GCT CCT CCT GCA CCA TGC CTG CCT GGA TGC CGC CAT TCT CAA CAT 561
  L   S   A   P   P   A   P   C   L   P   G   C   R   H   S   Q   H>
 GAT GAT AAT GGA ATG AAC CTC AGA AAC ATC ATT CAA GAC TGT CTG CAG CTG 612
  D   D   N   G   M   N   L   R   N   I   I   Q   D   C   L   Q   L>
 ATT GCA GAC AGC GAC ACG CCG ACT ATA CGA AAA GGA ACT TAC ACA TTT GTT 663
  I   A   D   S   D   T   P   T   I   R   K   G   T   Y   T   F   V>
 CCA TGG CTT CTC AGC TTT AAA AGA GGA AAT GCC TTG GAG GAG AAA GAG AAC 714
  P   W   L   L   S   F   K   R   G   N   A   L   E   E   K   E   N>
 AAA ATA GTG GTG AGG CAA ACA GGC TAT TTC TTC ATC TAC AGC CAG GTT CTA 765
  K   I   V   V   R   Q   T   G   Y   F   F   I   Y   S   Q   V   L>
 TAC ACG GAC CCC ATC TTT GCT ATG GGT CAT GTC ATC CAG AGG AAG AAA GTA 816
  Y   T   D   P   I   F   A   M   G   H   V   I   Q   R   K   K   V>
 CAC GTC TTT GGG GAC AAG CTG AGC CTG GTG ACC CTG TTC CGA TGT ATT CAG 867
  H   V   F   G   D   K   L   S   L   V   T   L   F   R   C   I   Q>
 AAT ATG CCC AAA ACA CTG CCC AAC AAT TCC TGC TAC TCG GCT GGC ATC GCG 918
  N   M   P   K   T   L   P   N   N   S   C   Y   S   A   G   I   A>
 AGG CTG GAA GAA GGA GAT GAG ATT CAG CTT GCA ATT CCT CGG GAG AAT GCA 969
  R   L   E   E   G   D   E   I   Q   L   A   I   P   R   E   N   A>
 CAG ATT TCA CGC AAC GGA GAC GAC ACC TTC TTT GGT GCC CTA AAA CTG CTG 1020
  Q   I   S   R   N   G   D   D   T   F   F   G   A   L   K   L   L>
 TAA ACT AGT CCT GAA TTC TGC AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG 1071
  * 
 CAT GCA TCT AGA GGG CCC TAT TCT ATA GTG TCA CCT AAA T
T7 HindIII
ps2583     m BAFF E247K full in PCR3
mBAFF 1-309
NotI XhoI
XbaI ApaI Sp6
EcoRI PstI
BamHI
EcoRI
E247K
TAATACGACT CACTATAGGG CGAATTGGGT ACCGGGCCCC CCCTCGAGGT
CGACGGTATC GATAAGCTTG TTGCATAACA AATGATATCC AAAGATGGAG 100
TCGTCTACTT CAGTTCTACA TTTTTCCTTC GTGGCTGAAA TGAAAATGAC
TTTGGAGAGT TGACCCTTTA TGAAGCCGCT TAGCTACATC CATTTGTTAG 200
TTTTGCTGGG TTGAATATCT GTTCCATAGA TGACTGCTTT GTGTGACAAC
AAACGGTTCT ACTTTACTAC TTTCAGTTGG ATGCCTTTCC TCCGGTTCAC 300
TTTGTATGCT GGCTGCTGTA GCTGGAATTC CAGTGCAGCA CTGGGCAGCA
GTAATAAAAA TCCTGTCCTG CACCCACCAA GGAGCATTGC ATCTACTTAC 400
ATGATTAATG TTTGTTATGG AGTTTCTTGT GGTTTCTGGC TTCAGGACCA
GGGTGATTCT AGCTTCACGT CATGAGTTAA TAACTATTCT GGTTTCTAGA 500
AGAATTTGAG GAAGTTATTG GAAGTGTCTT GTTTATATGT CACCATCCTG
GTTCCCTTCA GTTGCATAAA CATGTTTAAT AGTTCCATGT CTGGCATTTT 600
GGGGGATGGT TCCTGTTAAG GGGATCCCTG CAGCCCGGGG GATCCACTAG
TTCTAGAGCG GCCGCCACCG CGGTGGAGCT CCAGCTTTTG TTCCCTTTAG 700
TGAGGGTTAA TT
pBluescript
HindIII
ps2859      m BAFF 5ʼ probe for E247K
                  knock-in in pBluescript
mBAFF 5ʼ sequence
BamHI pBluescriptBamHI
TAATACGACT CACTATAGGG CGAATTGGGT ACCGGGCCCC CCCTCGAGGT
CGACGGTATC GATAAGCTTG CATCGCGAGG CTGGAAGAAG GAGATGAGAT 100
TCAGCTTGCA ATTCCTCGGG AGAATGCACA GATTTCACGC AACGGAGACG
ACACCTTCTT TGGTGCCCTA AAACTGCTGT AACTCACTTG CTGGAGTGCG 200
TGATCCCCTT CCCTCGTCTT CTCTGTACCT CCGAGGGAGA AACAGACGAC
TGGAAAAACT AAAAGATGGG GAAAGCCGTC AGCGAAAGTT TTCTCGTGAC 300
CCGTTGAATC TGATCCAAAC CAGGAAATAT AACAGACAGC CACAACCGAA
GTGTGCCATG TGAGTTATGA GAAACGGAGC CCGCGCTCAG AAAGACCGGA 400
TGAGGAAGAC CGTTTTCTCC AGTCCTTTGC CAACACGCAC CGCAACCTTG
CTTTTTGCCT TGGGTGACAC ATGTTCAGAA TGCAGGGAGA TTTCCTTGTT 500
TTGCGATTTG CCATGAGAAG AGGGCCCACA ACTGCAGGTC ACTGAAGCAT
TCACGCTAAG TCTCAGGATT TACTCTCCCT TCTCATGCTA AGTACACGGA 600
TCCACTAGTT CTAGAGCGGC CGCCACCGCG GTGGAGCTCC AGCTTTTGTT
CCCTTTAGTG AGGGTTAATT
pBluescript
HindIII
ps2871      m BAFF 3ʼ probe (in exon 7) for E247K
                  knock-in in pBluescript
mBAFF 3ʼ sequence
BamHI
pBluescript
 AATTAACCCT CACTAAAGGG AACAAAAGCT GGAGCTCCAC CGCGGTGGCG GCCGCTCTAG AACTAGTTGC ATCTATCCTG CCAGTGATGG ACTTATAGCC 100
 TGGAATTATA AGCTAACATA AACACTTCCT CCCTTAAGTT GCTTTTTTTT TTTTCAGAGT GGGACTCTGA AGCGTGTAAA TGTATACTTT AGGACATGTG 
 CTTGCACAAT GCATATGAAT TACCTTTACA TATCAATACC AAAGTCTTTA TTCCATTCAC ATTACTACAT GTTAACATAA TTATTTTCAG ACACTTCAAT 
 ACATCAGTGA CCTAAAACCT AGTTCACACC CAGAGTGAGG CATGTCATCT TAGAGTGTCT CTCAACAGGG GGACATCAAT AAAACCCAAA AGGTAGTACT 
 TTTTTTTATC TGTAGTTTAA CTAATATCCT GAAGTTCTAA GTACATTTTA AGTGGGCCAT GATATTTATA CTTAAGTTTT CAATTCCCGG AGCTGTTAAC 500
 ATGTCACTTG GTTTGCTCTC TTAGAGGATG TTCTGGTGGC ATTTGAAAGC ACAGTTAACT TTAATCAATT ATGATATGGG AGGTTATATA TAACCTATGA 
 TTGTGTGTGC CTATGTATTG TATTAAGTGT TGTGTATACC TGTGTTGTGT GCACCTGTGT TGTGTGCACT GTTATGTGTA CTGTGTTGTA TGAGCTGTGT
 TGTGTGCACC TGTGTTGTGT GCACCTGTGT TGTATACACC TGTGTTGTGT GCACTGTGTT GTATGAACTG TGTTGTGTGC ACCTGTGTTG TATGAACTGT
 GTTGTGTACA CCTGTGTTGT ATGTACCTGT GTTGTGTGTA CCTGTGTCAT GTGCACCTGT GTTGTGTTCA GTGTTGTATG CACTATGTTG TGTGCACCTG
 TGTTGTGTGC ACCTGTGTTG TGTTCAGTGT TGTGTGCACC TGTGTTGTGT GTACTGTGCT ATGTGTACCC ATGCTGTGTG CACCTGTGCT CATGTACACA 1000
 ATAGAAGAAG AACATGTAGA GTGAATGAAA ACAAACAAAA CAAAAGAAGC ATGAGCTCTA CCTTCTTAAT AAGAGTAGTT AACAAAAAAG TAGCTACAAT
 GTAAAGAGCC AGTAAATAAA TTTAAATTAA TGCAGAACAA AATTCAGTAA GTAAATACTT TGGCCTAGAA TATTTAAAAA GTACTTTTAG AAATCTATGT
 TTTACTTCAC TTTGGTATCT CTGCCAACTC TGTAATGGGT GGTGTTTCAT TTTCCAGAAT TTCAATAGCA TGTTTTGCCA AATGTTTTAC AAAGACAGGA
 AATTGCCTGT GGCTGATTAC CACAGCAATC ATCAGTTTGA ATTATGTTTT ACTTAATGTA GAACTTACTA ATTCAGTGAT TATTAGATGC ATATCTGCTG
 GGGGAAAAAT GTGGGATAAA AAGCCCAGGG AAATGTCAGG TAGACAAACA AGCTGGCCTG ACCCCAGAGG AGTTAGAACC CCAAGGTGGG GGAAGATGTC 1500
 CTCTATGTTC AAACGATCAA CTCATTTTTA ATAAACCATA AGCATAATCA ACTTTGATAT AATCATTGTT TTTAACTTTT ATAGCAATAC CTTTTCTCCC
 ACTGTTTGCT TTGTTTTGTT TGAGACAAAC AAAACATGTA ACCCTGACTC TATGTAACCC TGACTGTTCT GGAACTTGCT ATGATCGACC AGGCTGGCCT
 TGAACTCCCA ACTTGGGGTC TAGACTTGTA ACAATCTTTA TTTTACAATG CCCGAGTTGT TACAGTCTTT ACGTTAATTC TTTCTCAGGT TGTTCAGTAC
 TCAATGATCT AACACACCTT GGGCACAAAA TTCCATTTAA ACAAAATAAG CACTGGCTTG TTGGAGACGT CTTGCTAGGA TCTTGTTGTA CACAGAGAGT
 AAAGAGGGCT TGCTTTTGAT ATTCGTGTTT GATGTGACCT GCTTCTCTGA GTCTGTTATC CTGATGAGCA ATGGGGGAAT TTTTATTTAA GAAAATTCCT 2000
 TGACTTCCTA CTTGAGAAGA AAAGTGTGGT GACCATCCCT GTGGCACCTC AGGGCCGCTC CGCTCTCTGG AACACAAGCA ATGGAAGTAG CTCCAGGAAG
 TGAATTCGCA CAAGGTATAG GCTGAAGAGA AAGATCATCC ATGATTCCAT GATGCTTCTG TGTCTGCCCC ATCTCCAGCA CTGCCAGCTC ACATGCCCTT
 CCCCCCAGGA TCTCCCCAAC CCCCATCCAT CTATGATAAT GCTTCCTTGA GGAGCCAGCC TAACGATCCT TACTATGACC TGAATTCACG GTGGTCTTTG
 CTTTGTTTTA CTGTGGGCAT TTTTTTCTCA TTATTTTTCT TTTTGTTTGT TTTTCGAGAC AGGGTTTCTC TGTGTTGCCC TGGCTGCCCT GGAATTCACT
 CTGTAGACCA GGCTGGCTTA TGAACTCAGA AATCTGCCTG CCTCTCCCTC CCAAGTGCTG GGATCAAAGG CATGTGCCAC CACGCTCGGC TTGCTGAGGA 2500
 CATTTTTTTT TTTTTTTTTT TTAAAGATTT ATTTATTTAT TACATGTAAG TACACTGTAG CTGTCTTCAG ACACACCAGA AGAGGGCGTC AGATCTCGTT
 ACAGATGGTT GTGAGCCACC ATGTGGTTGC TGGGATTTGA ACTTTGGACC TTCGGAAGAG CAGTCGGGTG CTCTTACCCA CTGAGCCATC TCACCAGCCC
 TGCTGAGGAC ATTTTTAACT CCTTCAAATT TTCAGAAAAC ATGAGCTTCT TATTTAGTGT TCTTCTGGTA AGGACCTTAT TTGAATCAGG AATATAAATT
 AGTACATTTC TAATAAATTC TACATTGTAG AAAAATATAG AGCCCCTCCC ACACCCAAGA TATTAAAAGT AGAACTGCAG TATGATTTAG CAATTCCACT
 TCTGAGTTTA TAAAGAAAAC TAAATCAATA ACAAATAGAG ACACCTAGAC TCCCAAGTTC ACTGTAGCCA AGATTACAAC AGCCAAAAAA ATCAACTTGG 3000
 TGTCCGTCGC CAGAGGAACG GGTAATAGTG GTATGGGCAC TGGGCACTGA ATGAACCTGT GAGACAGACG CAGAAATATA AATGTCACTA CAGTATCGCT
 TTGGACTTGT TTGACTGGTC TTGGAACCCA TACCCCCTTT TTGCTTATTG AGGTGACATT TTTAGACTGG CTTAGTGTTT CCCATTGTAC AAGAATGGTC
 TGGTGTATTT AGACTTTCCA CACCATTGGT TGCTATTCTG TGCTCACTGT GCAGGGGCCC TAATCTTCTG CCAGCTGCTT CCCTTCATTT AGTGTGTGGC
 TCCCCTCATT GTCTAGCCTT GAGGCTCAGC CCGATGCCAC TGTTTGCAGA CAGCATCTGT GCCCACTACC GTATAGTAAA CTCTTCCCAT GAAATGCATG
 TTTTTCTCTC TTCCTGGGTG CGAGCTCTAG GAAGCGCCTT GCTCCAGTCT GGTCTGGTGG CTTGATTCCC TAGCCTGTTG CCCTTTCTGC TCTTCTTGTC 3500
 AACCCTGAGC ACAGTGTCTT CCTGTCACTC AGCATAGAAT TAAGGAAATG TCACTGTACT GAAAGCCCTT TCAGCTTCTG AACACTGTAG TCTTAGCACA
 CAGGTTCTGA GCAGTTTTCA GTGCAGGGCA TATCCTCGTT GCTGTCTGTG TCATTTCCTA GTTGTGTTTT ACGGCCAAGT TGGTGGTGGC CTCACTTCCT
 CCAGATACAT TTTGTTAAGT TCTTCACCGA ATCACCCAGG AGATGGAAGA AGACAATCTC CCAGTGTGTT GTGCAGAGGA ACAGGTACTC TCTCTCCTAG
 ATCCTCCCCA AAACCCGGCC TTTATCAGGA AATAGCCAGT GTGCAGAACA AGAAAAGAAA ATATAAGCAA GAGCTGTGGA ATGGGGTCTC TTAGCACATG
 CATCCAGGTT TCCCATGCTA AAAACATGTT TGGCAGATAG CCCAATGGAG GACAGTCCTT CTCCTCCTCC TCCTCTTCCT CCTCCTTTTG CATTTTAGAA 4000
 TATACGATGT GCTCTTTTAA ATGTAGTGGG AAGAAAAAGT GCTTTTTACG ATTTACTGTC TCATGAGTAA TTCTCTCTCT GCTGCAGGAA CTTACACATT
 TGTTCCATGG CTTCTCAGCT TTAAAAGAGG AAATGCCTTG GAGGAGAAAG AGAACAAAAT AGTGGTGAGG CAAACAGGCT ATTTCTTCAT CTACAGCCAG
 GTAGCGTCAA ACTCTCCCCT ACCCCTGGTC CGACGTTTTC ACTGTCCTTC ACGTCTGGTG ACATATCCCG GCTTGTTTCT CAGGTTCTAT ACACGGACCC
 CATCTTTGCT ATGGGTCATG TCATCCAGAG GAAGAAAGTA CACGTCTTTG GGGACAAGCT TAGCCTGGTG ACCCTGTTCC GATGTATTCA GAATATGCCC
 AAAACACTGC CCAACAATTC CTGCTACTCG GCTGGTATGT AGCTGTCCTA AGACCTGCTT AGCAAGATGG TGTAGATTGT GCTGGGGAAT CTTATTCCCC 4500
 CCAAAAGTGC TGCTTTGGGA TCTTAATGGA AAGACCTTCT GCCATAGACT GTGCTGTTTA TTTTACAATA ATTTGTGTTG ACGGAGAAAA CTGATGGCCG
 CATAACTTCG TATAGCATAC ATTATACGAA GTTATGAATT CCTCGAGCAG TGTGGTTTTC AAGAGGAAGC AAAAAGCCTC TCCACCCAGG CCTGGAATGT
 TTCCACCCAA TGTCGAGCAG TGTGGTTTTG CAAGAGGAAG CCCCGGGCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC
 TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA TATTGAAAAA GGAAGAGTCC TGAGGCGGAA AGAACCAGCT
 GTGGAATGTG TGTCAGTTAG GGTGTGGAAA GTCCCCAGGC TCCCCAGCAG GCAGAAGTAT GCAAAGCATG CATCTCAATT AGTCAGCAAC CAGGTGTGGA 5000
 AAGTCCCCAG GCTCCCCAGC AGGCAGAAGT ATGCAAAGCA TGCATCTCAA TTAGTCAGCA ACCATAGTCC CGCCCCTAAC TCCGCCCATC CCGCCCCTAA
 CTCCGCCCAG TTCCGCCCAT TCTCCGCCCC ATGGCTGACT AATTTTTTTT ATTTATGCAG AGGCCGAGGC CGCCTCGGCC TCTGAGCTAT TCCAGAAGTA
 GTGAGGAGGC TTTTTTGGAG GCCTAGGCTT TTGCAAAGAT CGATCAAGAG ACAGGATGAG GATCGTTTCG CATGATTGAA CAAGATGGAT TGCACGCAGG
 TTCTCCGGCC GCTTGGGTGG AGAGGCTATT CGGCTATGAC TGGGCACAAC AGACAATCGG CTGCTCTGAT GCCGCCGTGT TCCGGCTGTC AGCGCAGGGG
 CGCCCGGTTC TTTTTGTCAA GACCGACCTG TCCGGTGCCC TGAATGAACT GCAAGACGAG GCAGCGCGGC TATCGTGGCT GGCCACGACG GGCGTTCCTT 5500
 GCGCAGCTGT GCTCGACGTT GTCACTGAAG CGGGAAGGGA CTGGCTGCTA TTGGGCGAAG TGCCGGGGCA GGATCTCCTG TCATCTCACC TTGCTCCTGC
 CGAGAAAGTA TCCATCATGG CTGATGCAAT GCGGCGGCTG CATACGCTTG ATCCGGCTAC CTGCCCATTC GACCACCAAG CGAAACATCG CATCGAGCGA
 GCACGTACTC GGATGGAAGC CGGTCTTGTC GATCAGGATG ATCTGGACGA AGAGCATCAG GGGCTCGCGC CAGCCGAACT GTTCGCCAGG CTCAAGGCGA
 GCATGCCCGA CGGCGAGGAT CTCGTCGTGA CCCATGGCGA TGCCTGCTTG CCGAATATCA TGGTGGAAAA TGGCCGCTTT TCTGGATTCA TCGACTGTGG
 CCGGCTGGGT GTGGCGGACC GCTATCAGGA CATAGCGTTG GCTACCCGTG ATATTGCTGA AGAGCTTGGC GGCGAATGGG CTGACCGCTT CCTCGTGCTT 6000
 TACGGTATCG CCGCTCCCGA TTCGCAGCGC ATCGCCTTCT ATCGCCTTCT TGACGAGTTC TTCTGAGCGG GACTCTGGGG TTCGAAATGA CCGACCAAGC
 GACGCCCAAC CTGCCATCAC GAGATTTCGA TTCCACCGCC GCCTTCTATG AAAGGTTGGG CTTCGGAATC GTTTTCCGGG ACGCCGGCTG GATGATCCTC
 CAGCGCGGGG ATCTCATGCT GGAGTTCTTC GCCCACCCTA GGGGGAGGCT AACTGAAACA CGGAAGGAGA CAATACCGGA AGGAACCCGC GCTATGACGG
 CAATAAAAAG ACAGAATAAA ACGCACGGTG TTGGGTCGTT TGTTCATAAA CGCGGGGTTC GGTCCCAGGG CTGGCACTCT GTCGATACCC CACCGAGACC
 CCATTGGGGC CAATACGCCC GCGTTTCTTC CTTTTCCCCA CCCCACCCCC CAAGTTCGGG TGAAGGCCCA GGGCTCGCAG CCAACGTCGG GGCGGCAGGC 6500
 CCTGCCCCCG GGCGAGTCTA GGGCCGCATA ACTTCGTATA GCATACATTA TACGAAGTTA TGAATTCCTC GAGTCTAGAT CATTACTAAT AGTCATACCA
 TTTTTATAAA AATTAAGACA GAGATGGGGA TGGAGAGGCA GTCTCATAAT GAAGAACACT GGCTGCTCTT CCAGAGAACC TCAGCTTCAT TTCCAGCACC
 CACATGGCAG CGCACAACTC TCTGTACCTC TAGTCCCAAG GGACCTGGCA CTCTCTTATG GCCTCCTTGG GCCCTGCACA TACATAGTGC ACATAAAGAT
 ACGCAGGAAA AATACCAATA CACAGAAAAA AATAATTACA TTAAATAAAT GTGCTTTTAA AAAGTTAAAA ATGAGGGTCA CAGAATTTGA CATTGGAGCA
 TACCTTATTT CTCTCCTACT CTTTCTCTGA CACATCCATA AGTGATTATA ATGATTTCTA CCACAGATAC ACTCTTTAAC CAACTTCCAC TTCTGCCATA 7000
 TTCCTTCTTC ATCTAAACAT GGACCCTCCT GCTTTCCTGT CATTTTCTCT GTTAGCCTCA CTGAGTTTAA TTTGGGTTGC TTCAAGAGCA TGGGAGGAAG
 GTTATTTGCT TGAGCCTGGG CAAGTGTTAG TGGTTACACC ACTCGAGAAA ATGGCACTCC TCCCAGAAGC CATTAACCAT CAATAGTGTT TCATGGAGGG
 AAGTGGCTTT ATGAGCCATG AAGGAAAGCT GAGGTCCCAA TCTTGTTCTG GACCTGTGCT TGTAACCACA GCTGGGAATG TCCAGGAAAA GGCAAGTCTA
 AGGTAGATGC CCTTCCATCC ATTTTAAGAA CAGCAGCAGG AACAATGTCT GCTCGCTGCC AGCTGCAGAA ACCTGAGAGC CTTCTGGGGT TTCTTCTCTT
 GTTCCATTCT CTGTCAGCTT CACTGCCTAG CAGTCATGAT TCCTTACTCT TGTGACCTCC TCATCTCCGG AGAATCTGAG CTACAGAAAT GACAGGACAG 7500
 GTCATAACAT CATAATGTAA CACAACACAA CACAACACAA CACAGAAGTT CCTCAGCTCC TCAGCCTCAA GCTATAGCAT GCCTGGCCCC ACAATATGAG
 CATGTGATGG GAAAAAGTAG CTCCTGTTGG TCCTGAGTGC AAGGAAGGGC ATACTGCAGA ATGGCTGGGT TAGGTCTCAT GGTTAAACAG GTAGCCTCAG
 
 ATACCTGACT AGTGGATCCG GTACCCAATT CGCCCTATAG TGAGTCGTAT TA 
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